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, The investigations reported in this thesis were undertaken to 
xamine the clinical pharmacology of methotrexate. The following 
results have been observed. . 
'1) The radioimmunoassay employed for the measurement of methotrexate 
in these studies has a low 1im~1 of sensitivity and high 
precision. In addition it is highly specific and does not 
cross-react significantly with 7-hydroxymethotrexate •. 
2) Methotrexate was readily detectt.:d, soon after administration 
in mixed and parQtid saliva and also in tears. A close 
linear correlation was observed between methotrexate 
concentra~ions in tears and serum, and also between levels in 
paretid saliva and serum. No significant corrplation could be 
demonstrated between methotrexate conqentratio:.s in mixed saliva 
and serum. The ratio of drug levels in t,ears t: that unbound 
in serum was close to unity whereas methotrexate appeared to 
be secluded from saliva secretion. No relationship between 
, 
tear levels of drug and conjunctivitis could be demonstrated. 
The prediction of drug levels in serum based on the concentration 
measured in either tears or parotid saliva was considered 
impractical. 
J) ~ethotrexate was also readily detected in cerebrospinal 
fluid (C.S.F.) of children on high dose intravenous therapy. 
There was a highly sir~ificant linear correlation between 
the concentration in mixed salha. and concentration 1.n C.S.F. 
The need for further study was indicated since saliva levels 
of methotrexate may,provide a non-invasive and painless 
means of monitoring C.S.F. levels of this agent. 
4) Methotrexate persists in ervthrocytes for a long time probably 
several weeks after administration of high doses by continuous 
infusion. It is possible that this process may be described 
by two mechanisms, mainly, ~Jl initial rapiuly reversible 
uptake and a ~econd active uptake process. The concentration/ 
time profile is consistent ~~th erythrocytes being a slowly 
exchanging kinetic compartment. No immediate displacement 
of methotrexate was effected by folinic acid administration. 
The uptake of methotrexate may however, be influenced by prior 
chemotherapy. It is expected that this persistence in erythrocytes 
may influence the expression of toxicity and/or resistence. 
15 . 
r 
Continuous ultrafiltration was shovn to be a viable method 
for the elucidation of serum protein binding of methotrexate. 
Methotrexate is bound predominantly to serum albumin. In 
normal healthy volunteers the binding was linear over a wide 
range of total concentrations ~d is highly protein bound 
over the concentrations encountered after convential doses. 
Non-linear binding to albumin occurs at higher serum concentrations, 
such as would occur after high ~ose therapy. Two groups of 
binding sites were observed, one being a high affinity/low 
capacity group, and the other a low affinity group, with a 
higher capacity_ No significant difference in percent bound, 
nor in binding parameter.values could be demonstrated between 
newly diag~osed patients, with various forms o! neoplastic 
disease, in an age and sex matched group when :he group 
values were compared. The serum protein binding of methotrexate 
is dependent on the concentration of serum albumin. 
6) The absorption from the gastro-intestinal tract of methotrexate 
formulated as a syrup is saturable. The bioavailability 
can be conviently improved by dividing high doses into units 
of 25 mg. given at twC' hourly interv~ls. This regir;:en may 
permit oral administration to be considered as a reasonable 
alternative to intravenous therapy. 
7) Renal elimination is the main route whereby methotrexate is 
cleared from the body and it is dose dependent. The studies 
presented here show that while the exact relationsr~p between 
renal clearance and methotrexate serum levels awaits 
clarification, the effect of methotrexate saturable renal 
elimination can become apparent after modest doses a~nistered 
by bolus intravenous injection. 
Only smatl quantities of methotrexate are excreted into 
bile. While this amount i~ small and sugf.~3ts negligible 
enterohepatic recycling it is persistent and may contribute 
to gastrointestinal toxicity which has been observed after 
intravenous administration • 
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Principles of Cancer Chemotherapy I The basic assumption in cancer chemotherapy is that all 
Falignant cells should be destroyed or neutralised. Chemotherapy 
'alone, however, has failed to cure most human malignancies, since 
there is no specific molecular targ~i; unique to the cancer cell. 
The general chemotherapeutic approach is aggressive assault on 
the functional intergrity of tumour molecular biology (Fig 1). 
However, treatment is limited not br the extent of the disease, 
in contrast to surgery or radiothere.py, but rather b'y the total 
mass (Laster et al., 1969; Schabel Jr. 1968; Shapiro and Fugmann 
1957; Skipper ~t al., 1964). The evidence for this was provided 
from experiments conducted by Skipper and his co-workers in the 
mid 1960's (Skipper et al., 1964; Skipper et al., l~o5; 
ISkipper, 1968). It was then proposed that the abi1i~y to 
eradicate malignant cells vIas dependent not only on the dose of 
the drug employed but also on the number of tumour cells present 
I 
i.e., the total body cell burden. Further, the cell destruction 
"followed first ordeJ.' kinetics, 1. e., a given trt:atment will 
destroy a constant fraction of cells and not a fixed number. 
The obvious implications of this fractior. cell kill hypothesis 
are, that for drug treatment to be effective in obliterating a, 
tumour population, it would be necessary to:-
a) increase the dose of drug or drugs to just within the 
limit tolerated by the host. 
b) start treatment when the number of tumour cells present 
is small. 
Skipper et al:, (1965) also emphasised how critical the interval 
between doses was for effective therapy, since cell kill per 
treatment was shovm to be the initial cell kill less the re-growth 
of the tumour population between treatments. Although the 
fraction kill hypothesis was de:r:-:'ved from the l~ukaemia L1210 model 
system, the implications may be generally applicable, since the 
hypothesis has been validated in other animal tumours (Wilcox, 
et al., 1965; Goldin, et al., 1956; De Vita Jr. 1911) and appears 
to be true in some human disease (De Vita Jr. 1911). 
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~ The concept that effectiveness of drug treatm€ct increases ith decreasing volume of turr.our cells was obtained from exponentially growing malignancies. However, most tumours do not have a single 
'growth rate but one that varies continuously with age. Casey (1934) 
suggeste·d that tumour growth could :"e de3cribed by a Gompertzian 
curve, although at the time he felt that his data was not firm 
enough to permit generalisation. It was not un til thirty years 
later that Laird (1964) po~·tulated ti..is mode of growth in solid 
tumour types. For Gon:pertzian growth, the rate is least for beth 
very snaIl and very large tumours and is maximum at the inflection 
point when the tumour is about 37% of its maXimU111 size. 
The relationship between tumour size, sp~cific ~rowth and 
growth rate for unperturbed Gompertzian growth has "een well 
lillustrated by Norton and Simon (1977). The work shv"fs clearly 
the application of the fraction kill hypothesis to this type of 
growth is unrealistic and the clinical implications which have 
I 
been dra~n from this model ~re that:-
a) with a very effective therapy a small tu.mou.r may be cured 
by a dose of drug which would not cure a larger tumour. 
b) a dose schedule c~~able of causinG a dramatic rate of 
regression of a tumour of intermediate size may not cure 
a small tUr:J.otlr when therapy is either reduced or aI-'plied 
over a limited duration. 
c) high-dose therapy over a short period may be better than 
prolonged low-dose treatment in decreasing rates of 
recurrence. 
d) the use of high-doses and perhaps J!'lore prolonged therafY 
(more a.ggressive therapy) than t1igr.t otherwise be et;,;loyed 
1s advocated. 
e) intense alternating cycles of different drug corr.binations 
in full doses night pro~·.lce better sur'll va.l times than 
using one ~F.rticular combination of many agents in reduced 
doses. 
It has been proposed by :rorton and Simon (1977) that the rate 
of regression or growth inhibiting effect of therapy is proportional 
to the growth rate of an untreated tumov.r. 
20 
I Yillowledge of the process of the cell cycle has also increased 
t.he capacity for manipulation of chemotherapeutic agents. The term 
Incell cycle" describes the period between one mitosis and the next , 
in one or both daughter cells. Howa~d and Pelc (1951, 195) first 
characterised the sequence of evente occurring in this cycle by 
autoradiographic methods. They postulated that the cycle could be 
divided up, on a temporal basis, into four specific classical 
phases:-
G1: the period between mitosis and the onset of DNA synthesis. 
s: the period of mlA synthesis. 
G2: the period between completion of DU.\. synthesis and mitosis. 
M: mitosis. 
Animal cell populations are, however, heterogeneous and may be 
Idivided into three groups (Lajtha, 196); Baserga, 197', i lIill, 191·6; 
Prescott, 1968). (Fig.2). 
1) continuously dividing or cycling cells. 
2) resting or lion-cycling cells. 
) non-dividing cells. 
Most of the variabili t~· of cell cycle times for many cells 
growing under varying or constant conditivns arises as a result of 
the time spent in the G1 interval, the remaining phases being of 
relatively fixed duration (Sisken and Kimosita, 1961; Till et al., 
1964; Baserga, 1965; Mendelsohn, 1965; Prescott, 1968; Mueller, 1911). 
Lajtha (1963) introduced the idea that normal cells Can move out 
of the cycle or become arrested for extended periods of time, but 
still retain the capacity to be stimulated into proliferation •. 
Burns and Tannock (1910) proposed that this variability could be 
described by assuming that such clonogenic but non-dividing cells 
enter an intermediate phase, GO' which is part of G1• From GO they 
could proceed to the determinate phase 'e' (of constant duration 
and containing S. G~. U. and G1 phases), at randC'".'. with a constant 
specific rate (y). Experimental evidence for this theorJ was 
obtained from the fraction of cells continuously labelled with 
()H)-thymidine in labelled mitosis in the hamster cheek pouch 
epithelium. 
21 
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)' Smith and Martin (197); 1974) later proposed a simila~ model. 
According to this model the cycle can be divided into two parts:-
1) The B-phase (equivalent to the 'C' phase) where the cells 
are proceeding towards division. 
2) The A-phase (equivalent to GO) where the cells are awaiting 
a random ,triggering before proceeding. 
A cell may remain in the quiescent 'A' state for a~y length 
of time without progressing. towards ,ni tosis, but it always has a 
certain chance, called 'transition probs.bili ty' of entering the 
B-phase. Brooks (1975; 1976) has observed that the addition of 
serum to resting fibroblasts increases the transition probability 
value after a defined lag period. Credibility has ~een lent to the 
theory by the shape of frequency of labelled mitosis curves, obtained 
\ in vivo, since they can be predicted accurately frolQ the tra.'"lsi tion 
probabili ty theory (Burns and Tannock, 1910; Smith and l;artin, 
197); De Maertelaer and Galand, 1975; De Maertelaer and Galand, 
1977) • 
Knowledge concerning the cell cycle puts a temporal parameter, 
albeit a median, on a series of biochemical events which are 
peculiar to the cell repli~ation functio~. Since successful 
chemotherapy depends on a differential action of chemotherapeutic 
agents on malignant and normal cells, the work of Bruce et al., 
(1966) was of major importance. They demonstrated a kinetic 
difference between normal and malignant tissues and indicated how 
these differences may be exploited to achieve increased selective 
tOxicity of cytotoxic drugs. Further, their work formed the basis 
for a kinetic classification of anti-cancer drugs which depended on 
their action during certain pha~~s of the cell cycle and on resting 
cells. Three broad categories were suggested:·· 
Class I: Non-soecific: the agents appeared to be equally 
toxic for both proliferatL:.g and resting cells. 
Class II: Pha.~·~-snecific: proliferating cells were killed. 
during a specific phase or phases of the cell cycle. 
Class III: Cycle-specific: both proliferating and resting cells 
were damaged, however, dividing cells were more sensitive and 
were killed throughout the cell cycle. 
22 
· I The specificity of these agents was assessed by the spleen-
~olony assay developed in mice, in which slowly proliferating 
~aematoPoietic and rapidly proliferating mouse lymphoma colony-
forming cells were compared. The main implication being a safer 
cancer chemotherapy involving minimal toxicity to normal bone 
marrow without compromising antitumour effectiveness. Since this 
initial work a large number of agents have been classified according 
to the locus within the cel~ cycle t? which they show greatest 
activity (Fig. 3). 
These studies have provided a rationale for the ~se of chel:1o-
therapeutic agents in the treatment of disseminated disease, the 
role of adjuv~t chemotherapy, and helped in the chc:ce and scheduling 
of drug combinations. Cure is taken to mean that the life expectancy 
10f the treated patients is the same ~s that of a matC'~,ed cohort 
in the general population. 
Although cures or long-term remissions have been obtained in 
few diseases with ch~motherapy alone, extremely ~ncouraging results 
, 
have been observed in the following conditions: childhood acute 
lymphoblastic leukaemia has been effectively controlled with 
chemotherapy alone (Freireich, 1966; Simon9, 1974;) Hodgkins 
disease, which represents one of the more notable advances in the 
clinical control of cancer (De Vita et a1., 1970; De Vita and schein, 
1973; Stutzman and Glidewell, 1973; Frei et al., 1973;) Burkitt's 
lymphoma (Zeigler, 1973). 
It has been obvious for many years that surgical or radio-
th.erapeutic ablation cannot achieve the desired cancer control in 
a large number of patients. When the tumour is truly localised 
and can be totally excised or obl~terated by radiotherapy, these 
alone may be sufficient. However, many tumours -,which are apparently 
localised are, in fact, microscopically disseminated, and'unless 
some detectable che~ical substan~c is released from the tumour 
and thereby mark it~ presence, the process of disease may not be 
diagnosed until recurrence becomes obvious. The natural history 
of relapses after both surgical or radiotherapeutic approaches 
has indicated certain groups in whom metastatic disease can be 
assumed to have occurred at the time of diagnosis in a large 
percentage of cases. 
23 
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Figure 3 The cell cycle specificity of commonly used 
cytotoxic agents. 
~hese include breast cancer with positive axillary lymph nodes, arge bowel cancers with local infiltration and/or involving the regional lymph nodes, gastric, pancreatic and lung cancers. By 
its very nature, metastasising disease, even in microscopic amounts, 
is no longer cureable by surgery or :.'adiotherapy. 
Apparent remission of disease, therefore, does not mean that 
treatment can be stopped at this time, since tumour-cell numbers 
below 109 (equivalent to 1 ~m. in d:i.l:'.meter) are extremely difficult 
to detect clinically. Also tumour marker substances can only 
detect in the order of 105 cells and then only in a limited group 
of conditions. Adjuvant therapy has, therefore, enahled considerable 
improvement ~n prognosis in a number of disease st?~es in which 
the cure rate with surgery and/or radiotherapy was poor, e.g., 
lv/i1ms' tumour (Farber, 1966; D'Angio, 1912; D'Angio .,t a1., 1913;) 
Ewing's tumour (Huster et al., 1912; Rosen, 1914;) embryonal 
rhadomyosarcoma (Donaldson et al., 1913; Ghavini et al., 1915; 
,Pratt, 1912;) osteo~enic sarcoma (Jaffe et al., 1914; Rosen et al., 
1915; Suton, 1914). 
The choice of drug combinations has until recently been made 
on an empirical basis, as ilave the cri ti0Jll variables of sequence, 
schedule and ratio. Extensive use of cell-cycle information in 
the design of drug combinations has now been made. Combination 
therapy is now based on a number of genera~ principles:-
a) All the drugs used should have single-agent activity 
against the tumour. 
b) The drugs should have different types of toxicity so 
that each one can be used in,optimal dosage. 
c) The combination should ~e synergistic or at least addictive. 
d) The drugs should have different biochc~ucal sites of action 
and should take effect at different stages of the cell cycle. 
e) Agents may also be cho~cn for their ahility to reach 
certain si~es. 
Effective combinations of drugs may be obtained by attempting 
to exploit the prinCiples of 'synchronisation' and recruitment. 
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~ The purpose of synchronisation is to gather cells in a certain ortion of the cell cycle and then destroy theM by an agent or agents which maximally kill at this point. The term~recruitment 
I 
in this instance refers to the situation following chen:otherapy 
when the labelling index, or growU .. '_'raction, is found to rise. 
This increase often being associated with tumour regrowth, i.e., 
recruitment may be an indirect consequence of cell ki11ing~ when 
the cell depletion leads to. a simu1·~J'.neous recruitment of resting 
cells back into cycle. By inducing non-dividine turr.our cells to 
proliferate they are being delivered into a more vulnerable phase. 
Lankin et a1. (1971) have suggested teat cell synchronisation 
techniques could increase therapeutic efficacy in actlte lymphocytic 
leukaemia. They reported 3. greater therapeutic advantuge of a 
Isecond cycle dependent drug, after partial synchroni~ation with 
cytosine arabinoside, than after the second drug alone. Capizzi 
(1974) has studied. a combination of asparaginase and methotrexate, 
~n which he observe'! a cor::plete rcmj.ssion in nLd} out of eleven 
adults with acute lymphocytic leukaemia, all of whom were refractory 
to prior methotrexate. 
Clinical protocols have also been de~igned along synchronisation 
lines for solid tumours. Barranco at al., (1973) have observed 
that continuous infusion of bleo~ycin for 48 hours produced an 
in~rease in labelling index in the nodules of patients with mela.TloI:la. 
Costanzi (1976) atte~ptcd to use bleomycin to arrest the cycle at 
the S/G2 interr-hase, and subsequent treatrr.ent with methotrexate 
and hydroxyurea 24 hours later. It had been reasoned that the now 
synchronised cells would have been released froffi the biochecical 
block and transferred back toward~ the S/G2 interphase. Activity 
by the other agents was now predicted to give greater cell kill • 
. Although initially the results were not better than what rr~ght h~ve 
been ex~ected from methotrexate a.lone, thE'Y a.lso reported that by 
increasing the infu5~on time and DJethotrexate dose with citrovorum 
fac·tor rescue the results have looked more promising. There has 
been ~ome moderate success in the therapy of testicular ca.ncer 
usine vincristine to produce stathmokinetic arrest followed by 
bleomycin and adriamycin (Bureess et al., 1975). 
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The validity of this approach has, however, been questioned, 
ince there is no evidence to suggest that synchronisation does 
,occur to any great extent in vivo. Dethlefsen et a1., (1977) 
have stated that whereas partial synchronisation is real, it is 
poor and desynchronisation occurs wi ~;hin one cycle traverse. 
They suggest that to obtain any advantage from this procedure 
requires that the second drug be administered early when the 
ini tia1 cells are tightly g~ouped. ~·an Putten (1975) has 
pointed out that tumours are likely to contain cells vdth a 
range of different cell cycle properties. It is therefore 
unlikely that a tumour which contains a large population of 
resting cell~ will be effectively destroyed by this type of 
therapy. 
:1 
" 
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The l'.1echanism of Action of' Some Commonl Used Antineonlastic A ents 
At present there are a great many drugs employed in the fight 
against malignant dise~se. A very broad and brief classification 
of some co~~only used agents is outlined in Table., Since these 
drugs have now established places in chemotherapy, and to contrast 
their mode of action with that of methotrexate, their mechanism of 
action will be briefly discussed. 
ALKYI.ATING AGENTS 
T~e vesicant action of sulphur mustard on skin, eyes and 
respiratory tract gained wide medical attention during World War I. 
The pertinent observation that sulphur mustard also caused 
leukopaenia, aplasia of the bone marrow and dissoluLion of the 
I lymphoid tissue coming soon after. Later, studies or the biological 
nature of nitrogen mustard indicated considerable promise as an 
antineoplastic agent. The cytotoxic action on lymphoid tissue, 
particularly, prompted the initiation of clinical studies which 
. 
established the usefulness of the alkylating agents (Gilman, 1963). 
These compo1L~ds react co-valently with many cell constituents, 
however their main site of ~ttack is probably by inducing intra-
and inter-strand linking of DNA which subsequently loses template 
activity. Alkylating agents tend to be phase-specific in their 
action on the cell cycle f'or this reason. The active locus in these 
agents appears to be a carbonium ion or ions which reacts with 
great avidity with negatively charged molecules such asfnucleic 
acids. Alkylating agents react with non-dividing cells but their 
cytotoxic action becomes manifest only once the cells begin to 
divide. 
Cyclophospharride: 
This coopound is a cyclic N-phosphorylated derivative of 
nitrogen mustard. It was first ~ynthesised in an attempt to 
obtain a compound ~i·th greater antitumour specificity (Arnold and 
Bourseaux, 1958). It was soon shown to be active in experimental 
and clinical cancer (Arnold et al., 1958; Gross and Lambers, 1958). 
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", Cyclophosphamide " . Kustards 
" 
' , 
" 
Alkylating, Cross-link DNA Agent~ 
Carmustine (BCNU) " ' .. 
" Nitrosoureas 
" , 
Lomustine (CC~W) 
. , ... Semustine (r.:e-CClru) 
} 
. . 
.. Polic Acid Inhibits purine r,lethotrexa te 
, . Analogues biosynthesis 
. -, . " 
' . 
. . 
, , 
" 5-Fluoro- Inhibits dTIliP biosynthesis 
uracil (5-FU) 
Anti- Pyrimidine 
. Metaboli tes Analogues 
.. Cytosine Inhibits DlTA-
, , Arabinoside polymerase 
Purine 6-Mercapto- Inhibits purine ring 
Analogues purine (6-MP) biosynthesis & nucleotide interconversions 
Vinca Vincristine (VCR) Inhibits f'unction of' 
Alkaloids Vinblastine (VLB) . microtubules ,!'.~ .;~~.~~. ~ 
, , 
Actinomycin D Intercalate with DNA: 
Natural Adriarnycin prevents RNA biosynthesis Antibiotics Products Damage DNA & prevent 
" Bleomycin 
repair .. 
Deaminates asparagine. 
Enzymes L-Asparaginase ,inhibits protein 
biosynthesis 
Substi tuted" ' Hydroxyurea Inhibits ribonucleotide Ureas reductase 
Miscellaneous 
Agents, 
Hydrazines Procarbazine Undetermined 
Adrenocortico- Prednisone Lympholytic: suppresses 
steroids mitosis 
Hydroxy-
Progestogens, progesterone 
caproate 
Hormones 
Diethyl- Antaeonism of' endogenous Oestrogens 
stilbestrol hormones on dependent tumours 
Androgens Fluoxy-
mesterone ! 
~ Cyclophosphamide is inactive as such and must undergo biotrans-ormation before it can express its cytotoxic activity. Extravasation outside a vein does not therefore produce tissue 
necrosis as rdth nitrogen mustard. 
The complex activation of this i.rug with formation of active 
metabolites has been the subject of intensive study. Connors et al., 
(1914) have proposed the following scheme in which the hepatic 
cytochrome P-450 mixed function oxictp.se system first converts 
cyclophosphamide to a 4-hydroxycyclophosphamide. This in turn 
is in equilibrium wi th its a·~yclic tautomeric form, a+dophosphamide. 
The 4-hydroxycyclosphosphamide can also be converted by dehydro-
genation to y'ield 4-ketocyclophosphamide. This prC'~~lct can be 
further converted enzymatically by liver aldehyde oxidase, a~d 
I other aldehyde metabolising enzymes,. to carboxyphosp~amide. 
Aldophosphamide can also be cleaved by a~-elimination reaction to 
yield phosphoramide mustard and acrolein, both of which are 
,highly toxic. 
The active metabolite adophosphamide has been well characterised 
(Struck and Hill, 1912) but the other metabolites nlay contribute 
to t11e over-all cytotoxic effect. The 4-~ydroxycyclophosphamide 
he.s not been shovm to be efficacious but may still prove to be so 
(Takarnizawa at a1., 191.3). Phosphoramide mustard has, however, 
been shovm to have anti tumour activity against tumours and has 
also shovm some activity in clinical trials (Nathanson et al., 
1961). As expected, cyclophosphamide mediates an effect in the 
G2 phase of the cell cycle (Klein, 1912). 
Nitrosoureas: 
The first nitrosoureas were 3ynthesised by Johnston and his 
co-workers in 196.3 (Johnston et al., 196.3). Th ... ·ee ni trosoureas 
have COme into clinical use; these are:-
1,.3-bis 2-chloroethyl-1-nit.L'osourea (Carmuc;tine, BCW), 
1,2-chloroethy:-.3-cyclohexyl-1-nitrcsourea (Lomustine, cc~ru), 
1,2-chloroethyl-.3-4-methylcyclohexyl-1-nitrosourea 
(Semustine, methyl - CCNU). 
These compounds have the unique pro~erty of crossing the 
blood brain barrier (Oliverio, 191.3). 
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t' Nitrosoureas can react ,nth biologic macromolecules in everal ways. The chloroethyl portion of the molecule has alkylating ability and BC1~ having two such groups, is capable of 
I 
crosslinking DNA (Wheeler and Chumley, 1967). Other modes of 
action include carbomoylation by the isocyanate portion of the 
molecule and inhibition of DNA repair by the isocyanate metabolite 
(Kann et al., 1974). As with cyclophosphamide, nitrosoureas 
delay progression or arrest,cells in the G2 phase of the cell. 
,AUTU'ETABOLITES 
Folic Acid Analogues : r.'iethotrexate (MTX): 
The mechanism of action of MTX will be discussed in some 
detail later in this chapter. 
Pyrimidine Analoeues : 5-Fluorouracil (5-FU): 
I This was originally synthesised by Duschinsky et al., (1957) 
and was shown to be a potent inhibitor of thymidylate synthesis. 
However, its cytotoxic action is not limited to the phase of DNA. 
.synthesis (S-phase) and it is active throughout the cell cycle. 
Activation of 5-FU proceeds to the formation of 5-fluorouridine 
monophosphate and 5-fluorodeoxyuridylate (Kent and Heidelberger, 
1972). In the presence of the co-factor 10;-5, ~ 0- methylene 
tetrahydrofolate, 5-fluorodeoxyuridylate binds stronely to the 
enzyme's active centre. In fact the binding is quite stable and 
appears to be covalent in nature (Santi et al., 1974). Although 
considered to be of secondary importance, 5-fluorouridine 
monophosphate is readily incorporated into RNA, altering RiTA 
, , 
synthesis and function, and ribosomal stability. 
Cytosine Arabinoside: 
The synthetic pyrimidine nu~leosides of which cytosine 
arabinoside is a member, are a class of nucleos!des having 
D-arabinose as the pentose moiety. The major biochemical mech~~ism 
leading to cytotoxicity has bee14 ascribed to cc·mgeti tive inhibition 
of DNA polymerase (~,~onparler, 1972). Arabinoside cytidine 
triphosphate is also incorporated into DNA leading to premature 
termination of the nucleic acid chain (r.Ionparler, 1969). Creasey 
(1975) has confirmed that incorporation into DNA and RN'A occurs 
in human leukaemic cells. Cytosine arabinoside has been shown to 
delay progression from the S-phase to G2 -phase in the cell cycle 
(Karon and Shirakawa, 1970). 
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,Purine Analo ues : 6-l.:ercaptopurine (6-MP) 
A large number of natural purine base analogues have now 
been prepared and studied. The first clinically effective antipurine 
was 6-MP which was synthesised by E1ion et a1., (1959) and was 
found to have significant activity a/;ainst human leukaemias 
(Burchena1 et a1., 1953). 
A variety of biochemical effects of this agent have been 
found in both normal and ma;tignant ·~J.ssues. It has been shoYm 
tha t 6-r1:p is enzymically converted into di- and tri-phosphates 
. (Way et a1., 1959) and can be incorporated into both DNA and RNA 
although the incorporation is small. It also inhibits the 
incorporatio~ of formate (Skipper, 1954i Heide1bergwr, et a1., 1960{a» 
and glycine (Le Page and Green1ess, 1955). As expected 6-fuP 
\ shows activity in the G1 phase of the cell cycle (Va".devoorde, 
et a1., 1970). 
NATURAL PRODUCTS 
Vinca Alkaloids: 
, 
Nobel et a1., (1958) working on extracts of the periwinkle 
were unable to confirm the alleged hypog1ycaemic activity. They 
did, however, observe granulocytopaenia &!".d bone-marrow 
suppression in their rats. Fractionation of such extracts have 
subsequently yielded four active alkaloids of which vinblastine 
(VLB) and vincristine (VCR) have received extensive clinical 
investigation. Both VLB and VCR bind to mirotubules (Benesch 
. 
and Ma1awista, 1969) and cause dissolution of the mitotic spindle 
apparatus (Sartore11i and Creasey, 1969). As expected, these 
drugs most acutely influence the cell when in metaphase (Palmer 
et a1., 1960i Cardinali and Mehrcta, 1963). 
Antibiotics : Actinomycin D: 
The first crystalline antibiotic agent to be isolated from 
a culture broth of streptomyces das actinomycin-A (Waksman and 
Woodruff, 1940). S~nce then many related compounds have been 
isolated including Actinomycin-D. The actinomycins are chromo- .. 
peptides, most of them containing the chromophore actinocin. 
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~CytotoxiCity is due to its ability to bind to DNA and inhibit JA synthesis. These complexes require tho presence of deoxy-osine and apparently intercalation of the antibiotic occurs 
between a. base-paired dG-de sequence. Al tera tions in the physical 
properties of DNA are induced by thed(' complexes (Reich, 1963). 
Evidence has been ~resented which suggests that actinomycin D 
acts at tile G2 phase of the cell cycle (Iaein, 1972) whereas 
earlier workers have indicated activi~ at the G1 and G1/S 
boundary (l1shimoto and Liberman, .1964) and at the S/G2 bou.."ldary· 
(Epifanova et al., 1969). 
Adriamycin: 
Adriamycin (ADR) is a glycosidic anthracyclene c.~tibiotic 
and is a fermentation product of streptomyces pencet.:.'..As var-
\ caesius. It in tercala tes be-v .... een base pairs of DNA, ";.'1e amino 
sugar daunomycin playing an essential role in this binding. 
The DNA helix is wi s ted to prevent in tercala tion, producing a 
1 
larger, th1~"ler molecule and causing inhibition of template 
acti vi ty (Di f':arco e ~ al., 1969; Pigram et al., 'j :772). Adriamycin 
has been shown to be ac ti ve at the S-phase (Hi ttelmall and Rao, 
1974) and at the S/C2 bound~~7 (Epifanova ~t al., 1969). 
13leorlycin: 
The bleomycins form a group of water-soluble, basic glycopep-
tides produced by streptomyces verticullus (Umezawa et al., 1966). 
It seems most likely that their cytotc::ic action relates to their 
ability to cause chain schism and fragmentation of tNA molecules. 
Suzuki et al., (1968) have shown that these drugs react wi th DrA 
causing single-strand breaks. Also Umezawa (1973) has shu~~ 
evidence that bleomycin 132 in very low concentrations can bind 
to DNA, possibly by a chemical reaction involvin5 reactive groups 
on the bleomycin and Dr;A to cause "niclr..1ng". Studies wi t.'1 
synchronised ce;t.ls have indica ted that the bleomy~ins block t..'1e 
cell cycle, causing accumulation of cells, some severely damaeed, 
at G2 (IlittleI:lan and Rao, 1974). Ot.'1er studies have shown that 
cells in :nitosis are sensitive to these antibiotics (U:tezawa, 
1973(a); Umezawa, 1973(b). 
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~~~m~e~s : L-Asparaginase (L- asparagine amidohydrolase E.C. 3.5.1.1). 
Guinea pig serum was observed to have anti tumour activity 
some murine tumours (Kidd, 1953). The factor responsible for 
the suppression of the malignant cells was later discovered to be 
L-asparaginase (Broome, 1963). Its 'Jffect is dependent On the' -
fact that some tumours lack the endogenous capacity to synthesise 
asparagine. In these cases depletion of plasma asparagine by 
asparaginase can result in 1;umour c(~ll death. L-asparaginase 
appears to be effective at the G1 phase of the cell cycle (Klein, 
1972). 
MISCELLANEOUS AGENTS 
Substituted Ureas : Hydroxyurea: 
I -
This drug was first synthesised in 1869 by Dresler and Stein, 
-
"but it was not until about sixty years later t~at the first 
indications of cytotoxic activity were noted. It was found to 
produce leukopaenia, anaemia and megaloblastic changes in bone 
,marrow of rabbi ts (~osenthal et al., 1928). Hy~roxyurea inhibits 
the enzyme ribonucleoside diphosphate reductase which mediates the 
conversion of ribonucleoti~es to deoxyribonucleotides, a probable 
rate limiting step in the synthesis of m:!.. The action of these 
compounds is therefore specific for the S-phase of the cell cycle 
(Yarbo, 1968; Krakoff, 1975). 
Hydrazines : Procarbazine: 
The U-methylhydrazines were originally synthesised as potential 
monoamine oxidase inhibitors. Antineoplastic effects could, 
however, be demonstrated in a number of these compounds including 
procarbazine (Bollag, 1963). The mechanism of action has not, 
as yet, been determined with certainty although it is knovm to 
be metabolised to active compounds, (Weinkam an~ Shiba, 1978). 
HORl'::mmS 
That tumours deriving from certain tissues 3Xe honnone-
dependent has been ~own since the end of the last century. 
Following the observation that removal of endogenous production 
of hormones could induce re~issions in patients with certain 
disseminated cancers (Huggins and Hodges, 1941) there has been 
extensive study of exogenous hormonal therapy in selected tumourS. 
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Adrenocorticosteroids: 
Compounds such as prednisone have been extensively used in 
reating acute lymphoblastic leukaemia and malignant lymphomas 
because of their lympholytic effects and ability to suppress 
mitosis in lymphocytes. Effects of p:oednisone have been observed 
in the G1/S boundary (Ernst and Killman, 1970). 
Progestogens : Hydroxyprogesterone caOToate: 
The main role of this drug is i~ the chemotherapy of endometrical 
. 
carcinoma (Kelly and Baker, 1961). These compounds were initially 
examined because of the concept that carcinoma of the endometrium 
results from prolonged, unopposed overstimulation of oestrogen 
(Hertig and Somrners, 1949). 
Oestrogens : Diethylstilbestrol: 
\ The predominant use of oestrogens such as diethylstilbestrol 
is in the treatment of breast carcinoma in post-menopausal women 
and in metastatic prostratic, cancer. McGuire et ale (1975) has 
shown that these tuwours which have detectable oestrogen receptors 
. 
are more likely to respond to hormonal manipulation than those 
with no detectable oestrogen receptors. 
Andro&ens : Fluoxymesteron~: 
Androgens are used as palliative agents predominantly in 
pre-menopausal wooen who have responded to oopherectomy, but they 
are also useful beyond the menopause. 
" 
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SECTION 2 MET}!OTREXATE PHARMACOLOGY 
.. , 
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The Mechanism of Action of Methotrexate 
Methotrexate (r~TX). is an antimetabolite in that by virtue of 
chemical similarity interferes with the utilisation of a natural 
metabolite (Fig.4). It inhibits the enzyme dihydrofolate reductase 
. + (5,6,7,8 - tetrahydrofolate; NADP o~idoreductase. EC 1.5.1.3.) 
thereby blocking the conversion of dihydrofolate to tetrahydrafolate 
(FH4) (Venditti et al., 1960(a); Venditti el al., 1960(b); 
Venditti et al., 1960(c); B~rtino, 1)63). The folic acid vitamins 
/. serve as growth factors by controlling the metabolism of one carbon 
compounds, formate and forme.ldehyde. These are implicit in the 
biosynthesis of purines, pyrimidines and certain arrdno aCids, 
transformations generally occurring via co-enzymes 1erived from 
tetrahydrofolic acid FH4 (Fig.S ). 
The inhibition of dihydrofolate reductase has 10en described 
by Werkheiser (1961) as stoichometric, i.e. the inhibitor is so 
firmly bound to the enzyme ~hat, at levels inadequate to cause 
complete inhibition, by far the greater portion of the drug is 
enzyme bound. Also removal of the drug from the enzyme by dialysis 
against folic acid resulted in precisely equivalent reactivation 
of the enzyme. While the 'einding of meth()trex;!.te to the enzyme 
has been shown to be of a reversible and competitive type (Bertino, 
1974), the affinity of a partially purified dihydrofo1ate reductase 
for methotrexate was found to be about 100,000 times greater than 
for folic acid (Werkheiser, 1961). ~ndeed, in earlier work 
Werkheiser (1959) observed that some 80'~ of methotrexate activity 
remained in the supernatant after sucrose fractionation of treated 
rat liver, which could not be rerr.oved by prolonged dialysis. 
It now also seems likely that methotrexate can persist in tissues, 
in vivo, for long periods of time without under60ing biotransformation 
(Fountain et a1., 1953). Schrecker et al., (1960) suggested that 
the sustained antimetabolite ac+'ivity could be connected to the 
affini ty of drug-e~1.?;yrne binding. They observed that although 
incorporation into adenine in 1eu~ae~ic mice was inhibited over 
20 minutes equally by both methotrexate and its dich1oroderivative, 
the action of the former was sustained for longer than the less 
strongly bound derivative. 
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Goldman (1974) has reported observations in L-cell fibroblasts 
~hat saturation of high-affinity intracellular binding sites 
!:n1Y depressed the incorporation of deoxyuridine into DNA by 
27%. Further exposure of cells to methotrexate Vias necessary 
to increase inhibition of incorporai;.ton. There would appear 
to be a need to maintain levels above that necessary to saturate 
the enzy~~ for maximum effect. Rosenblatt et a1., (1978) have 
recently reported evidence of accunrulation of methotrexate 
polyglutamates by cultured human cells which was associated 
with prolonged inhibition of DlTA synthesis. They have demonstrated 
that polygluta~late synthesis is dependent on the presence of 
methotrexate in amounts greater than was necessary for inhibition 
of dihydrofolate reductase. 
Hoffbrand and Tripp (1972) have established, in normal human 
phytohaemaglutinin - transformed lymphocytes, that the most sensitive 
locus to depletion of folate coenzymes, due to methotrexate, is 
thymidylate biosynthesis (Fig.6 ). This'conclusion was based on 
'the observed imbah:~ced nucleic acid synthesis :mch that DNA 
biosynthesis was inhibited to a much greater extent than that of 
RNA. On the basis of this mechanism methotrexate would be expected 
to be cell cycle specific, acting predominantly in the S-phase. 
There is considerable evidence that methotrexate can indeed delay 
the passage from G1 - to S-phase and arrest the cycle in S-phase 
(Rueckert and fuueller, 1960; Ernst a~d Killman, 1971; Tobey and 
Crissman, 1972; l;:auer, 1975). Ernst and Killman (1971) have reported 
-2 that dos~ 1 mg. m could arrest leukaemic myelob1asts in the S-phase 
for about 20 hours but had no direct influence on cells in G1 , ~~ 
or }.I-phase. Mauer (1975) has shown that higher doses 00 mg. m ) 
can arrest human myeloblasts in the S-phase fo~ a much longer period, 
exceeding 48 hours, and also slow entry from G1 into S-phase. 
Folic acid coenzymes are a130 required for the biosynthesis 
of certain amino a..:~.ds. The interconversion of glycine and serine 
has been extensively studied and the involvement of tetrahydrofolate 
1s well established (Deodhar and Sakami, 1953; Blakley, 1954; 
Alexander and Greenberg, 1955; Jaenicke~ 1955). 
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~imilarlY the involvement of tetrahydrofolate in the biosynthesis of methionine from homocysteine has been demonstrated (Nakao and Greenberg, 1955). Bleyer (1977) has pointed out that by preventing 
amino-acid interconversions rnethotrexate may also inhibit protein 
synthesisand may be the mechanism by which high-dose methotrexate 
can arrest cells in the later stages of the S-phase. There is also 
some evidence to sugGest that reduced rolates are necessary for the 
N- and 0-methy1ation of biopenic amiI.'.es (Banerj ee and Snyder, 1973; 
Lauduron, 1972). The effect of methotrexate on these systems has 
not, however, been assessed. 
Methotrexate has been der.1onstrated to med.iate an effect at 
other metabolic sites. In human lymph01lastic cult"red cells of 
the L1210 line these other sites of action include ~nhlbition of 
I thyroidy1ate synthetase and serine hydroxymethy1tran8ieraee 
(Niethammer and Jackson, 1975). Jackson and Niethammer (1977) 
have, however, dismissed the inhibition of serine hydroxmethyl-
transferase as not heing significant, since their results 
indicate the inhibition is too weak. Further, they suggest that 
the inhibition of thymidy1ate synthetase would only be effective 
in the highly drug resistai4t cells with {!l.'eatly elevated dihydro-
folate reductase where free intracellular methotrexate can accumulate 
to sufficient levels to exert significant inhibition. 
There have also been a number of reports on the effect of 
. . 
methotrexate on the glycolytic enzymes and the metabolic energy state 
of cells. It has been kno~n since the reports of Warburg 
(1930), that glycolysis is notably enhanced in cancer cells. 
Desoize et al., (1978) have studied the induced alteration of 
glycolysis in L1210 cells in vivn with non-lethal doses of 
methotrexate. They found that glucose uptake i~creased and a 
significant enhancement of key glycolytic enzymes (pyruvate kinase, 
fructose - 1,6- diphosphate aldclase). Also an increase in ATP 
concentration was o~served to the extent of 2.5 times control 
values. The results of these workers would suggest a specific 
induction of key enzymes of glycolysis, but they offer no expl~~ation 
why glycolysis is not inhibited by the intracellular ATP accumulation. 
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~aminSkaS and Nussey (1978) used Ehrlich ascites carcinoma cells in their tissue culture studies, which are kno~n to be dependent on glycolysis for generation of metabolic energy in the form of ATP. 
I 
At growth inhibiting concentrations of methotrexate they observed 
an inhibition of glycolysis and a del~rease in adenylate pools 
which could be overcome by either hypoxanthine or thymidine. 
Since the effect on cell viability were also found to be somewhat 
dependent on the concentrat~on of g:LUcose, they concluded that a 
major cytotoxic effect of MTX appeared to be due to an energy-
depleted state. They further suggested that the pote~tiation of 
MTX effect by hypoglycaemia and the antagonism of hyperglycaemia 
may also have therapeutic implications. 
Inhibition of transport of reduced folates by methotrexate 
I may also playa positive role in its cytoxicity. In leukaemia 
L1210 cells the same transport mechanism has been reported to be 
responsible for the uptake of 5- methyltctrahydrofolate (5- Me FH4). 
citrovorum factor en.F.) and MTX (Nahas et al., 1972; Rader et al., 
1974). Since these compounds compete with each other, the effect 
of MTX in limiting the uptake of these reduced folates should 
augment the principal activn on dihydrof~late ~eductase. By virtue 
of the similar transport specificities it might be feasible to 
exploit carrier mediated transport mechanisms to induce selective 
tumour deficiencies in folate co-factors. Nahas and Bertino (1970) 
~ave already shown that 2,4 - diamino derivatives with a methyl 
group on N-2- position, are poor inhibitors of dihydrofolate 
. , 
reductase, because of steric interference, but are good inhibitors 
of transport. 
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Metabolism of Methotrexate I A partially purified enzyme from rabbit liver which catalysed 
Ithe 7-hydroxylation of MTX was originally described by Johns et al., 
(1964). They referred to this enzyme as methotrexate oxidase but 
it was later shown to be identical tCI aldehyde oxidase (Johns et al., 
1965) which was first described by Knox (1946) and later by 
Rajagopalan (1962). Johns and Loo (1967) confirmed that oxidation 
by this enzyme occurred onl~ on the ,-position to form the 
7-hydroxymethotrexate (7-0HMTX) metabolite (Fig. 7). 
This metabolite remained undetected at conventional dose 
levels and led to the erronious conclusion that methotrexate was 
not metabolised to any significant extent in man, a~1 was excreted 
un-changed (Freeman, 1958; Johns et al., 1964; IIend~rson et al., 
\1965). Recently it has been identified in urine after high doses 
of MTX (Jacobs et al., 1976). The aldehyde oxidase capable of 
this bio-transformation has been found in human liver but not in 
kidney (Jacobs et al., 1976). These workers have also quantified 
. 
the amount of metabolite in urine, and have shown that in early 
-1 . time intervals after intravenous MTX (5-200 mg. Kg l.nfusion 
over 6h) the excretion of fu~tabolite constitutes from 0.7 - 9.6% 
of total drug excreted, whereas at later times (18 - 24h), it can 
- be as much as 7 - 30%. Johns and Loo (1967) have shown, using a 
partially purified preparation of dihydrofolate reductase from 
L1210 mouse leukaemia cells (Bertino et al., 1964), that 7-0H 
MTX is two orders of magnitude less effective as an inhibitor 
than' is Ji.TX. 
It has ~lso been proposed that MTX is metabolised by int€stina1 
bacteria. Zahaska et a1., (1969). reported that significant amounts 
of MTX metabolites are present in both urine an.:! faeces of mice 
and rats after intraperitoneal administrations. Since the amounts 
of these metabolites were significantly reduced in germ-free mice 
and in mice pretrea+'I';d with neomycin, it VIas considered likely 
that intestinal bacteria were responsible for the biotr~~sformation. 
Valerino et al., (1972), have made an intensive study of the 
metabolism of MTX by intestinal flora. 
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CH3 (CH2) I 2 
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The structure of 7-Hydroxymethotrexate (7-0FJ~TX) 
r: 
incubating }lTX wi th caecal con ten ts of mice they were able to 
emonstrate at least three metabolites. T.rle principal metabolite 
as identified as 4-amino - 4-deoxy - N,10 - mcthylpteroic acid 
I 
'(APA), and it could be recovered from urine and fa.eces of mice 
after intraperi toneal injection. Th'~ :netaboli te "as detcnnined 
to be a moderate inhibitor of dihydrofolate reductace with a 
similar affini ty to 7-0H-HTX, but was considerably less toxic than 
MTX in mice. It could also !'Lct as a s'J.bstrate for aldehyde 
oxidase yielding 4-amino - 4-deoxy - 7-'r.ydroxy - N,10 - methylpteroic 
acid (7-0H-APA). A metabolit9 has been observed, in small &~ounts, 
in hUman urine with elution characteristics on DEAE cellulooe 
similar to this pteroic derivative (Johns and Valeri~', 1971; 
Huffman et ale, 1973). A number of ",orkers have reported that 
imetaboli tes account for less' than 10% of the total adrl:.nistered 
dose if the drug is gi ven intrav~nously at 30 mg. m-2 (Anderson 
et al., 1970; Huffman et al., 1973; "'an et al., 1974). However, 
I 
if this same dose "las 6i ven orally as much as 35~~ may be excreted 
'as metabolites (\,I/an et al., 1974). 
Polygluta~ate derivatives have also been founc in h~~an liver 
(Jacobs et ale, 1975). ROS':::lblatt et ale, (1978), have examined 
the accumulation of lITX polyglu tam a tea in cuI tured hu.'nan fibroblastl:: 
and obtained evidence that the metaboli te may be responsi'ble, 2.t 
least in part, for prolonged inhibi tion of DNA synthesis. 
40 
Jiochemical Resistance to fiTethotrexate 
I The term 'resistance' describes a variety of biochemical and 
pharmacological phenomena. 'Natural resistance' may be defined 
as lack of tumour response to a give~ drug regimen despite significant 
host toxicity, and is often referred to simply as insensitivity. 
The emerge-rIce durin£; or after treatment of a cell population 
that is less sensitive to the drug than was the original population 
is kno~n as 'acquired resistance'. Although the therapeutic 
history of the cells involved is different in cases of natural 
resistance and ~"cquired resistance, the types of biochellLi.cal 
mechanisms responsible for this failure to respond to dl~g 
treatment are· fundamentally the same. 
Resistance to r,:TX therapy has been attributed to one or more 
of three mechanisms:-
1) Decreased ability to transport the drug across the 
cell membrane. 
2) Synthesis 0~ more dihydrcfolate reduct?~e and increased 
cellular activity. 
3) Synthesis of an aberrant dihydrofolate reductase insensitive 
to methotrexate due to a change in enzyme affinity for 
the drug. 
There is extensive evidence in the literature that both 
n"atura1 and acquired resistance may be due to failure of the target 
cells to accumulate sufficient r.:TX. iiiost of the model systems 
have employed leukaemic cells invitro and attempted comparison 
with response in vivo (Kessel et al., 1965; Kessel et al., 1968). 
Ryser and Shen (1978) appraised tne use of 1:TX conjugated to 
poly-(L-Lysine) in overcoming transport difficulties and therefore 
drug resistance in culture Chinese hamster ovary cells. The 
conjugate appeared to be taken ~~ by pinocytosis (Shen and Ryser, 
1978; Ryser et a1., 1978) and although the conjugate itself is 
not active in inhibiting dihydrcfolate reductase, it has been shOun 
by these workers to be degraded within the cell releasing native 
methotrexate. They have also shown that absorption by this method 
is comparable to unconjugated MTX in cells with proficient 
transport capability. " 
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Several reports on the nature of the increase in enzyme 
concentration and the mechanism of the increase in activity have 
. appeared. Moderately resistant mutants of L1210 mouse leukaemia 
i cells shovling a seven-fold increase in dihydrofo1ate reductase 
activity were also sho~~ to synthes~E.e the enzyme at seven times 
the normal rate, but to degrade the enzyme at the normal rate 
(Jackson and Huennekens, (1973); Huennekens et a1., 1973; Jackson 
et a1., 1975). A highly resistant L~210 mutant has also been 
observed with an enzyme level eighty times higher than expected, 
which not only synthesised the enzyme at a greater rate but also 
degraded it slower than normal (Jackson and Huennekas, 1973). 
Further characterisation of this enzyme showed that it had different 
electrophoretic properties from normal L1210 enzym~ and it bo·and 
I NADPH with greater affinity (Jackson et al., 1973; N~ethammer et al •• 
1973). An increase in total dihydrofolate reductase with altered 
properties has also been reported in a mouse leukaemia L4946 
Bubline (Blumenthal and Greenberg, 1970). 
Some studies have indicated that varying intrinsio sensitivity 
to MTX of different mammalian cell types may oorrelate with the 
affini ty of the binding of !.'!TX by the cell' s dihydrofolate reductase 
(Harrap et a1., 1971; Jackson et a1., 1976). Clear differences 
in the natural resistance between Yoshida sarcoma and L1210 
leukaemia cells have been demonstrated, which correlated with t~e 
affinity of the enzyme drug binding (Jackson. 1976). Despite the 
fact that the two cell lines had similar activities of dihydrofolate 
reductase and similar rates of membrane transport of MTX, the 
Yoshida sarcoma cells were seventy times more resistant than 
the leukaemia cells and the enzyme from the L1210 leukaemia cells 
bound lilTX twenty-five times more tightly. 
Jackson and Niethammer (1977) have also described the phenomenon 
-
of acquired resistance in human lymphoblastoid ~e1ls resulting from 
altered kinetic pr0r.erties of the reductase. They observed that 
the affinity for ~TX was reduced by fifty-fold, which at low UTI 
concentrations would provide these cells with a selective advantage. 
However, they point out that at high intracellular concentrations of 
MTX these cells would be compromised, since it would be expected 
that free MTX could accumulate to sufficient levels to exert 
significant inhibition of thymidylate synthetase. 
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Methotrexate Toxicity I Methotrexate chemotherapy is limited by the overt toxicity 
rhiCh it can promote. The most commonly encountered toxicities 
are myelosuppression; gastrointestinal mucositis and hepatitis. 
Other toxic reactions generally depLnd on the regimen imposed on 
the patient. These are broadly outlined in Table. 2 
Neph~otoxicitY,which has been observed with high dose therapy 
(Condi t et a1., 1969) is particularl~' vexing since MTX can be 
retained due to the renal' dysfunction and further toxicity may 
I ensue (Frei III, 1976). ' 
Chemical c.rachnoiditis associated with intrathecal r.'ITX is a 
distressing acute syndrome characterised by headache, backache, 
vomi ting, fever, meningismus and a cerebrospinal-fL·:'d pleiocytosis 
\(Mott et al., 1972). Motor dysfunction of the brain or spinal 
column is occasionally manifest, and may include paraplegia, 
quadriplegia, cerebellar dysfunction, cranial nerve palsies and 
. 
seizures (Gagliano and Obstanzi, 1976; Weiss et aI, 1974; Weiss 
and Kahn, 1978). Si~Ce these neurological syndlomes occur in the 
presence of elevated C.S.P.'concentrations of MTX (Weiss and Kahn, 
1978; Bleyer et al., 1973), it has been s~ggested that frequent 
monitoring of C.S.F. drug concentrations may be predictive of 
serious neurotoxicity, and drug dosage and drug interval could be 
adjusted accordingly (Beyer et al., 1973). However, neither 
the minimal effective concentration o! MTX in C.S.F. nor the toxic 
concentration is known (Shapiro et al., 1975) and therefore can 
not serve as a safe guide in treatment or prevention of neurological 
complica tions. 
A necrotising demyelinating leukoencephalopathy has also been 
well described (Bresnan et al., 1972; Kay et a1., 1972; Shapiro, 
1973; Hendin et al., 1974; Norrell et al., 1974; Smith, 1975; 
Price and Jamieson, 1975) and is 'r-eflected in t}:.;) clinical pattern 
of progressive neur.)Jogical deterioration (evolving into severe 
dementia, dysarthria, ataxia, spasticity, seizures and coma). 
Price and Jamieson (1975) found a direct correlation between the 
incidence of leukoencephalopathy and the cumulative dose of KTX. 
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RBG Ilif EN 
Ironic Low Dose 
-
systemic Administration 
irrhosi.s/focal necrosis 
ntestinal pneumonitis 
Osteoporosis 
Alopecia 
Immunosuppression 
Pulmonary reaction 
High Dose systemic Administration 
Renal dysfunction 
. 
Vomi tine 
Acute desquamous dermatitis 
Immunosuppression 
Reae ti va ti on of solar derma ti ti s 
Vasculi tis of hands and feet 
Conjunctivi tis 
Intrathecal Administration 
Chemi cal arachnoi di ti s 
Motor dysfunction 
Leukoencephalopathy 
Seizures 
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Table 2 Common manifestations of methotrexate toxici ty. 
: The maximum tolerated dose of MTX varies widely from person 
I
to person, e.g., Hanser et al., (1971), have reported that this 
. -2 
can vary from 80-900 mg. m • Further, the study of r.:TX pharma-
. cokinetics has been able to assert the role not only of concentration, 
but also the dependence of drug exrusure time to toxicity. If the 
concentration/time threshold is exceeded toxicity will ensue. 
The threB:l0ld for a few tissues have been estimated and found to be 
profoundly different. For bone marrow and gastrointestinal 
epi thelium the thresholds a'ppear to be about 2 x 10-8 M and 42 hours 
(Levitt et al., 1973; Young and Chabner, 1973), and for lung 
(Sostman et al~, 197G) and liver (Podurgiel et al., 1973) the 
plasma concentration threshold is similarly relatively low, beine 
10-8 - 10-7M; The concentration threshold for kidl'lpy is probably 
dependen~ on urine pH, but appears to be quite high at about 
10-4M (Stoller et al., 1975). Skin and brain also appear to have 
a relatively high tolerance to intravenous ~TX, with a concentration 
threshold in the region of 10-5M (Weinstein, 1977). Pulmonary 
'toxicity on the otb~r hand has been obtru.ned af~er weeks to months 
of oral therapy and rarely with intermittent high-dose intravenous 
therapy (Nesbit et al., 1976; Sostman et al., 1976; Viall et al., 1977). 
The severity of toxicity also seems to be directly proportional 
to the duration of MTX exposure beyond the time threshold, and less 
dependent on the magnitude of N.TX elevation above extracellular 
concentration threshold (Goldie et aJ., 1972; Chabner and Young, 
1973) • 
Over the past few years a number of compounds have been 
examined in an attempt to increase host tolerance without loss 
of therapeutic effect of MTX. The use of citrovorum factor (folinic 
acid; 5-formyltetrahydrofolic acid) (Fig. 8) iF. now well established 
and is obligatory in high dose MTX regimens. The first suggestion 
that therapeutic effectiveness ~~.ght be increasp.d by administering 
high doses of 1.TX v • .: th ci trovorum factor was made by Goldin et al., 
(1966) in leukaemic mice. The rational for high dose therapylis 
to produce ser~m levels of the drug high enough to permit facilitated 
diffusion into tumour cells deficient in transport sites, and 
subsequently permit the accumulation of sufficient MTX to saturate 
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The structure of citrovorum factor 
(C.F., folinic acid, 5-formyltetrahydrofolic acid) 
all the high affinity sites on dihydrofolate reductase, and ideally 
!enough free I.iTX to bind to low 8ffini ty sites thus hopefully . circumventing the excess productj.on of dihydrofolate reductase 
'by the resistant cell. It has been demonstrated that when citrovorum 
factor is given after MTX it can pre,·ent much of the toxicity 
without reversing .the oncolytic effect of the drug (Levitt, et al., 
1973; Bender, 1975(a);Bonder, 1975(b». It has been possible to 
show that citrovorum factor may pref~rentially rescue normal cells 
(Frei et al., 1975) and also that those tumour cells which are 
resistant to f.iTX because of a defective transport system are also 
resistant to citrovorum factor 'rescue' since both drugs share the 
same transport system (Goldman, 1971; Nixon and Ber~ino 1972). 
Bender (1975) has indicated three basic elemen~s of citrovorum 
I factor rescue:-
1) The interval between the flITX dose and folinic acid 
administration. 
., 
2) The total dose of folinic acid administ.ered. 
3) The period over which the dose is adminlstered. 
Alteration of these parameters may significantly alter the 
therapeutic index of the d~~l drug administration. Pharmacologically 
citrovorum factor by-passes the MTX induced inhibition of dihydrofolate 
reductase since it can enter the folate cycle directly \vithout 
prior reduction by this enzyme(Fig.9), Mead et aI" (1963) have 
shown that tetrahydrofolate and 5-metnyltetrahydrofolate are also 
capable of reversing the toxicity and antileukaemic effect of 
~TX in mice. Blair and Searle (1970) have also demonstrated that 
5-methyltetrahydrofolate can protect against the lethal effects of 
repeated injections of li.TI to mir.P., and further that this protection 
did not differ greatly from that obtained using citrovorum factor. 
This is perhaps not surprising since Blakely (1969) has sho.m that 
5-methyltetrahydrofolic acid is the main storage form of folate3 
in the bod.y. More :rocently Kishuik et a1., (1977), have substantiated 
that other reduced folates can prevent 11:TX activity in mice. 
They have observed that dl, L-5, 10-methylenetetrahydrofolate, 1, 
L-5, 10-methylenetetrahydrofolate, dl - 5-methyltetrahydrofolate 
and dihydrofolate all show activity. However, they found d, 1-5, 
10-mcthylenetetrahydrofolate to be inert. 
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!i Another potentially important approach to toxicity rescue is not to restore the reduced co-factor pool but to provide the , end products of the co-factor dependent reactions. The ability 
of thymidine to reverse the impairment of DNA sj~thesis was first 
demonstrated by Killman (1964) in pernicious anaemia. Whereas 
citrcvorum factor.relieves the cell frOm the three major effects 
of MTX (inhibition of DNA, RNA and protein synthesis), thymidine 
selectively rescues cells from inhi:'".tion of DNA synthesis. 
It has been reported that in murine systems, normal marrow and 
gut cells in vivo can generally be protected by thymi.dine alone 
(Seman and Grindley, 1976; Tattersall et al., 1975), whereas some 
tumours requ~re a source of purines in addition to ~hymidine 
(Borsa and Whitmore, 1969; Hryniuk et al., 1975). It is t~erefore 
\ possible that rescue with thymidine may protect norn:e-,l host 
tissues while leaving turnour cells partially unprotected which 
may result in selective cell kill and an improvement in the 
. therapeutic index 0: r.:TX. Thymidine has also r :'en shown to have 
potential in the protection against MTX toxicity in humans 
(Ensminger and Frei III, 1Q77; Howell at al., 1978). 
If the reduced folate stores in the ~ody are depleted it may 
therefore influence other me~hyl transfers, such as those occurring 
via s-adenosyIoethionine which is required for the synthesis of 
choline. Since choline is the major lipotropic compound in the 
body, a deficiency could lead to impaired transport of fat from 
the liver resulting in fatty metamorphosis.· Custer et al., (1976) 
have demonstrated that hepatic lesions comparable to that in m~~ 
can be induced in rats in which signs of nucleic acid deprivation 
could also be clearly observed. With this observation as the basis 
of a model, Turna et al., (1975) and Freeman-NaI'rod, (1977) 
have sho\'m that choline provides protection to the lives of rats 
after prolonged treatment with kl'X. Freeman-NE..t':!'od, (1977) 
also indicated that the therapeutic effects of ~TX via inhibition 
of nucleic acid synthesis did not seem to be impaired by choline 
rescue. 
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t,urther, their results support the above hypothesis that MTX inhibits biosynthesis of choline, at least in rats, leading to fatty metamorphosis and other subsequent lesions in the liver. 
r\~ethionine has also been shown to provide some protection against 
hepatoxicity (Yourtree et al., 1971). 
It is also possible to rescue patients by lowering the plasma 
levels of MTX. A method which has been shown to have potential is 
infusing carboxypeptidase -. G 1 (Chatn'.er et a1., 1912). This 
enzyme inactivates methotrexate by molecular cleavage thereby 
effectively lowering the plasma concentration of available drug. 
" 
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A BRIEF HISTORY ArID CURRENT USAGE OF rllETHOTREXATE 
Vfuile the concept of specific drugs active against cancer 
goes back to the work of Paul Erhlich in the latter part of last 
century, modern cancer chemotherapy had its beginnings in the 
1940's. The observation that oestr~gens could induce remissions 
in some o~ses of prostate cancer (Huggins and Hodges, 1941) was 
followed by the use of nitrogen mustard to induce remissions in 
malignant lymphoma (Gilman and Phil:!.:"ps, 1946). The introduction 
of folic acid antagonists rapidly followed. 
The first antifolates to be synthesised were aminopterin 
(Seege.r et a1., 1947) and MTX (Seeger et a1., 1949), and although 
various other analogues with antineoplastic effects have been 
prepared (Snuth et al., 1948) these remain the agents of greatest 
intel'est. These folic acid antagonists (methotrexatd and 
aminopterin) have been the subject of extensive laboratory and 
clinical investigations. 
Aminopterin Wr..b originally shown to inhibi~ the growth of 
Streptococcus faecalis (Seeger et al., 1947; Olesen et al., 1948) 
and later to retard the gr~'I'{th of transplanted sarcoma in mice 
(Schoenbach et al., 1949). Great interest was focused on antifolates, 
particularly after the demonstration, in 1948, that aminopterin 
was capable of producing temporary remissions in acute leukaemia 
in children (Farber et al., 1948). Indications that folic acid 
could reverse the growth inhibitory ~ffects of aminopterin-in 
mice (Franklin et al., 1948), rat and chick (Olsen et al., 1948) 
was observed, and Goldin et al., (1949) demonstrated that folic 
acid was also capable of reversj~g arriinopterin-induced inhibition 
of Sarcoma 180. Folic acid was also found to influence the anti-
leukaemic effectiveness of 11TX (Burcl:enal et a1., 1949) and some 
time later folinic acid was sho~ to have a similar protective 
effect (Burchenal et al., 1950). Increased att:ntion was directed 
towards r.:TX when Goldin et al., (1955) found that it was more 
effective in the treatment of L1210 leukaemia than was a~inopterin. 
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! Methotrexate has since found broad usage in the treatment of a large number of malignancies. Both experimental and clinical studies have shown that both the dose and schedule of administration 
may have a:prdfound influence on efficacy. Both Goldin et al., 
(1956) and Skipper, et al., (1957) nave suggested that the ability 
of liITX to totally eradicate a tumour population is related to the 
dose of drug that can be employed. Although the dose of drug is 
limited by overt toxicity, the antaG~nism of such effects with 
, 
folinic acid has permitted greater manipulation of the basic 
I regimens. 
Three bas!c treatment schedules are currently in use:-
1) Conventional low-dosage without folinic actd 
2) High-dosage with folinic acid 
3) Intrathecal MTX therapy 
-2 Methotrexate was initially aQministered in doses of 1 to 5 IDgm 
until the early 1960's when intermittent parenteral doses of 
-2 t 30 mg. m twice weekly was introduced. This regimen was found to 
'be more effective fur maintenance therapy of acute childhood 
leukaemia (Anderson et al., 1970; Selawry and Hansen, 1965). 
Intermittent low dose ther~,y has proved -::0 be highly effective 
against a number of malignant diseases including choriocarcinoma, 
acute lymphocyte leukaemia and breast carcinoma. 
In high-dose regimens with folinic acid rescue, MTX is either 
administered by infusion over a short time period of 4 to 6 h. or 
over longer times of 20 to 42 h. (Penta, 1975). In the former 
infusion regimen an attempt is made to maximise intracellul~r 
drug levels in poorly perfused or transport resist~t tumours 
(Anderson et a1., 1970). 
The rationale behind the longer infusion is to encompass 
more of the cell-cycle of the neoplastic cells and to reach an 
equilibrium between plasma conc~ntration and th~ levels of drug in 
intersti tial and int-race11uler compartments. Concentrations. 
-1 
ranging from 50 mg Kg to gram quantities have been employed in 
high dosage regime~s. 
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Folinic acid rescue is generally initiated between 24 h. and 
42 h. after the start of high-dose methotrexate therapy. 
Significant toxicity may occur if folinic acid 'rescue' is delayed 
I or if discontinued before the plasma MTX level falls below the 
concentration threshold of vulnerabln tissues. The serum r;:TX 
concentration 10 a useful index of when folinic acid 'rescue' can 
be safely wi thdravm (Isa.coff et al., 1976; Nirenberg et a1., 1976; 
Stoller et al., 1976). Serum conce~~rations can also be of use in 
determining folinic acid r~scue dosage (Frei III, 1976; Isacoff et al., 
1976; Jacobs and Dihettuso, 1977). Alkalinisation of the urine 
in patients receiving high doses of ~iTX is contmon practise and is 
useful in preventing nepb.rotoxici ty and wi thou·t altering myelo-
suppression (Patman et a1., 1976; Sadoff and Ri ttrnb.-.l, 1976). 
Such high-dose infusion regimens have been succ~ssfu1 in 
promoting responses in a numbe~· of otherwise resistant diseases, 
e.g, malignant 1ymphorr:a (Djerossi and Kim, 1976; Pittnan al'ld Frei III 
1 
1977) and epidermoid carcinoma of the head and neck (Khandekar 
'and Vlo1ff, 1977; Le~itt et al., 1973). 
Penetration of MTX into the cerobrospinal fluid (C.S.F.) is 
poor although objective re~~onses in medu~lobla~toma and gliomas 
are obtained from high-dose infusions (Pittman et a1., 1975; 
Kim et al., 1976; Rosen et a1., 1977). Intrathecal therapy is an 
important therapeutic modality recently explored for the treatment 
of leukaemia and lymphoma (Bagshawe ct a1., 1969;) the major 
limitation being neurotoxicity. The conventional dose is 12 mg m-2 
but a modified dosage schedule has been proposed (Bleyer, 1977). 
It was observed that C.S.F. levels of MTX in patients receiving the 
conventional dose are inversely proportional to age. Bleycr (1977) 
therfore proposed that children under one year of age should 
receive 6 mg. and that the dose should increase by 2 mg. for each 
year until three years of age ana over, when all patients should 
be given the same C.O;3C of 12 mg. 
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SECTION 3 , PROTEIN BINDING OF DRUGS 
51 
• 
PROT En; BINDING OF DRUGS I Drugs are carried from their site of injection or absorption fO different sites within the body by the circulating blood. Although 
'some drugs are simply dissolved in serum water, e.g. ethanol (Feller 
and Ie Petit, 1977), the great majority are associated with blood 
constituents such as albumin, globulins, and lipoproteins. 
. . 
Bennhold (1938) proposed that serum proteins constituted a specialised 
transport mechanism essential for thp distribution of endogenous 
substances. Extensive experimentation and examination of the binding 
of numerous compounds has indicated that serum albumin is the principle 
component in s€".'um to which drug molecules bind (Goldstein, 
1949; Meyer and Guttman, 1968). 
Almost every drug mediates its pharmacological -{.nfluence by 
linteracting with some macromolecule at particular sites in the body, 
such as specialised receptor sites, transport systems, membranes 
and enzymes. However, from the standpoint o·f direct therapeutic 
effect the sites of action on serum albumin have been termed 'silent 
receptors'. Nevertc~less, it is imperative that drug-protein inter-
actions be studied as anomalies therein could profoundly alter the 
elimination, distribution and activity of many drugs. 
Protein binding is defined as the reversible interaction between 
a small molecule and a macromolecule. It is analagous to the enzyme-
substrate interaction with the fundamental difference that the 
complex does not decompose to form ne~ products. Although this 
definition is assumed in virtually all binding studies, there remains 
the distinct possibility that a small amount of irreversible 
co-valent association may occur, e.g. Ron~~n and Zacchei (1967) 
have found evidence of some irreversible as well as revers"ible 
binding of ethacrynic acid to serum albumin in y';.tro. 
52 
I 
}.~ETHODS OF IJ:EASURIUG BOUND A:ID UNBOUND DRUGS 
Over twenty methods have been employed to study the protein 
binding of drugs. They can, however, be summerised into two 
broad categories. Horecker et al (1969) divided them 
into:-
1) equilibrium methods based upon measu.ring changes in ligand 
concentration as a result of the establishment of a 
binding equilibrium. 
2) direct measurement methods in which a property of the drug, 
protein, or complex may be examined during the binding 
process. 
This classification is based on the principles originally 
proposed by Goldstein (1949). 
I Chignell (1971) has categorised them according ~o:-
1) non-spectroscopic methods. 
2) spectroscopic methods. 
The first grou~ of both classifications inr.ludes tecrilliques 
such as equilibrium dialysis, ultrafiltration, ultracentrifugation, 
gel filtration, bioassay, electrophoresis, conductivity and osmotic 
pressure, The second grou~ includes some of the most complex methods 
such as, fluorescence spectroscopy, ultraviolet and visible 
absorption spectroscopy, optical rotatory dispersion, circular 
dichorisrn and nuclear magnetic resonance. 
Each of these methods has its advantages and limitations which 
are briefly summarised in Table. 3 
53 
~ .. 
': .. 
... ~ 
'.:. 
" : •.... : 
.. 
'. . . 
Advantages 
'. 
.'. Disadvantages 
. . 
Simple Ulltrafiltration Thermodinamically sound; Binding to membranes; equilibrium altered by' 
rapid; quantitative change in protein concentration .. 
'. 
No Donnan inequalitiesr Quantitation can be difficult; alteration of Ultracentrifugation quantitative equilibrium due to protein concentration chanee 
I 
I 
'.~ I 
Gel Filtration Thermodinamically sound; Dilution causing alteration of equilibrium due 
separation of binding proteins to protein concentration chanee 
Equilibrium Dialysis Thermodinam1cally sound; Donna.n inequalities; nonphysiolut;ical; l)os.:.;ible 
reproducible; quantitative bacterial contar.ir!iltio:l a.llc:.. ljrotein u.erlaturation 
Bioassay Historical interest only 
Electrophoresis Qualitative data; separation Quantification difficult; binding to support of binding proteins medium 
Conductivity Historical interest only 
Osmotic Pressure Historical interest only 
.. '~ 
'. 
. .. ~ 
;~ 
I 
: 
Qualitative and quantitative; Fluorescence Spectroscopy homogenious system 
Absorption Spectra; Sensitive; can detect 
Ultraviolet conformational changes; 
Visible homogenious .system 
Optical Rotatory 
Dispersion Can serve as a probe for 
binding site; qualitative or 
quantitative 
Circular Dichorism 
Nuclear l:agnetic Sensitive to changes in 
Resonance molecular geometry 
-.--~---- -----~-- .. ----.---~-- ----
Table :3 The advantages and disadvantages of the most commonly 
employed methods of studying protein binding. ";, 
.-;. 
";~ 
i, 
Some druBs may cause no spectral change; minor 
filter effects; changes not always due to 
drug/protein equilibrium 
Some drugs may cause no spectral change; need 
to compensate for absorbance of compound. 
I 
I 
Interpretation difficult; not always due to 
changes in association or dissociation of protein 
drug complex 
Interpretation difficult 
.~------ - .. 
'METHODS OF A~~AI,ySING BINDING DATA ! Goldstein (1949) indicated that expressing binding data simply as percentage bound is meaningless unless qualified by an indication Qf the unbound drug concentration at equilibrium. 
Even for those drugs where the per .. antage bound does not vary 
greatly over the therapeutic range, this method of expressing 
results is clearly unsatisfactory. A plot of the percentage 
bound drug against total drug conc~~tration can, however, pr0vide 
.. 
extreri:ely valuable information, since the percentage bound drug 
decreases with increase in total drug concentration. Therefore, 
if binding me~surements are made at a number of drug concentrations 
and if the concentration of the binding protein can be determined 
the following binding parameters can be estimated:, 
a) The number of classes of binding sites. 
b) The number of binding sites in each class, n1 , n2 etc., 
c) The association co~stant for each class, K1 , K2 etc., 
Knowledge of these parameters would characterise the binding 
'between drugs a~d ~roteins. It would enable a comparison to be 
made between the interaction of different drugs and also between 
data obtained for a parti("~lar drug by d:!.fferent methods of measuring 
bound and free drug. It would be very difficult to interpret a 
comparison based solely on the value of percentage bound. 
The reversible association can be described by the application 
of the law of Mass Action:-
" 
K1 (p) + (Df)~ = (PD) 
2 
where (p) = free protein c0ncentration 
(Df) = free drug concentration 
(PD) = drug-protein complex concentration. 
K1 :: rate constant for the forward reaction. 
K2 :: =-1.te constant for the backwal"d reaction. 
54 
)IAt equilibrium, the .aSSOciation constant for this reaction will be:-
_ k, _ (PD) _ .L 
, Ka - t; - (P)(Df) - Kd (dissociation constant) ••••••• , 
therefore (PD) = Ka (p) (Df) 
The quantity'r' defined as:-
r = 
= 
moles of' drug bound 
moles of protein 
(PD) 
(PD) + (P) 
substituting Ka (P) (Df) for (PD) from equation 2 
therefore r = 
= 
Ka (P) (Df) 
Ka (P)(Df) + (p) 
_ Ka (Df) 
i + Ka (Df) 
••••••••• 2 
• • • • • • • • •• :3 
This derivation is fo. one binding site, therefore if there 
are 'n' independent sites, a series of independent equations can 
be written and summated:-
r 
NKa (Df) 
+ r 2 + r3 + -------- rn = rtntal = '1 + Ka (Df) 
•••••••• 4 
Further, there are often more than one type of binding site, 
i.e. more than one class of binding si~e, for a particular dl~g 
on a given protein, each with it~ own association constant. 
This can be expressed in a more general form of equation 3:-
rtotal = 
n1 K, (Df) 
1 + K, (Df) + 
n2 K2 (D:f) 
I + K2 (Df) 
+ ni Ki (Df) 
1 + Ki (Df) •••••• 5 
which has the form of an hyperbola. Since (Df) and (PD) can be 
measured, rtotal can be calculated knowing the protein concentration •. 
In this form, therefore, the equation allows for the experimental 
determination of the binding parameters. 
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The equation can be rearranged in a number of different ways 
o facilitate a number of graphical expressions of the data. 
As mentioned above, the direct plot of r against (Df) is an 
hyperbola (Fig. 10). The equation is analogous to the Michaelis -
n 1 Menten equation. At the plateau r = ~, and when r = 2' Df = K • 
A satisfactory fitting of experimental data is difficult ~~d therefore 
accurate values for nand k will not be obtained. 
If both sides of equation 4 are inverted and rearranged to give:-
1 1 1 
r = + n rilC (Df) 
1 1 
a plot of r vs (Df) should produce a straight li]"l.':' (Fig. 10) 
analogous to the Lineweaver - Burk plot. In this plot the slope 
1= Lk and the y intercept = 1. Al thoueh this plot cat. give a good 
n n 
statistical fit it has the disadvantage of heavily weighting data 
points obtained at low (D) which can lead to misinterpretations 
of binding behaviour. 
A straight line plot of a different type used by Scatchard 
(1949) is given by the following form of the bi~ding equation:-
r 
(Df) = nRn - rKa 
in which (~f) is plotted against r. The number if bindine sites en) 
is determined from the intercept on the abcissa and nK (the product 
of tt.e association constant and the number of binding sites) from 
the intercept on the ordinate. This method places less stress on 
'r' values at low (Df) giving a more even distribution to the data 
points. Curvilinear plots are often obtained with this method, (Fig. 11), 
indicating more than one class of binding sites. These curves 
can be fitted as the summation of two or more st::'aight lines, 
each due to a different class of binding sites. 
Sandberg and Rosenthal (1967) have discussed the treatment of 
binding .data when tr. p nature and concentration of the protein is 
not y,nown. The recommended plot is based on the following 
rearrangement of equation 4:-
~ = n K(Pt) - K(Db) (Df) 
where (Pt) = total binding protein concentration 
(Db) = concentration of bound drug. 
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Figure 10 Different methods for the graphical representation 
of protein binding data. 
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Figure 11 Sea tchard representation of protein binding. 
a. One class of binding sites 
·b. Two classes of binding sites 
~ 
f: 
plot of (Df) vs (Db) is independent of protein concentration 
and allows estimation of K from the slope. This plot will also 
be curved if more than one protein or class of binding sites are 
involved. This treatment is particularly useful when studying 
mixed protein systems, such as serum or plasma, when it is not 
known to which fraction the drug binds. 
In all the above mathematical treatments of drug binding 
data it is assumed that the. binding ~.i tes of a given class are 
independent of each other. While this may be true for many drugs, 
there are examples of co-operativity, e.g. the binding of oxygen 
by haerr.og1obin. Scatchard et ale (1950) have devised a rather 
complex expr~ssion to overcome non-ideality due to ~lectrostatic 
interaction in the binding of charged molecules. however, most 
\ workers accept that it is adequate to report uncorrel~ted data. 
-1 
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of Protein Bindin 
ubiquitous nature of protein binding has been recognised 
and presumed to be a determining factor in drug disposition and 
effect (Martin, 1965; Levy, 1976; BOJker and Darcy, 1973i Schoeman 
and Azarnoff, 1975). Most workers now accept that drug disposition 
and pharmacological activity is a function of unbound drug rather 
than total plasma levels. 
There is also clear evidence that the distribution of certain 
drugs is controlled, at lea&t partly, by protein binding. Studies 
in epileptic patients has indicated that the ratio of the'C.S.F. 
to plasma concentrations for diphenylhydantoin (Lun~ et al., 1972; 
Paxton et al., 1977; Hanghton et a1., 1975) phenobl::..cbita,l and 
primidone (Hanghton et al., 1975) in the steady-stato are about 
equal to their unbound concentrations in plasma. Further, there 
is a close correlation between the unbound drug in plasma and the 
concentration in erythrocytes (Borandy et al., 1973) and saliva 
(Svensmark et al., 1960) over a wide range in plasma concentrations. 
Also the steady state concentrations of nortriptyline in C.S.F. 
is only 3-11% of the stead/-state plasma levels, which agrees 
well with the unbound plasma levels of about 6% (Borga et al., 1969). 
The penetration of ampicillin and cloxacillin into synovial 
fluid of patients with osteoarthritis or rheumatoid arthritis 
has been examined (Howell et al., 1912). Both drugs diffused 
rapidly into synovial fluid, but the concentration attained 
differed appreciably and appeared to be related to the unbound 
concentration in plasma. Ampicillin is not highly bound and the 
concentrations in synovial fluio were similar to the total plasma 
level. Cloxicillin is about 95$~ protein boun~, and unbound levels 
in plasma and synovial fluid were similar. 
Linear correlations betwe6~ the ratio of &ne concentration in 
erythrocytes to thQ'~ in plasma and the percentage unbound drug in 
plasma for propranolol (Evans et al., 1973) and quinidine (Hughes 
et al., 1975) has been observed. 
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' Of the first demonstrations of a relationship between unbound 
rug and pharmacological activity were the experiments of Anton, 
/(1960). He studied the effect that sulphonamide binding to plasma 
proteins had on antibacterial activity using an equilibrium dialysis 
technique and demonstrated that only mbound dia1ysib1e drug 
mediated an effect~ However, these were invitro experiments and 
the extrapolation to the in-vivo situation is tenuous. More convincing 
evidence was initially obtained in t~~3 work of Taylor, et al., (1954), 
who reported that recovery from thiopental anaesthesia was directly 
related to the decline of unbowld drug in the blood of nephrectomised 
rabbits. 
Most of the evidence for the pharmacological effect being due 
to unbound drug has been obtained by observing the l~sponse to 
ia1terations of protein binding induced by disease. ~~any patho-
physiological states will cause a change of plasma alb~~n 
concentrations as a result of modifications in the synthesis rate, 
, 
catabolic rate. or the distribution between the extravascular 
. 
and intravascular spaces. Most disease states cause a lowering 
of plasma albumin levels (Table 4 ). The extent to which a drug 
is protein bound depends on the concentra·~.ion of the drug. the 
association constant of the drug protein complex, th~ concentra·tions 
of the protein and the number of binding sites. These inter-
relationships are extremely complex, but there have been a number 
of reports shovdng the incidence of auverse drug effects is greater 
in patients with hypoa1buminaemia. 
Unwanted central nervous system depression in patients on 
diazepam occurs in about J% of patients with normal serum albumin 
levels. However, this can be as high as 9% in patients with lew 
albumin levels (Greenblatt and Kock-Weser, 1974.>. There is a close 
correlation between unbound diphenylhydantoin in plasma and 
concentrations in C.S.F. (Lund ~t a1., 1972; P~xton et a1., 1977). 
Hypoproteinaemia haq been reported to be associated with an 
increased incidence of adverse reactions to this drug in treated 
patients (Lunde et al •• 1970i Boston Collaborative Drug Surveillance 
Programme 1973). 
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A. Large Changes 
B. Small Changes 
. Disease State 
Liver Disease 
Renal Disease 
Burns 
Surgery 
Febrile Infections 
Prolonged Rest or 
Immobilisation 
Pregnancy or Women on 
Oral Contraceptives 
Neoplastic Disease 
Gastrointertinal Tract 
Disease 
Chronic Bronchitis 
Cystic Fibrosis 
Ageing 
~ ; 
Reference 
Skrede et al., 
Jensen et al., 
Birke et al., 
Casten et al., 
Casey et al., 
Plantin et al., 
Gleichmann et al., 
Midler et al., 
Steinfeld, 
Cas ey et a1., 
Rothschild et al., 
Bonomo and d'Addabbo 
Strober et al., 
Wallace and Whiting 
Table 4 Disease states and physiological conditions causing a reduction in 
serum albumin concentration 
-, 
,.1" 
.--., 
A 
1975 
1967 
1960 
1943 
1973 
1971 
1973 
1950 
1960 
1973 
1972 
1964 
1969 
1974 
, .~ .. 
,'. 
,', 
':~ ... '. 
.' .:" 
" 
....... 
; ........ . 
',-
. - . 
) 
Patients with impaired renal function have a high incidence 
of adverse drug reactions. Adreason, (1973) has demonstrated 
decreased binding of salicyclic acid, acetylsalicylic acid, 
phenylbutazone, phenytoin, thiopental and sulphadiazine in patients 
suffering from acute renal failure. Although these patients had 
lower than normal serum albumin levels, upon correction of the 
'data for albumin concentration, the binding capacity was still 
diminished. Reduced capacity and a~finity has also been shown for 
a number of drugs in uraemic sera(Schoeman and Azarnoff, 1972; 
Reidenberg and Affrine, 1973; Steele et al., 1979). 
The rate of certain elimination processes has also been 
considered to be a function of free rather than tot~l drug 
concentration. In healthy individuals the glomerul~r filtration 
is an ultrafiltrate of plasma, and only free (unbour.J) drug io 
filtered. Kunin et al., (1959) has shown, for example, that the 
rate of renal excretion of several tetracyclines is inversely 
I 
related to their extent of plasma protein binding. 
Drugs may also be excreted by the liver into bile, and 
subsequently into the intestine. This process can result in 
enterohepatic cycling whic~ may continue ~til elimination by 
metabolism, renal and faecal excretion is complete. The initial 
process in biliary excretion is the entry into liver cells 
(Combes, et al., 1956) which has been reported to be influenced 
by the degree of protein binding (Bri::l.uer and Pessotti, 1959; 
Prieotley and O'Reilly, 1966). LasGer et al., (1962) observed 
that in a homologous series of labelled agents, the highly bound 
homolagues were excreted in the bile, whereas the poorly bound 
members tended to be excreted in the urine. Knoefel (1965) 
suggested that certain highly bound drugs are e~~creted in bile 
because they are not available for glomerular filtration. 
Drugs apparently diffuse p~ssively into s~iiva, the transfer 
depending on lipid ~olubility and pKa. Also the extent of this 
transfer is related in some instances to the plasma protein 
binding e.g. a good correlation between free drug levels in plasma 
and drug levels in saliva have been reported fo~ salicylates 
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(Graham and Rowland. 1972). digoxin (Huffman, 1975). tolbutamide 
/
(Martin et al., 1974), diphenylhdydantoin (Paxton et al., 1977). 
Although the tone of this section is somewhat bland it is 
understandable. The effect of protein binding on drug distribution 
and pharmacological activity is not thought to be as important 
as it was considered to be a few years ago. It should nevertheless 
be emphasise~that for particular drugs, e.g. diphenylhydantoin, 
knowledge of the degree and nature ~~ the plasma or serum protein 
binding is a necessary prerequisite to sound drug therapy. 
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CHAPTER 2 
lM.TERIALS A1W r.~ETHODS 
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Ma terials: 
All inorganic reagents and organic solvents were obtained from 
Chemicals Limited unless ot.~erwise stated. 
Ponceau S was obtained from: G.T. Gurr Limited, London. 
Salicyla te, sulphadiazine, diphe.lylhydan toin and cyclophosphamide 
ere purchased from Sigmia London Limited. Phenylbutazone was 
generously supplied by Geigy Pharmaceuticals and adriamycin by 
Farmi talia Products Limi ted, Barnet, P.:ertfordshire. 
I Methot-rexate was obtained from t.'1e British Pharmacopoeia 
Commission Laboratory, stanmore, Middlesex and Lederlie I,imi ted, 
London. 1-Hydroxymethotrexa te was kin~ly gifted by: Dr. D.G. Johns, 
Na tionalpancer Ins ti tu te, Be thesda, 11aryland, USA, wrf. rabbi t 
an tisera was kindly supplied by Dr. J.W. Paxton, the t.d versi ty of. 
~uckland, Auckland, New Zealand. 15Se_ and 31I_ labeleC: me tho trexa te 
were supplied by ,the Radiochemical Centre, Amersham. 
'!he Nul t:imi ero Coneen tra tor (NNC) apparatus and Diano 
u1 trafil tra tion membranes were obtained from Amieon Lind ted, 
. . 
Woking, Surrey. 
/ 
RADIOIMHUNOASSAY OF MEnIO'mEXATE 
. 
. ,' 
RadioimmlL'l'1oassay Procedure 
I The assay procedure and quantities of reagents used are 
outlined in Table 5 • 
I Di 1 u.--,-e.;...n_t~J3..;;.;u;;.;..f_f __ e__ r: 
'--
0.05 If. phosphate buffer, pH 7.4 containing 0.1% sodium 
azide and 0.1% bovine serum albumin. 
Label: 
---
75Sclenium - methotrexnte (Fig. ~2 ) specific activity (s.a.) 
! 20 Ci ml,:ol-1 in aqueous arnmonia./20% ethanol. (v/v) was dissolved 
1:1000 for use. 
1st Antibody: 
Rabbit antiserum, diluted 1:200 for use. 
I Zllii Antibod;y:: 
Donkey anti-rabbi t precipitating serum. Diluted '): 5 for use. 
Standards: 
Dissolved in diluent (Table 6 ). A typical standard curve 
'is shorm in Fig. 13 • 
Quality Controls: 
Dissolved in diluent (~able 7 ). Quality controls were set 
up immediately after the standards, after every twenty samples e.nd 
again at the end of the assay. 
Samples: 
10 - 200 ~l quantities were used in the assay or dilutions 
made depending on the concentration of methotrexate in the sample. 
An equivalent amount of nor:nal human serum (N.H.S.) was added to 
the standard curve and quality controls, since the assay is 
sensi ti ve to the presence of senul1 or plasma proteins (Fig. 14-). 
The sta:1dard curve, quality controls and p.,tients' sa:~ples 
were done in duplicate. After the addition of all the reagents" 
the LP3 tubes were rr.ixed, wi t:!out frothi!1E, on a vortex :nixer 
and incubated at 4°C for one hour (minimum period) then centrifuc~d 
at 4°C for 30 trinutes at 80C g and the supernatant as?irated off. 
The tubes v/ere counted on a Wallae garr,rr.a counter for 1-2 minutes 
to accu::;ulate 10,000 counts in the total tubes. 
The inter a"'.d intra assay precision of 3)ikcd sa:ples are 
shown in Ta'-le 8 • a""ld the precision of control ~s.:::ples e3tir..u.tecl., 
\/i thout !,rior kno\'lledc~e of the co:-.ce.",trc.:;lo:..-,s, over =-- !",eriod -J:' 
ono i,~I)ntl:. are S:lO'\'"'"!l in Taole 7 • 
· . 
Diluent Sample Label 1st Ab. 2nd Ab. Buffer + NRS 
4 Total counts 
- - 50 - -
2 Serum blanks 400 
-
50 
-
50 
Standard curve 300 50 (st.) 50 50 50 
Quality controls 300 50 (Q.C.) 50 50 50 
Patients' samples 150-340 10-200 50 50 50 
(Pat.Sam.) 
~.'" .. ,~~ 
Table 5 The radioimmunoassay procedure indicating the vOlume{fl} of 
reagents and patients samples used. 
.. ' . 
. . '. '. . ~:'. ":.' 
Figure 12 The structure of 75sel enium methotrexate 
Standards 
;. . Table 6 
p g/50 1'1 0 10 20 40 
ng/ml 0 0.2 0.4 0.8 
-
~-~- ---~- -- --- --
f~' ~'. 
, . 
1,-. 
60 
1.2 
~-.---
100 
2.0 
200 400 .. 600 
4.0 8.0 12.0 
Concentration of solutions used to constrUct a standard curve 
1000 20000 40000 
20.0 40.0 80.0 
.", ."" 
. '". 
70 
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20 
" m" 
en 
,te I 10 
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. 0 _T __ ~ ______ ~ ____ ~~ ____ ~ ____ ~ ____ ~I 
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Methotrexate Conc~ (ng.ml~1) 
Figure 13 A typical radioimmunoassay standard curve 
. a. 
A B c 
pg/50 1 75 750 2,250 
. Quali ty controls 
ng/ml 1.5 15.0 45.0 
b. 
A B C 
Inter-assay Precision (c.v.) 8.7 7.5 8.5 
Intra-assay Precision (c.v.) 6.5 5.1 7.2 
c.v. = coefficient of variation' 
Table 7 (A) The concentrations of quality controls 
(B) Precision of quality controls measured over 
one month 
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Figure 14 Effect of normal hUman serum (N.H.S.) on the 
binding of 75Se-methotrexate to antisera 
a: buffer only 
.: 2% N.R.S • 
• : 1 o-%: : N • n. S • 
• : 40% N.H.S. 
': ...... . 
. . 
..... , ": .. 
,.:.> .. " 
Intra Assay Precision Inter Assay Precision 
NO of (MTX) Added·. *(MTX) Measured • 'I: Recovery 
Tu~ ~Molarl ~Molarl C~V~ % 
*(MTX) Measured C.V. Recovery·· {Molar) _ L}~ 
----' 
8 2.20 x 10 ... 8 2.38 x 10~8 6.5 108 2.33x.10 -8 8.7 106 
8 2.20 x 10 -6 2.24 x 10 -6 3.6 102 2.20 x 10 -6 7.5 100 
8 1.10 x 10-4 2.08 x 10 -4 2.8 98 1.08 x 10 -4 8.1 98 
Table 8 Methotrexate radioimmunoassay intra- and inter- assay precision 
.... ; . 
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'PROTEIN 13 Ii:lDING 
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Protein B:i.ndin~ .. _,!:>"y' Continuo':ls Ul tre.fil.tIi" ti on 
The Amicon 1,:ul timicro Concentrator (1,'].10) apparatus (Fig. 15 ) 
was used to study the protein binding of l .. TX by continuous 
ul trafil tration. Serum, in Cll).anti ties of 4 mI., ,"/ere introduced 
into the l,;.l{'. C. chamber via filling ~Jorts using disposable plastic 
syringes. A known qu anti ty of I.ITX was dissolved in phosphate 
buffered normal saline (pH 7.4) and pla.ced in the reservoir. 
By locating the n:c equipment wi thLl an incubator at 37 0 C the 
protein binding experiments were performed at normal body ter:1perature. 
The MlilC system was connected throu8h a selector valve to a 
nitrogen cylinder, which provided the driving pressure for ultra-
filtration. The tubing connectine t:~e reservoir ar.~ ultrafiltration 
chamber were filled with drug solution. The selector valve on 
the fa,;C VIas opened to allow equilibration of the gas pressure in 
the chamber and reservoir. The selector valve was then immediately 
changed to connect the reservoir solution to the chamber, and 
continuous ultrafiltration commenced. Diaflo X~50 ultrafiltration 
membranes were used and the procedure Vias carried out. at 40 psi 
which permitted a flow ratp of ultrafiltrate from the chanber of 
3 ml h-'. Ultrafiltration volumes of O.~ - 0.7 ml were collected 
into preweighed tubes and the exact volume determined by 
re-weighing to five decimal places. The terr.perature effects on 
the buffer volume at room temperature were found to be negligible. 
The serum within the chamber was continuously agitated by a magnetic 
stirrer mech~~ism during experiments. This not only facilitated 
mixing of !{TX solution and ser-u.I:1, but prevented plaguing of serum 
proteins on the ultrafiltration membranes which would otherwise 
tend to occur due to lamina flow through the chamber. 
In each collection period 
bound !.:TX could be IDeasured or 
Let v. = volume of the 
~ 
V = volume of the 
the concentrativ~.l of free, total and 
calculated as follows:-
~th ultrafiltr~te in litres. 
serum in the char:lber in litres. 
= MTX conce!ltration in the reservoir in ~ioles 1-1 • (R) 
(M) = ',,,TX concentration in the ith collection in toles -1 1 • 
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Figure 15 The Amicon l';ul timicro Concentrator (MMC) Unit 
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Since it is a closed system, the volume entering the chamber 
the ith period exactly equals the volume leaving the chamber 
(vi) 
• 
. . ri;oles entering chamber 
Moles leaving the chamber 
r.lo1es retained in charr.ber 
= vi (M) 
= vi (R) - vi (Ll) 
At the end of the ith period the 
in the chaLlber during the ~th perioa: 
increase in total concentration 
= 
1 
V 
At the end of the nth period the increase in total concentration 
in the chamber: 
i:::n 
= -v1 ~. (v. (R) - .'1. 0:.).) Moles 1-1 -------------1 ~I·J. ). ~ 
3.= 
During the nth period the MTX concentration in the ultro.filtrate 
collected: 
. 
= Moles 1-
1 
unbound in chamber 
= (U)n 
-1 Therefore at the end of the nth peri~d the moles 1 bound: 
1 i::n 
= - '" (v. (R) - v. (1.1). ) - (M) ----------------2 V ~1). ).). n 
Thus, the continuous ultrafiltration technique allows in a 
single experiment a preCise invcstig~tion of ligand-macro~olecular 
interaction over a vade range of ligand concentration. A scatchard 
plot for IIITX - protein interaction such as in Fie. 16 could be 
constructed from a single experiment from which an estimate cf 
the binding parameters could be obtained. 
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Figure 16 A typical scatchard plot for methotrexate 
Df = concentration of free drug (li:01es 1-1) 
r = Moles of drug bound per mole of albumin-
/ 
PEAPJ'lAcorn:-STIC AND STATISTICAL ANALYSIS 
I~ 
Pharlr)Acokinetic Analysis 
1 The following formulae were applied to the elucidation of 
!tine ti c parame ters: 
Biological half life (t~) = O-~93 
2 
Where p is the slope of the te'I'Ill~:lal phase of the concentration / 
time curve~ 
Area u..>1der the concen tra tion/ time curve (AUC): 
Linear trapezoidal method: AU~ _. ~(CPi+1 + Cpi )-(\+1 - t i ) 
i:m 2 
lo.gari thmic trapeziodal me thod: 
AU~ = ~ (Cpi+1 - Cpi )-C\+1 - \) {-i In (C ) 
I:m Pi+1/C pi 
Where (\+1 - t i ) is the time interval between COl':3ecutive 
measurements of methotrexate concentrations (Cpi and Cpi+1 ) • 
llie linear trap~zoi dal me thod of es tima ting AUC was used during 
t,he absorption phase clfter orally adminis tared dr-.... ~. The logari thnic 
trapezoidal method was used after intravenous administration or 
during the post absorption phase after oral dosing. The logarithmi~ 
trapezoidal method gives a better estimate ~f the area under curves 
with logarathmic decay, especially where large gaps between sampling 
poin ts occur. 
fue area under the curve be tween 
CD is given by the expression: AUCr = 
the las t data poin t and infini ty 
C 
...E 
J3 
Where Cpr is the concen tra tion a t the las t da ta poin t on the 
concentration/time curve_ Since this area is relatively small any 
error in its estimation 'Would have a negligible effect on the 
overall area. 
+ 
[t (Cni+1 + Cp~) • (t1+1 
[
i:mr(c _ C ) - (t L pi+1 pi 1+1 
ln (C ) 
i:n pi+1/C pi 
• 
- . 
AUC
o 
(oral) = 
+ Cyr 
p 
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I 
AUC<7:) (i.v.) = 
o rt<Opi+1 - °pi> · <\+1 - ti>l 
ti:m In (Cp1+1 ) J /Cpi 
+ C 
...P!. 
ID is zero time and n and rare later times. 
tal body clearance o-n (CL tot) = ~~ 
AUCn 
o 
Renal clearance 
o-n 
(CL
r
) = Amo'V.nt of drug excreted in urine 
AUC n 
Extra-renal clearance (CL ) 
ex 0-110 = 0-110 
o 
(CL ) 
r O-Ol 
P 
o-n 
Biliary clearance (Cloil ) o-n = !mount of drug excreted in bile o-n 
AUC 
o-n 
Where n is any time after intravenous drug administration. 
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+ Resul ts fro;n each subject group were expressed as mean 
tandard deviation (3. D.) using the equation: 
S.D. ::~ (~ y)2 \-!here X is ru1~' sine-Ie value 
-
1 is the x mean 
n is the nur.'1ber of values in 
eaC'h sroup 
The coeffecient of variation (C.V.) was obtained from the equ8.tion: 
c.V. = s.}). x 
x 
Correlation analysis was performed using the Pearson's·prod.u~t 
moment correlation test in wrich the correlationcoefficit:>nt is 
obtained from the exp~ession:-
. 
r = L;ry - y) (x - i) 
~lL:(:{ - ;f)2 .L:(x - x)2] 
Wi t.'1in subject differences were tested for siC!:ifica.'1ce usir.g 
the Hilcoxon oa tched - pairs siC;!1ed - ranks :test e.g. comparing the 
AUC after 100 mg. bolus and after 25 mg. x 4. 
T'ne Iv!ar.n - Whi key signed - ranks test for tyro independent 
sa-nples' was used to test for :oicnificance bet-,:een cifferen t £TOUps 
e.g. comparison of protein bineing paranete:rs of control a!1d patier:.t 
groups. 
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CHAPTER :3 
RESULTS 
73 
SECTION 1 
Antibody studies 
74 
j 
1.1. The Cross-reactivity of 7-Hydroxymethotrexatc 
75 
1.1. Cross-reactivit 
Paxton et al. (1978) have measured the cross-reactivity of 
a number of similarly structured folates and other anti-metabolites 
with the antisera used in this methotrexate assay. Only 
dihydrofolic acid and folic acid sh~~ed any degree of cross-
reactivity and then only to a negligibly small extent (0.03% and 
0.01% resvectively). However, the cross-reactivity of 7-hydroxy-
methotrexate (7-0HMTX) had not been ... xamined. It is known that 
the proportion of 7-0H1'lTX to MTX in serum and urine increases 
with time after administration of !.1TX (Jacobs et a1., 1976). 
The possibilit~ of cross-reactivity is therefore very real, 
particularly after high dose MTX and in samples col}ected more 
than 24 hours after the parent drug has been given. It is 
\ therefore of paramount importance to determine if su~~ cross-
reactivity does occur, and to what extent, since it could cause 
considerable error in the estimates of kinetic parameters. 
I 
7-Hydroxymethotrexat~: The sample of metabolite weighed 2.9 mg. 
and was composed of 90% 7-0IDJTX, 2% l'~TX and 7% other undescribed 
compounds. 
l!:ethod: The specificity of the assay for ~ITI was calculated by 
adding increasing amounts of 7-0IDJTI in place of non-radioactive 
MTX to the assay tubes and the percentage 75sele~ium (75Se ) label 
bound measured as described in the assay procedure. The cross-
reactivity was then expressed as (§ x 100%), where I is the 
molar weight of UTI and Y is the molar weight of 7-0HUTX, each 
required to produce 50% inhibition of specific binding of 
the label. 
Resul ts: The specificity of antisera using 75Se - fllTX is 
illustrated by the displacement curve shown in O?ig 17). The 
cross-reacti vi ty of 7 -OHlVITI was 1.8%, therefore it would require 
a 55-fold higher concentration thnn MTA: to produce a comparable 
displacement of 75Se - label. 
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Figure 17 7-Hydroxymethotrexate (7-0HKTX) displacement curve 
Discussion: The antisera used in the radioimmunoassay does 
Inot bind, to any great extent, the major metabolite (7-0InIlTX) of MTX. Considering the work of Paxton et al., (1978) the antisera 
would appear to be exceptionally sFe~ific. The high degree ·of 
specificity would permit the measurement of MTX in the presence 
of other naturally occurring folates. Further, it would permit 
the measurement of MTX in the body ~luids of patients receiving· 
high dose therapy with folinic acid rescue. Under this regimen 
considerable amounts of folinic acid and 7-OIn~iTX would be expected 
to co- exist with lfiTX in plasma and other body fluids. 
The value obtained for the cross-reactivity of 7-0m~TX is 
very close to the percent MTX in the sample, being 1.8% and 
2.0% respectively. It is therefore very likely that this degree 
of cross- reactivity simply reflects the assay of 1ITX in the 
sample. In any case it is clear that 7-0HI.!TX does not interfere 
1 
sienificantly in this radioimmunoassay of 1.'!TX. 
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SECTION 2 Methotrexate Disposition 
78 
2.1. : Intravenous stu~ies 
79 
~ethotrexate in Tears and Saliva 
/
2.1.1. 
Althoue;h r.lTX treatment schedules have been modified in an 
attempt to abrogate toxicity, oral toxicity and conjunctivitin 
are still frequently observed. In the past few years there has 
been considerable interest in the £alivary excretion of drugs 
and a good correlation has been sho\'ffi between salivary concen ... 
tration add unbound fraction of drug in plasma or serum (Graham 
and Rowland, 1972; Kaysooko et a1., 197.3; Huffman, 1975; I{:artin 
et al., 1974; Paxton et al., 1977; Horning et a1., 1977; stephen 
and Speirs, 1976). The excretion of drugs in tears, however, 
is essentially unexplored. 
The concentrations of r.r:TX in mixed and parotid saliva and 
tears were therefore determined and related to the :evels in 
serum particularly to the unbound fraction. The cop.:'.entration 
of MTX in tears and saliva were also related to the incidence 
of ocular and oral toxicity. 
Patients: Four patients with psoriasis and eleven patients 
'with various forms vf malignant disease. gave th~ir informed 
consent and participated in the study. Each was given either 
loVi dose (15-50 mg) or high dose (500 or 1000 mg) ~ilTX intravenously 
J 
to be consistent with their norn~l therapy. A psoriatic was 
included in this study although she was given 25 mg. intramuscularly. 
Patient details are SUIT~arised in Table 9. Patients on the 
high dose regimens, were also given fclinic acid rescue (15 mg. 
folinic acid given 24 hours after drug administration followed 
by 5 mg. folinic acid q.i.d.). 
Sample Collection: Serum: Blood samples In quantities of 5 mI. 
were obtained from an indwelling heparinised polyethylene catheter 
introduced into the left anteCUbital vein. Serum was rerr.oved 
by centrifugation after clot formation was complete. 
Tears: Tears were collected on Schirmer test strips on which 
the sar:c.ple volur:le (20-.30p-l) was deterr.>.ined by weighing. :OtTX 
was eluted using metha~ol (2 x 0.5 ml) which was subsequently 
evaporated to dryness and the tITX redissolved in 400 fl of buffer 
. 0 
"at 37 C. Standard solutions absorbed on the strips and eluted 
according to this procedure gave a good recovery (90-S5~n. 
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IF"tient 
D.H. 
R.N. 
M.L. 
A.S. 
R.P. 
VI. N. 
A.C. 
R.P. 
• M.G. 
D.C. 
B.H. 
M.B. 
J .M. J. 
A.H. 
*A.M. 
Table 9 
Primary Age Dose % Unbound Oral 
Sex Disease (y) 
Al~1 
(C;l ) (me.) DruEj Toxicity Conjunctivitis 
M 
M 
F 
F 
1'1 
M 
F 
M 
F 
M 
F 
F 
M 
M 
F 
Carcinoma 51 33 1000 4.15 + 
Rib 
Carcinoma 51 35 1000 6.31 
Maxilia , 
Carcinoma 60 31 1000 5.16 
Breast 
Carcinoma 90 29 500 3.13 
Leg 
Cal"cinoma 11 36 500 
Penis 
Carcinoma 61 39 50 2.11 + 
Bronchus 
Carcinoma 60 38 50 3.31 + 
Breast 
Carcinoma 11 36 50 5.13 + 
Penis 
CarcinolT'a 44 48 50 3.92 + 
Breast 
Carcinoma 56 38 50 4.61 + 
Lung 
Carcinoma 16 33 50 3.15 
Breast 
Pustular 50 40 20 3.11 
Psoriasis 
Psoriasis 43 50 15 6~03 
Psoriasis 62 46 15 4.03 
Psoriasis 10 43 25 11.14 
Summary of patient details, drug dose, percent unbound 
drug in serum and the incidence of oral toxicity 
and conjunctivitis 
500 - 1000 mg i.v. infusion over 12 h. 
15 - 50 mg i.v. injection 
25 mg i.m. 
Parotid Saliva: Parotid saliva was collected using a parotid 
I
cup (Stephens and Speirs, 1976), salivary secretion being 
stimulated with citric acid (0.5 ml of 1~~ solution). The pH of 
the parotid saliva was checked using indicator paper to deterrrjne 
whether any citric acid was contami!'.:.ting the sample. Approxi-
mately 1 mI. samples were collected. 
r.~ixed Sal~~: Samples of about 1 mI. in volume were collected 
by direct expectoration into plain tubes. 
The patient's mouth VIas washed vut with water and swabbed 
I dry before the collection of each sample. Mixed saliva was 
collected and cfter resvlabbiilg the parotid cup was placed in 
position. Blood, tears and parotid saliva were then obtained 
simultaneously. All sampling was completed within 3-5 minutes. 
I Samples were collected at appropriate intervals from zero time 
until between 24 and 30 hours after initiation of therapy. 
All specimens were kept at _20oC. until assayed. 
Methods: Protein binding vms determined by continuous ul tra-
£iltration as described previously. A reservoi~ concentration 
of 12 pmol.1-1 was employed, which enabled the study of binding 
-1 
over the range 1-30)1 mo1.1 Adjustments in drug concentration 
within this range were performed stepwise yielding ten to 
fourteen estimates of protein binding, each pertaining to a 
different drug concentration. 
Results: Soon after administration, ~TX was detectable in tears 
and both parotid and mixed saliva (Fib .10:19)Regression analysis 
showed a close correlation (p<~.001, r=0.714) between UTX levels 
in tears and serum (Fig. 20). Parotid saliva and serum MTX also 
showed a close correlation (p<0.C01, r=O.557, Fie.21). No 
significant correlation was found between AITX cC':"lcentrations in 
mixed saliva and serum (p<O.1, r=0.232). The ratio of YlTX level 
in tears: level in serum was 0.0~7: 1, while the ratio of !Y~~Z: 
level in parotid saliva: level in serum was 0.003.1. The 
protein binding WaS found to be 95.11% ~ 2.26 (s.d.) and remained 
-1 
constant over the ran~e 1 -30 pmol 1 • 
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Figure 18 Serum (0), tear (,,), parotid (a) and mixed (~) 
salivary methotrexate (MTX) concentration time curves 
in patient A.C. after a single 50 mg. i.v. injection 
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Figure 19 Serum (0), tear (T), parotid (a) and mixed (+) 
salivary methotrexate (~TX) concentration time curves in 
patient A.S. following a single 500 mg. i.v. infusion 
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nelationshi~ between parotid salivary and serum levels or methotrexate O:TX) 
in eleven pati~nts (p < 0.001; r = 0.551 ) 
~ •• io,. .• 
I, No oral toxicity was observed in any of the patients during this study but a number showed signs of conjunctivitis. Table 9 shows the dose of drug given, the unbound drug level in 
! serum and the incidence of ocular toxicity (viz. conjunctivitis). 
Having established that the ratio of MTX levels in tears to 
unbound drug levels in serum is very near unity, no I'clationship 
between tear concentrations of MTX and the incidence of conjur.Lc-
tivitis could be demonstrated. The incidence of conjunctivitis 
did not increas~ with increase in serum concentration even 
although higher levels of MTX were observed in tears. 
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.1.2 Methotrexate in Cerebrospinal Fluid (C.S.F.) 
The concentration of a number of drugs in C.S.F. correlate 
.well ~~th the unbound drug in serum (Hanehton et al., 1975; 
Borga et al., 1969; Paxton, et al., 1977). Since central nervous 
system toxicity in children, on high dose I\lTX chemotherapy, is 
occasionally observed (Wang, et al., 1976) a non-invasive method 
of assessing C.S.F. concentrations would be extremely useful 
in monitoring therapy. 
The concentration of ~TX in C.S.F. was measured and related 
to the levels of drugs in plasma and mixed saliva. 
Patients and ~ethods: Nine children, aged between 3 - 12 years, 
on high dose MTX for leukaemia relapse were observe;!. This 
-2 therapy consisted of 500 mg. m ,a third of which was administered 
I as an intravenous boluG inj ection (over three minutE'F) and the 
remainder by infusion over eight hours. A few blood samples were 
taken during and after drug administration and C.S.F. withdrawn 
,via an Omr.:laya tube, 1 hour after the bolus inj e~tion. Mixed saliva 
was collected by direct expectoration, in~ediately after'blood 
was withdrawn. The collection of parotid saliva was found to be 
impractical and no attempt was made to impose the collection of 
tears. Five of the children were observeocon two separate 
occasions. 
Results: A typical concentration-time profile for plasma and 
mixed saliva is shoVln in Fig.22. No sienificant cor!'clation 
was found between either the concentration in mixed saliva ~~d 
plasma (p<0.05; r=0.55) or the level in C.S.F. and plas!l"..a 
(p<0.1; r=0.40). However, there was a sig..'YJ.ificant correlation 
between the concentration in mix:d saliva a~d the concentration 
in C.S.F. (p<0.001; r=0.91, Fig.2.3). 
, 
The concentration of 1~TX 
,in C.S.F. Vias approximately 0.1% of that in plasma. Similarly 
the concentration in udxed sali .... o. was in the region of 0.1% 
of the level in pls3rr.a. Since there was a significant correlation 
between the concentrations in C.S.li'. ar.d mixed saliva, the ratio 
of ri:rrX concentration in C.S.F. to that in mixed saliva was 
0.93 : 1.0 • 
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levels of methotrexate. (F< 0.001 : r = 0.91) 
·Discusslon: It has been possible to demonstrate, in patients 
!receiVinB !liTX, significant linear correlations between drug concentrations in tears, serum and parotid saliva. Since the 
. mean unbound fraction of lIlTX is 4.89%, it is likely that free 
drug in serum is in 'passive equilibrium with drug in tears. 
Furthermore, there is a predictable relationship between I,i'l'X 
in serum and drug in parotid saliva. However, the drug levels 
in parotid saliva were considerably lOVler than levels in tears. 
A possible explanation for 'this would be that MTX secretion 
is dependent on the rate of salivary flow. However, in view 
of the very low concentrations in parotid saliva, it 'is more 
likely that MTX is secluded from the secretions of the 
parotid glana. 
There are a number of parameters which influence the 
partition of drugs between saliva and serum. These include 
the pKa value, the pH of the two fluids and the lipid solubility 
(Linde,. 1932; Glynn and Bastain, 1973; Feller and Ie Petit, 1977). 
'Feller and le Petit (1977) have pointed out that considerable 
differences in concentration may arise between plasma and saliva 
due to different storage of the dissociated part, according 
to the pH-partition theory, if the pKa of an acid drug is lower 
than 8.5. Since the pKa values of MTX are 4.8 and 5.5 it would 
be expected from this concept, that MTX would be retained in 
the plasma compartment. Also drugs ~th low lipid solubility 
measured by the n-octanol/water partition coefficient, do not 
permeate lipid membranes well. Again from this theoretical 
approach it would be unlikely that MTX would have a 1:1 ratio 
wi th unbound drug in plasma since I.1TX is a highly polar molecule 
with a log P octano1 of - 1.85 (Leo et a1., 1971). 
Although physico-cherr.ieal processes reay determine a 
parti tion of I\iTX. between serum and saliva, very little information 
is available concerning the factors responsible for this 
phenomenon in tears. Indications to study drug concentrations 
in tears are few, therefore one would hesitate to extrapolate 
these observations to other compounds. Ocular toxicity did 
not correlate with drug levels in tears. Higher concentrations 
of ~TX were present in tears of those patients receivine the high 
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dose infusions and only one patient showed signs of conju...'1ctivi tis 
in this group. However, these patients were 'rescued' from 
toxicity with folinic acid whereas the patients given 10\"' doses 
were not. In contrast, the group given 50 mg. by intravenous 
injection, conjunctivitis VIas evident in all but one patient I , 
at 7~14 days after drug adreinistration. At this time no MTX 
could be detected in tears, but persistence of low residual 
levels could contribute to .the obse.t'ved ocular toxicity when 
folinic acid is not given. 
No advantage would be served by the prediction of serum 
concentrations from that found in tears and saliva. The collection 
procedures are time-consuming· and require special c':..;vices end 
materials which would be quite inappropriate under clinical 
conditions. Further, the collection of these fluid£» particularly 
tears, would be unsuitable in children, where development of 
non-invasive and painless techniques for monitoring drug levels 
is most desirable. Further serun: levels of MTX cannot be used 
to predict C.S.F. concentrations in children. However, a highly 
significant correlation wa,:, observed between the concentrations 
in mixed saliva and C.S.F. After high i~trave~ous doses an 
estimate of C.S.F. concentrations could be made from that 
measured in mixed saliva obtained by simple expectoration. 
This could have great potential in determining not only possible 
central nervous system toxicity due to high C.S.F. levels of 
!i:TX, but also distinguishing between meningeal relapse and 
toxicity. One patient VIas excluded from the study due to overt 
oral toxicity with bucal ulceration. The source of salivary MTX 
in this patient was uncertain since the saliva Vias more clou1y 
than normally observed and some samples were flecked with blood • 
. Salivary levels were six times higher than the C. S. F. concen-
trations in this patient. This illustrates one limitation of 
predicting C.S.F. l~vels from that in saliva, since oral toxicity 
may alter the ratio due to presence of blood or to increased 
05 
jpermeability of the mucus membrane resulting from desqu~mation of epithelial cells. Since there is insufficient data ut present 
. to determine the confidence with which one could predict the 
levels of UTX in C.S.F. from that mp.asured in a single mixed 
salivary sample taken at random, th~se results should be 
considered with caution. The data does, however, indicate 
the need for further study since mixed saliva samplel3 can be 
collected with ease and could provi~.e a simple means of 
monitoring children on high dose MTX sbhedules without causing 
the stress involved in the withdrawal of C.S.F. 
,., 
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,2.1.). Distribution of Methotrexate betv!een Plasma & Erythrocytes 
I 
Apart from a few reports (Bobzien and Goldman, 1972; 
Rothenberg, et al., 1976) little attention has been focused on 
I the distribution of MTX between erythrocytes and Plasma. There 
. have, in particular, been no studies of MTX levels pertaining 
in erythrocytes in vivo. 
The specificity and sensitivity of tho radioimmunoassay 
has enabled levels of r,lTX i? serum, whole blood and erythrocytes 
to be IT!i;asured up to a time after adndnistration when serum 
concentrations have been hitherto undetectable. 
The changes in MTX concentration with time in plasma, 
whole blood ~nd erythrocytes ~ere monitored during ~nd after 
high dose intravenous infusion. 
Patients: Three patients with various forma of mali,.:;nant disease 
were given 250 mg. MTX by intravenous infusion over 12 hours as 
part of their reeular chemotherapy. In one patient the course 
of drue; levels was observed on two separate oc~asions with an 
interval of one month. On the first occasion this patient had 
no previous history of chemotherapy, but, the other two patients 
had been"'receiving cytotoxIc therapy for a few months. FoB.nic 
acid 'rescue' was a routine part of the chc~otherapy received 
by these patients, and comprised 15 mg. folinic acid given 
intravenously 24 hours after initiation of therapy followed by 
5 mg. folinic acid q.i.d. 
Sample Collection: Whole Blood: Heparinised blood speCimens 
of 10 mle were withdrawn at appropriate intervals froID zero 
time (pre-treatment oample) until between 8 and 16 days after 
administration. About 3-4 ml.aliquotes of whole bloed were 
. haemolysed by freezing and thawing, and in some opecimens this 
was aided by dilution in distilled water. 
Erythrocytes: The erythrocyte ~raction was prepared by the 
followine method. Irr~ediately blood was withdrawn the packe1 
cell volume (P.C.V.) was found for each specimen of blood. 
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A 1.0 ml. quantity of blood was then centrifuged and the plasma 
wi thdravm. The volume of the packed cells was made up to 2.0 mI • 
. with normal saline and the tube mixed thorou~hly, but gently. 
by repeated inversion. The specimen was then recentrifueed at 
800 g. for ten minutes. The supernaotant was removed without 
disturbin~ the erythrocyte pellet and discarded. This washing 
procedure was repeated twice, and when the last supernatant 
was removed the volume was made up tr) 1.0 ml. with normal saline. 
After mixing thoroughly a second P.C.V. measurement was found. 
The specimen was again centrifuged, the supeI'natant d.iscarded 
and the volume again made up to 1.0 ml. with distilled water 
to cause haemolysis. The washing procedure and ceh~rifu~ation 
o 0 
were performed at between 0 - 4 C. The difference between the 
pre- and post- washing P.C.V. allowed a correction f0r loss of 
erythrocytes in the procedur-e to be made. Haemolysis, was 
further encouraged by dilution in distilled water immediately 
,before the samples were assayed. 
Plasma: The plasma fraction was removed from the remaining 
sample of whole blood afte~ centrifugation. After re-centrifugation 
the plasma was carefully removed from the tube leaving 200-300 pl. 
to be discarded. This procedure was undertaken to ensure that 
no erythrocytes were carried over from the initial separation. 
All specimens (haemolysed whole blood, hacmolysed erythro-
cytes and plasma) were stored at _20uC. until assayed. 
Methods: r~TX concentrations were measured by a specific and 
sensitive radioi~.unoassay (Paxton, et al., 1978) employing 
75 Se-label. 
The biologic half life of IliTX in plasma was determined from 
the slope of the log/linear regression line (l~ast squares 
fitting) drawn through the terffiinal portion of the serum 
concentration/time curve. 
The increase in hlTX concentration in erythrocytes with time 
observed when patient J .1,:. was studied on the first occasion 
was determined from the log/linear regression line (least squares 
fitting) drawn through the data from day 2 to day 16. This was 
used to determine the maximum MTX level attained on day 16. 
i~ltS: The concentration in the three fluids increased with time, reaching a peak at the end of infusion. The concentration in plasma and whole blood followed a similar pattern with tho plasma 
I 
levels consistantly higher than that in whole blood. The 
ratio of peak concentration in whole blood : concentration in 
plasma varied between 0.82:1 and 0.56:1. The concentration 
peak in erythrocytes at the end of infusion Vias very much lower 
than in serum, the peak concentratior. in erythrocytes : peak. 
co~centration in plasma varying between 0.03:1 and 0.01:1. 
Immediately after completion of the infusion the. r.1TX 
concentration in all three compartments fell sharply but the 
mean plasm~ 1?io1oeic half life (ti ) measured over tl.e terminal 
. portion of the concentration time curve was 43.0 h. ± 6.22 (s.n.), 
\ The concentration in plasma fell below the limit of pensitivity 
of the assay between days 8 and 10. As this time was approached 
the concentration was much greater in the erythrocytes and 
whole blood. The c:'ncentration of liiTX in erytb:::-ocytes tended 
to plateau and did not have an apparent elimination phase. 
At day 8 the erythrocyte concentrati.on : concentration in plasma 
ratio, varied between 145.~0:1 and 18.75:1 and the whole blood 
plasma concentration ratio varied between 20.80:1 and 4.19:1. 
The individual data is summarised in Table 10. and Fig. 24 and 25 
In one patient (J.t;.) the course of drug levels was 
observed on two occasions with an interval of one month. On the 
first occasion the patient had no previous history of chemotherapy 
and there was a general increase in erythrocyte !;;TX concentration 
starting on day 2, after the initial drop at the end of the 
infusion, which continued until <lay 16 (when drug monitoring was 
stopped). The concentration increased from 46./8 nmol.1-1 at 
-1 46 h. to 185.0 nmol.1 at 381 h. This increase in concentration 
persisted at a time when plasma levels were decaying and even 
after the levels hau become undetectable. The peak whole blood 
level: peak plasma level ratiO, was 0.82:1 and the peak 
erythrocyte level: peak plasma level ratio was 0.03:1. 
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I Peak Ratios Pla teau Radios Plasma 
Pa tient W_B_ : P R_B_C. : P W _B_ : P R.B.C. I P 1: (h) 
J _M_ (1 ) 0-82 0-03 20-80 145 -50 36-0 
J.M. (2) 0-63 0-01 7·33 34-50 40-0 
J.C. 0-56 0-01 1~·73 18-75 46·0 h 
M_K. 0-75 0·01 4·19 19-45 50-0 
Table 10 Peak and plateau ratios for the individual patients_ 
~gurc 24 
, 
. . 
I 
figure 25 
-
'Ihe concentration time curves for me tho trexa te in 
plasma, whole blood and erythrocytes for patient 
J .}1. 
The concentration time curves for methotrexate in 
plasma, whole blood and erythrocytes for pa tien ts 
J .C. and M.K • 
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Figure 25 
, When the study was repeated the concentration in erythrocytes 
!fell to a plateau level and no net increase in drug concentrations was observed at the end of the study after 14 days. The mean 
, -1 
'drug concentration between 24 h. and 336 h. was 33.58 mol.1 
±. 3.08 (S.D.). Further, the peak e::.'ythrocyte concentration 
was very much lower, being about 50~0 of that observed on the 
first occ~sion. The peak concentration ratio, whole blood : 
plasma was also different, being OoO~:1 • 
. ", 
!'DiSC1.1SSion: The persistence of drug in erythrocytes would suggest that MTX is bound in some way either within the cell , or on the cell membrane. Indeed it is possible that the process 
may be described by two mechanisms. The initial rise in 
concentration during the infusion followed by a sharp drop in 
erythrocyte concentration immediately following the termination 
of the infusion would suggest that some hlTX is partly associated 
with erythrocytes in a rapidly reverzible manner. This initial 
association being influenced, perhaps, by the concentration 
gradient with uptake mainly by diffusion. Also, sin~e, MTX 
concentration in erythrocytes increased after day 2, in the first 
treatment Of. J.M., apparently against a concentrat~0n gradient 
an energy dependent process j.s possible. This proiile is also 
consistent with erythrocytes being a slowly exchanging' 
kinetic compartment. 
However, other explanations for the persistence of 1uTX :i.n 
erythrocytes could be postulated. Dihydrofola~e reductase 
activity would be expected to be high in blast cells and may 
bind considerable quantities of fuTX. The increase in erythrocyte 
1,=TX levels from day 2 after the first tr~atment i may reflect 
denovo erythrocyte synthesis and erythrocyte turnover. The MTX 
levels in the reticuloendothelial system may be considerably 
higher than serum levels and encapsulation into erythrocytes 
may occur. 
The peak and plateau ratios found in this patient on the 
first occasion were also considerably different, not only from 
that obtained when the treatment was repeated but from the other 
two patients who had received regular chemotherapy. The peak 
erythrocyte concentration : peak serum concent:'ation was 0.31: 1 
compared to 0.01:1 found in the other two patients, and when 
this patien.t was restudied. Aloio, when measuI'ed on day 8 the 
plateau erythrocyto level : serum level was 145.50:1 compared 
to values between 18.75:1 and 34.50:1. It is therefore possible 
tha t distribution of r.:TX between pll'l.sma and erythrocytes Inay 
change with repeated chemotherapy. 
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IPrOlOnged exposure to low concen tra tions of M'rX may promot e 
IbiOChemiCal resistance by mechani~ms discussed previously, i.e. associated vdth decreased binding or altered transport 
I 
properties. This might explain why the second uptake phase 
was not observed in the other two patients or when the treatment 
was repeated in this patient. 
The persistence of MTX in erythrocytes may also contribute 
to toxicity since wTX toxicity is dependent not only on the 
concentration but also on the length of time exposed to the 
drug (Goldie, et al., 1972; Young and Chabner, 1973). Therefore 
even although the concentration in erythrocytes is relatively 
low, MTX never the less persists for long periods 0:1" time 
. after high doses and may exceed the time threshold tor toxicity. 
I Changes in nutritional status could also affect the 
phenomenon since there is considerable evidence that other 
folic acid analogues can displace MTX from intracellular 
sites (Johns et al. s 1961; Sheehy et al., 1963; Johns and 
Penderleith 1963; Johns et al., 1964). However, it would 
appear that folinic acid did not effect the release of ~TX 
from erythrocytes, since tl!e slope of the concentration/time 
curve did not alter in response to initiation of 'rescue'. 
It is possible that the relatively small concentration of 
folinic acid used in rescue compared to the dose of MTX might 
not cause detectable displacement of MTX from erythrocytes. 
Another possibility is that folinic acid is taken up by 
erythrocytes by the same process and therefore over a similar 
time course to MTX. Folinic acid may therefore be progressively 
a1 tering the uptake of ~.iTX, the ~aj or effect of which is not 
observed until later times than covered by thiE study. In 
this context it is unfortunate tr~t a pretreatment sample was 
not withdrawn before the second ~our$e of chemotherapy was 
initiated in patient J.U. Indeed, folinic acid 'rescue' may 
be, at least partially, responsible for the change in 
distribution when this patient was studied a second time. 
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. The distribution of' 1i;TX between plasma and erythrocytes iappears to be mediated by complex mechanisms. Methotrexate persists for a long time in erythrocytes compared to plasma 
land may therefore contribute to the expression of toxicity 
by exceeding the time. threshold for toxicity. Exposure to 
low concentrations of' MTX f'or suell long periods of' time may 
also promote tolerance as reflected initially in altered 
association/uptake properties observ~d when treatment is 
repeated. The study does not show evidence that folinic 
acid can influence the distribution of MTX between erythrocytes 
and plasma. The possibility remains, however, that folinic 
acid can influence this phenomenon by a more occult mechanism • 
. It is also expected that the progress of disease rna:" have a 
I bearing on the nature of this distribution • 
.. ~, 
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2.2. ABSORPl'IOlT STV,C IES 
94 
2.2.1 Bioavailability of a r.Iethotrexate Oral Syrup Formulation 
I Methotrexate has been given by mouth for the mainteYlance of ,remission in childhood leukaemia for many years. The drug is 
provided in tablets of 2.5 mg. which is convenient for such low-dose 
maintenance chemotherapy schedules. Recently intermittent hieh-dose 
MTX therapy with folinic acid rescue has been developed in the 
treatment of solid tumours and lymphomas (Jaffe et al., 1974; 
Levitt et al., 1973; Turman. et al., 1977; Rosen et al., 1974) 
with subsequent improved efficacy. Clearly such low-dose formulations 
are unsuitable for high-dose oral therapy. Therefore in an attempt 
to save patients consuming up to forty or fifty tablets, or being 
adrni tted to ~ospi tal for intravenous infusions of I.::X, en alternative 
, oral formulation in the form of a syrup has been evolved. 
\ The extent of absorption of N.TX in oral syrup form was 
compared with the same dose administered intravenously. 
Patients and Kethods: 
Six patients who were to receive chemother:py for a variety 
-2 
of solid tumours were given a dose of MTX of 50 r.'g. m either 
as the syrup or as an intravenous bolus, one week apart, the 
order being determined on a random basis. After an overnight fast, 
a heparinised polyethylene catheter was introduced into the 
. left antecubital vein under local anasthaesia. A pre-treatment 
blood sample was taken and the patient was instructed to empty 
the bladder. ~TX was then adrranistered either by mouth or 
intravenously into the free arm. A ndnimum of eleven 5 mI. 
blood sa~ples were taken at appropriate time intervals up to 
eight hours. After centrifugation plasma was removed and frozen 
o 
at -20 C. Urine samples were collected and the volume measured 
and aliquots of 20 mI. kept for assay of KTX cc~centration as 
previously described using 75Se-labelled derivative. The area 
under the individual MTX serum (";mcentration time curve (AUC) 
VIas computed using the trapegoidal rule and the r;lTX plasma half 
life (t 1 ) was derived from the slope of the regression line 
~ (log/linear least squares fitting). drawn through the terminal 
portion of each concentration time curve. The plasma half life 
(ti ) estimates were compared according to treatment using the 
Wilcoxon signed ranks test. 
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IMethotrexnte Formulation: The composition of the MTX syrup was as shown in Table 11 • . The preparation was found to be stable for periods of up to one , 
month in a variety of storage conditions including clear and 
o brown glass bottles at room temperat'.lre and at 4 c. 
Res'.ll ts: 
The sites of tumour in each patient is ShOVlll in Table 12 • 
Patient E.D. VIas found some. weeks lv~er at autopsy to have 
metastases involving the kidney, and patient A.C. had already 
had a nephrectomy for hypernephroma but had residual tumour. 
Patient A.F. became progressively debilitated within a short 
time of starting the study due to a combination of generalised 
. weakness, dehydration and incurrent infection and went into renal 
\ failure and died a fortnight after the last dose of ~':TX. 
The fuTX syrup .was tolerated extremely well by all six patients. 
There Vias a three-fold variation in peak J.1TX concentration 
and the time taken ~"o reach these peake varied .trom 70 - 150 m1nut~s, 
after oral r.ITX (Table13). The area under the oral concentration 
time curve also varied conziderable with a range of 2.26 to 
~ -1 7.94~ dose 1 h. In each case the area '~der the oral curve was 
very much less than that under the intravenous curve indicating 
that the absolute bioavailability was poor, the ratio ranging from 
15 - 54%. Renal clearance for the first eight hours were co~pared 
with serum creatinine levels, but the data failed to show any 
obvious relationship between these parar.-.eters (Table 14). 
The renal clearance. values (0-8 h.) of l.:TX in pa.tients E.D.·~ A. c. 
and A.F. were very much lower tha~ in the other three patients, 
but these values were in accord with their medical history. 
No significant group difference could be demonstrated 
between the plasma half-lives when compared according to route 
of administre.tion. It was clear, hov:ever, when the results 
were scrutinised that patients E.D., A.C., and A.F. showed 
differencies in their plasma half-lives between treatment days. 
These results were explicable in terms of the progressive nature 
of the disease in these patients. 
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I Consti tuent 
Sodium Bicarbonate 
Injection Methotrexate Liquid B.P. 
Syrup B.r. 
Chloroform Water B.P. 
Final Concentration 
Quantity 
20 g. 
80 ml (25 mg ml-'). 
250 mI. 
To final volume of 1.0 1 • 
10 mg. ~ethotrexate/5 mI. 
Table 11 The composition of the Methotrexate syrup formulation 
) 
Patient 
C. G. 
A.P. 
}.i. B. 
E.D. 
A.C. 
A.F. 
Table 12 
Primary 
Tumour Site Age Sex Dose (rng) Remarks 
Bronchus 44 M 10 No side effects 
E:ceast 62 F 50 No side effects 
and Colon 
Head 15 M 80 No side effects and Neck 
Bronchus 62 M 95 Diarrhoea 
Renal ~etastases 
Kidney 51 M 80 Post Nephrectomy 
Breast 76 F 10 Rena! failure 
Patient particulars including tumou~ site and 
dose of drug. 
Oral Peak -1 Ratio of 
Concentration AUC (% Dose 1 h) AUO oral 
-1 
'" -1 
Time =to 
Patient re ml I" Dose 1 Oral Peak (h). Oral 0 - 8 h iv 0 - 8 h :AUC iv 
C.G. 0.42 0.60 2.5 2.26 10.62 0.21 
A.K. 0.72 1.44 2.0 5.12 9.42· 0.54 
M.B. 0.54 0.70 1.5 2.22 11.52 0.19 
E.D. 0.62 0.60 1.8 2.35 13.18 0.18 
A.C. 0.74 0.90 1.2 3.0 19.8) 0.15 
:.; 
A.F. 1.25 1.80 1.5 7.94 26.46 0.30 
liiean 0.71 1.01 1.75 3.82 15.17 0.26 
+S.D. 0.29 0.50 0.46 2.30 6.64 0.15 
Table 13 Parameters of methotrexate syrup absorption. 
Serum JV:TX Rena.l Half Life 
Patient Creatin!tjle Clearancr (mg. ml ) (mI. mtn- ) Oral 
-
C.G. 77 136 2.4 
A.K. 85 130 3.8 
M.B. 67 126 2'.1 
. 
E.D. 131 85 3.3 
A.C. 87 61 2.0 
A.F. 87 25 6.3 
,'1 
3.31 mean 
±.S.D. 1.62 
Wilcoxon Test N. S. 
Table 14 Serum creatinine and pharmacokinetic parameters 
of methotrexate elimination. 
(t 1 ) h. 
"2" 
i.v. 
2.8 
3.9 
2.0 
4.1 
4.1 
7.7 
4.10 
1.95 
The Absorption of a Series of Different Oral Methotrexate Doses. !2.2.2 The bioavailabili ty of r.:TX in doses of 50 mg. m -2 formulated , as a syrup has been shown to be poor and therefore of doubtful 
therapuetic usefulneso. It has been reported in the literature 
-2 that the absorption of doses greate~ than 80 mg. m are protracted 
and incow~lete leading to poor bioavailability (Henderson et al., 
1965; Wan et al., 1974). In contrast the absorption of doses 
-2 less than )0 mg. m are generally w'3ll absorbed (Henderson et a1., 
1965; Huffman et al., 197); Wan et al., 1974). 
Chungi et al., (1978) have studied the kinetics of gastro-
intestinal absorption of MTX from the lumen of rat small intestine 
and demonstrated that absorption obeys Michaelis - l~ienten kinetics. 
The above observations have implicated the presence of a saturable 
intestinal transport mechanism for MTX in man. 
The absorption of a series of MTX doses was studied to 
determine at what concentration saturation of this mechal'1ism 
. occurs when r,:TX is administered as a. syrup. 
Patients and r\~ethods: 
Four patients with ma.lignant disease participated in this 
study (Table15). Each patient was given either a 25, 50, 75 
or 100 mg. single oral dose of MTX, followed at weekly intervals 
by the other three doses. The order of dosing was determined 
by a Latin square design. Methotrexate formulation was as 
previously described (Table 11) and was always administered on 
an empty stomach after an overnight fast. A pre-treatment serum 
sample Vias obtained and after drug administration samples were 
collected frequently for the first 8 h. and at appropriate 
intervals thereafter until 50 h. Drug levels were measured by 
radioimmunoassay using 75se-labe1. The AUC was computed by the 
trapezoidal rule and the serum MTX half life values were determined 
by the slope of the log-linear regression line dravm through the 
terminal points of the individual concentration time curves. 
Results: 
--
The time to peak serum concentration varied from 1 - 2 L. but 
higher doses were not consistently associated with longer times 
(Table 15 ). 
9'7 
-------- . 
' 1 "{;~ 
------ '" Clinical Dose Peak Concentration Ratios of . Half life I,iean 
~ -1 cf. -1 Time to Peak (h) -1 AUC :1\.UC25rr.~ t-} (h) Patient Details pp; ml /::J Dose 1 . AUC (flr: h ml ) n mg ± £.Jh 
Carcino:na 25 0.53 2.12 1.5 2.56 1.00 11.0 
M.C. of 50 1.00 2.00 2.0 4.35 1. ']0 10.5 75 1.15 1.53 1.5 5.2~ 2.03 12.0 10.95 Ovary 100 1.32 1.32 2.0 10.30 4.02 10.3 ± 0.76 
Carcinoma 25 0.38 1.52 1.0 1.00 1.00 5.0 50 0.40 0.80 1.0 1.59 1.58 5.2 7.325 
. A.P. of 75 0.47 0.63 1.5 2.03 2.02 13.5 4.12 Breast 100 0.60 0.60 1.5 3.21 3.21 5.6 
25 0.30 1.20 2.0 
-' 1.70 1.00 7.0 Carcinoma 50 0.44 0.88 2.0 2.62 1.54 7.3 7.45 J.S. of 75 0.51 0.68 1.0 4.01 "2.36 7.9 ± 0.39 Bro!lchus 100 0.8) 0.83 1.5 5.11 3.01 7.6 
Carcinoma 25 0.52 2.0S 1.0 1.10 1.00 1.4 50 0.52 1.04 1.0 1.11 1.01 1.0 1.33 M.McB of 75 0.85 1.13 1.0 2.38 2.16 1.0 ± 0.43 Lip 100 1.20 1.20 1.5 3.81 3.46 1.9 
Table 15 Pharmacokinetic parameters showing dose dependent methotrexate absorption. 
f
here was wide inter-individual variation in the peak 
btained for all four doses, ranging from 0.30 - 0.5) 
concentration 
-1 p.g ml 
-1 
:after 25 mg., 0.40 - 1.00 r g ml after 50 mg., 0.44 -1 - 1.15 )lg m 
6 -1 after 75 mg. and from O. 0 - 1.)2 J1 g ml after 100 mg. However, 
in each individual the peak height increased with increasing dose. 
In patient M.C. the peak heieht increased from 0.5) pg ml-"after 
-1 25 mg. to 1.)2 pg ml after 100 mg., in A.P. it increased from 
-1 6 -1 0.)8 )'lg ml to O. 0 y.g mle, in ,J.S. from 0.)0 - 0.8) pg ml 
and in patient rr..r:lcB from 0.52 - 1.20 p; ml- 1 When expres3ed 
in terms of percent dose per litre (% dose ,-1) there ,was a 
consistent trend towards lower values as dose increased. In patient 
M.C. this dro'pped from 2.12 - 1.32 % dose 1-1, in A.? from 
1.52 - 0.60, in J.S. from 1.20 - 0.8) % dose 1-1 and in M.McB 
Ithis fell from 2.08 - 1.20 % nose 1-1. 
There was also a wide inter-individual variation in AUC 
obtained after each dose. This ranged from 1.00 - 2.56 pg h. 
-1 
-1 1.11 - 4.)5 2.0) - 5.21)lg ,ml after 25 mg, )~ h. ml after 50 mg. 
-1 after 75 and after 100 mg it ranged from ) • 21 - 1 0 .)0 P g h. ml mg. 
-1 
ml • The ratio, AUC after each dose : AUC after 25 mg. for each 
individual increased with increasing dose but did not do so 
proportionately. In patient M.C. the ratio rane;ed from 1.00 after 
25 mg. to 4.02 after 100 mg., for patient A.P. this ranged from 
1.00 - ).21; J.S. from 1.00 - ).0', and in M.McB from 1.00 - ).46. 
The individual UTX serum half life (ti ) did not alter greatly 
with increasing dose, the mean values being 10.95 h. ±. 0.76 (M.C.), 
7.)) h. + 4.12 (A.P.), 7.45 + 0.39 (J.S.) and 1.3) h. + 0.4) (hl.~cB). 
- - -
Patient A.P. became progressively dehydrated over the course of 
the study Y/hen given 75 mg r.:TX, 'i,hich probably explains why the 
serum (t 1 ) was so long. There was, as can be s~en above, a wide 
"2" 
inter-individual variation in the values of this parameter. 
A su~£ary of the individual parameter values are listed in 
Table 15 • 
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h. 
2 2.3 The Effect of Subdiyision of Dose on l.~ethot:r-exa~~Absorption. 
I · · Low doses of MTX have been reported to be almost completely absorbed from the gastro-intestinal tract whereas higher doses are 
less well absorbed (Henderson et aI., 1965; Wan et a1., 1974) 
and these observations have been co~firmed by the studies of 
KTX a.bsorptio~1 presented here. Thls suggests saturation of a 
specialised intestinal transport process similar to that observed 
with riboflavine (Levy and Jusko, 1956). Since MTX is a highly 
polar molecule (Log P octanol = -1.85; Leo et al., 1971) it is 
unlikely to be absorbed from the intestine by passive. diffusion. 
Further the close structural similarity of r.:TX to folate vitamins 
(Fig. 4 ) points to the strong likelihood of the folate active 
. transport pathway being responsible for the absorption of the drug. 
I By administering the drug in divided doses of 2~ mg. in a 
formulation designed to dela;,>, gastric emptying, and thereby 
retarding transit of the drug to the site of intestinal absorption, 
.it might be possible to avoid saturation of th~ uptake process. 
Since sugar solutions are known to retard the rate of stomach 
emptying (Vlagner, 197.3), f:rmulating NITX as its sodium salt in 
syrup, the above criteria may be conveni~ntly achieved. 
The effects of divided doses were compared to single doses 
containing the same quantity of UTX, both formulated as a syrup. 
Patients and ~ethods: 
Eight patients with various forms of malignant disease 
(Table 16) for whom If:TX was considered appropria. te therapy, 
consented to participate in this study. Methotrexate formulation 
\,/as as previously described (Table 11 ). Each pa tient receiv~d 
100 me. I.ITX either as a single dose or else in the form of four 
divided doses each of 25 mg. taken at two-hourly intervals. 
~'he drug was always adrdrlistereCl on an er::pty stoli.:aC!l, after an 
overnight fast. After a minirr.um period of one week, each patient 
received the alternative treatl::ent sctedule. The alloca.tion to 
initial dose sc~edules (i.e. single or divided do~age) waG on a 
random basis. 
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-1 Peak le!rls Ratio of AUC (ng h ml ) Half life (h) AuC 25n:::; x 4 
Clinical (ng ml ) : AUC 10Cmg 
P~.ttent Details Order of Stud;y: 100mg 25mc x 4 100mg 25mg x 4 100mg 25mg x 4 
B.L. Breast Carcinoma 25mg x 4/100mg 2,657 7,406 487 1,014 . 6.49 5061 2.79 
Stace II 
J.(?(. Carcinoma cf 25mg x 4/100mg 1,350 4,739 608 640 1.98 4.52 3051 
Bronchus 
B.R. Carcinoma of 25mg x 4/100mg 8,829 10,449 1,235 811 11,03 6096 1.18 
Bronchus 
A.G. Breast Carcinoma 100mg/25mg x,4 6,436 5,995 929 657 16.22 12.73 0096 
Skin/Skull 
secondaries 
J.E. Carcinoma of 100mel25mg x 4 4,890 8,883 787 793 11.21 10.17 1.82 
Bronchus 
C.N. Anaplastic 100me/25mg x 4 3,522 7,054 783 690 8.61 7.90 2.00 
Lung Carcinoma 
T.D. Breast Carcinoma 100mg/25mg x 4 7,225 7,732 1,309 1,160 4.47 2.97 1.07 
Stage II 
A.G. Penile Carcinoma 100mg/25mg x 4 5,014 7,737 903 961 3.87 4.87 1.54 
-ineuim.l node 
involvement 
fi,ean 4,990 7,499 880 841 7.99 6.97 1.86 
+ + + + + + + + 
S.D. 2,469 1,724 283 188 4.71 5.22 0.90 
p 0.025 H.S. N.S. 
':'able 16 Pharmacokinetic parameters of methotrexate absorption after a 100mg. bolus a."ld 25mg. x 4. 
~: pre-tr0atLlent serum sarr.ple vras wi thdraVffi and after the initiation of therapy serUD saL1ples were frequently taken durine the first 10 h. then at intervals thereafter until 50 h. The complete 
work sheet for thi.s study is outlined in appendix· 1 
Drug levels Ylere determined by radioir.1munoas'::ay using 75Se_ 
labelled derivative. The area under the individuQ.I 1.1TX serum 
concentration time curve (AUe) was computed using the trapezoidal 
rule. 1~ethotrexate serum half-life (t 1 ) ViaS derived from the 
. .~ 
slope of the regression line (log/linear least squares fitting) 
through the terminal portion of each serum concentration time curve. 
Differences in MTX pharmacokinetic pC:'.rameters between do sase 
rec;imens wer~ tested for significance using the Wil:'('lxon matched 
. pairs signed ranks test. In order to minimise inter-patient 
\ variations the kinetic parameters (t~. peak MTX level and AUe) 
obtained in each individual were compared according to the treatment 
regimen. 
Results: 
·'f 
Typical serunl concentration time curves generated following 
the administration of 100 mg. and 25 mg. x 4 to a single patient 
are sr.ovTn in Fig. 26. In this example A.ue following 25 mg. x 4 
is considerably greater than AUe after 100 mg. and this was true 
of tl:e patient group as a whole. Thus mean AUe after 25 me. x 4 
was 7,499 ± 1,724 n8. 
-1 
mle after 100 mg., 
level (Table 16). 
-1 h. mI. compared with 4,990 ! 2,469 ng. h. 
this difference being significant at the 2.5% 
Peak serum t:TX concentrations were similar after both dose 
-1 forms, mean values being 880 ± 28) ng. ml after 100 mg. and 841 
-1 (± 188) ng. mle after 25 mg. x 4. Likewise, l':TX serum (t~) 
values did not differ significantly between tre~tment days. 
After 100 mg. the mean (tt) was 8.0 (± 4.7)h. compared with 7.0 
(± 5.2)h. after 25 mg. x 4. Th(;~ . .'e was, however, marked inter-
individual variatio~ in r:'TX (t,) values. Scrutiny of the individual 
~ 
results shows that in th.ree patients (E.R., A.G. and T.D.) the 
AUC after 25 mg. x 4 . t 
ratios AUC after 100 me. were near unl y. In these three 
individuals peak ~TX levels following 100 mg. were considerably 
greater than after 25 mg. x 4 and r.iTX (t.~) values were longer in 
association with hieher !{,TX peak levels. 
100 
tOtODO -
100 
... ·ID 
1.0 6"--------lro-··---2 .... jO-- - 3'0 I 40 
TinJ~ (~.) 
FigurE' 26. A typical serum concentration/time curve gen~l'ated 
follo,'ling the administration of 100 mg ar.d 25 rng x <4 
to pati£.i.t A.G. 
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The results of this stuqy were prp.sented to the British 
i Pharmacological Society, London, January 1979 and subseguent.ly 
I 
: published. 
~a t dividing high oral doses can improve bioavailabili ty 
was later confinned by Christophidis et al., (1979) • 
. , 
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Discussion: 
~TX syrup formulation was found to be palateable by the 
imajority of the patients. For the estimation of absolute 
Ibioavailability tIle apparent volume of distribution and the 
elimination rate constant should be independent of the route 
of admini.3tration." In the determination 6f the absolute bio-
-2 
availability of 50 mg. m ,as in the first study, this is clearly 
not so. The plasma half lives (t~) Jetermined for p~tients 
E.D., A.C. and A.~. were considerably different between doses 
(Table 14). It is nevertheless evident that the bioavailability 
of this dose of MTX in syrup form is extremely poor. 
in plasma (t f ) values for MTX in these patients were 
2 
. with the clinical profile in that their disease state 
\ advanced than was believed at the time of the study. 
The alteration 
consistent 
Vias more 
Althoue;h 
kidiley involvement per se does not necessaril~ affect the elj.mination 
rate constant, it seems likely that in this case it has, since 
.the 0 - 8 h. MTX renal clearance values were very much lower than 
in the other three patients. 
It was possible to demonstrate that the relative bioavailability 
of lower doses is better. Doses of 25 mg. were generally much 
better absorbed than doses of 50, 75 or 100 mg. (Table 15 ). 
This observation is in agreement with previously published data 
(Henderson et al., 1965; Huffman et al., 1973; Wan et al., 1974) 
" -2 Vlhich has suggested that doses less "than 30 mg. m are well 
-2 
absorbed in contrast to doses greater than 80 mg. m which are 
poorly absorbed. It Vias also evident that there was wide inter-
individual variation in the capa:ity for absorption of [TX in 
syrup form as indicated by the broad range of values for the area 
under the !i:TX concentration time curve, peak concentration and 
time to peak concentration for t~e same dose of drug. In patient 
M.C. (Table 15) the ratio AUC100 : AUC25 was 4.02 : 1.0 mg. mg. 
v:hich was not consistent with the trend set by the other doses. 
This was obs~rved in spite of a lower peak concentration and a 
serum (t;) not much dif:erent from the values obtained after the 
other three doses. 
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A possj_ble expllnation is that the absorption of this dose was 
/
Isome-;Jhc..t protracted thereby producing a more rounded peak which 
Vlould increase the value for the AUC. Su.ch a profile was indeed 
observed for patient M.C. . It was also demonstrated that 
the AUa is generally greater when tile same total dose of the drug 
was divided into units of 25 mg. given at two hourly intervals. 
A likely explanation is that by dividing an oral dose overcomes 
at least partially, saturable intest~nal absorption. 
Renal clearance, which is the major process of MTX elimination 
from the body, is by active secretion (Liegler et a1., 1969), and 
it has been reported not to be altered by high doses of drug 
(Hoffman et a1., 1973). The data presented here re"eals comparable 
MTX serum half life values for the two dosage rcgiml;;l1s, hence 
I I saturation of renal transport processes is unlikely ~~ have been 
a significant contributing factor to the effect of dividing doscs • 
It is however, noteworthy that three patients (patients E.R., A.G. 
and T.D., Table 16) with AUC 25 4 : AUC. oo ratios mg. X I me. 
near unity all shovlcd considerably hiEher peak MTX levels and 
longer serum half lives after 100 mg. than after divided doses. 
Althou.gh it is possible the.t the intestin!:11 transport systems of 
these patients had not been saturated by the 100 mg. doses, 
the data also provides evidence that altered r::.TX AUC cannot be 
attributed solely to a bioavailability difference. Further study 
of li:TX renal clearance would seem justified. 
The results reported here, however, have inunediate relvance 
to clinical practice. MTX toxicity is known to be dependent on 
the persistence of drug concentrations above a certain minimum 
level for a critical time period (Levitt et al., 1973), and tnds 
may also be true when considering response to wrx therapy. 
Increasing At;C after oral r.:TX Vlould thus contribute to enhancement 
of 11TX effects overall (efficacy and toxicity) so that an improved 
response to c~e~otherapy will result if toxicity can be satisfactorily 
controlled (e.g. using citrovorum factor). Dividing therapeutic 
doses into units of 25 mg. eiven two hourly may therefore 
perwit oral adrr~nistration to be considered as a reasonable 
alternative to intravenous tr.erapy. 
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2.). PROTEIN' BINDING STUDIES 
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2.3.1. Validation of Methods 
I. 
The main limitations of continuous ultrafiltration, as 
indeed for simple ultrafiltration, are:-
f 1) The requirement for a suitable membrane; and 
2) The accuracy and specificity of the drug aSBay procedure. 
Most drugs are bound or retained on ultrafiltration 
membranes to some extent although these are made from :inert 
material. In order to test the suit~bi1ity of membranes, drug 
recoveries where measured when only buffer was present in the 
ultrafiltration chamber. However, the assessm~nt of the mem.Q 
branes proved to be far from simple. When the concentration 
of drug in the u1trafiltrate (Df) was plotted against the 
. concentration' in the M.M.C. chamber (Dc) a series o~ lines 
\were generated (Fig.27) which depended on the flow rpte which in 
turn was related to the gas pressure at which the experimen'~ 
was run. The observed membrane effect was therefoI'e the sum 
., 
of the membrane binding and a practical experimental factor 
which depended on the appa~atus. The overall effect was 
measured by defining a reflection coefficient (a) which related 
the drug concentration in the ultrafiltrate to the concentration 
in the M.M.C. chamber:-
0'= 1 _ Df 
Dc 
This value waS measured at the flow rate encountered 
during, protein binding experiments, Le. 3 ml h-1• This process 
was also used to determine the relative suitability of continuous 
ultrafiltration and simple ultrafiltration. A comparison of 
these techniques for methotrexate, salicylate, su1phadiazine, 
phenylbutazone, diphenylhydantoin, 'cyc1ophosphamide and adriamycin 
using XM50 ' PM10 and m:10 Diaflo untrafi1tration membranes Was 
made (Tab1e'7) to validate the systems for the measurement of 
drug-protein binding interactions. 
Considerable advantage over simple ultrafiltration was 
obtained by employing continuous ultrafiltration for each of 
these compounds, since the reflection coefficient Was much lower 
by this method. 
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I REFLECTION COEFFICIENT ( c~:) * Drug Continuous Ultrafiltration Simple Ultrafiltration 
D"50 l'M10 UM10 XM50 PM10 UM10 
Methotrexate 0.01 0.10 0.20 0.35 
Salicylat~ 0.05 0.06 0.13 0.25 0.35 0.51 
sulphadiazine 0.10 0.10 0.10 0.54 0.81 0.29 
Phenylbutazone 0.27 0.35 0.35 0.47 
Diphenylhydantoin 0.07 0.14 0.09 0.77 0.50 
Cyclopho.s pharoi cle 0.01 0.01 
Adriamycin 0.05 0.10 
1* Reflection Coefficient a= 1- ill: Dx: 
Table 17 The reflection coefficient of a number of drugs obtained 
by simple and continuous ultrafiltration 
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Figure 27 The influence of flow rate on drug recoveries from 
the r-21~C chamber 
500 
Further, when employing simple ultrafiltration, considerable 
J
differences between membrane batches was observed, which could 
alter drug recoveries by as much as .:t 15%. Simple ultrafiltration 
is therefore not a wholly satisfactory method for the estimation 
of protein binding parameters. In ccmtrast continuous ul tra-
filtration can be.eQployed with confidence to the assessment of 
drug-protein binding phenomena. Since the reflection coefficient 
for methotrexate using XM50 membranE::~' was consistently very 
low (0.01) no correction factor for membrane effect was considered 
necessary. 
The accuracy, which embraces the concepts of both precision 
and sensitivity, and specificity of the radioimmuno~ssay method 
has been discussed. It was concluded that this ass~y method 
was ~n acceptable procedure for the measurement of dLUg concen-
trations in the elucidation of binding parameters by continuous 
ultrafiltration. However, large cumulative errors could 
potentially occur, since the chamber concentration is the sum 
of a number of preceding estimates. Therefore, at the end of 
each experiment, the calculated total concentration was compared 
to the value obtained by ar;say of the concentration of the drug 
in the chamber. The experimental results were rejected if the 
calculated concentration differed by more than 15% from the 
assayed value. 
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. J. 2. Bindinr; of 1,~ethotrexate to Different Serum Protein C~.!!!IlOnent§. 
.Normal hUIT:an serum contains a total complement of approxi-
.mately 70 g 1-1 of protein. Serum protein, of which there are 
I 
over twenty-five distinct entities, differ in size, shape, 
composition, charce, solubility a.nd (;he<ica1 reactivity (Goldstein, 
1949). T!1ere area nunber of thcse serum proteins which l.:.rc 
ca.pable of binding or interacting with a large number o! exoc;enous 
and endogenous compounds. ~efore exeminins the nature of the 
methotrexate-protein interaction it was necessary to dcterllline 
to y,that serum TJroteins this acent will bind. 
Method A 10 pI aliquot of JH - MTX was added to 200 pl of hurJ1nn 
serum pooled.from eight normal subjects, mixed thor"ughly and 
placed in an incubator at J7oC. for JO minutes to ensure 
equilibrium had been reacbed. The serum proteins in 20pl of 
this mixture were then separated by elcctrophoresis on cellulose 
acetate strips at pH 8.6 (barbiturate buffcr I = 0.05). 
,A narrow band along the side of the cellulose 9~etate strip was 
cut off and stained by 0.2% ponceau S. in J% trichloracetic acid 
and v~shed in 5% acetic acjd. The resulting bands were used to 
locate the various proteins on the electrophoresis strip (Fig. 28 ). 
The protein bands were cut off and eluted with 0.5 mI. of 
0.01 N sodium hydroxide and thc radioactivity in 100 pI counted 
on a Hewlett Packard Tricarb liquid scintilation counter 
(Table 18). Quenching, deterrrdned by the channels ratio method, 
was low (1 2%) • 
Results !l1ethotrexate is bound to serum proteins predominantly 
to serum albumin, 87.3% of activity being present in this 
protein fraction. 
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Figure 28 The separation of serum proteins on cellulose 
acetate strips 
'I 
/serum Protein Counts/min. % Bound. 
2688 ' Albumin 
Globulins 
a. 
~t 
~~ 
-y 
Table 18 
87.30 
108 ).51 
107 ).48 
115 3.73 
. 61 1.98 
Percentage of N:TX bound to the different protein 
components of serum. 
,.3.3. The Protein Binding of l.:ethotrexnte by the Serum of 
Normal Subjects 
The protein binding studies of 1!TX reported in the literature 
have been of a limited nature and have yielded disparate results 
(Henderson, et al., 1965; Liegler et alo, 1969; Kocle-Wesser and 
Sellers, 1976; Taylor and Halprin, 1977). It was therefore 
necessary to examine the interaction between lr.TX und albumin 
in normal human serum. 
Since 1Il1'X has found application in the treatmE'nt of psoriasis 
and in long-term treatment of breast carcinoma, in which 
conditions the patients are relatively fit, the results may 
have immediat,e clinical relevance. 
Subj ects Only serum from subj ects wi th no clinics.l or bio-
.... \ chemical manifestation of disease was used (Table 19). 
JI"ethods The protein-methotrexate interaction wa~ elucidated 
by continuous ul trafil tration using the Amicon Diafl0 Xi.150 
membranes as previo~sly described (Page 67). A reservoir 
. 6' 
concentration of 20-25 x 10- t'I was employed which enabled the 
study of the protein bindip~ over a ranee in total concentrations 
of 5-50 x 10-6M. For the determination of binding parameters 
a reservoir concentration of 750 x 10-611 was used and the 
binding examined over a total concentration range of 50-1000 x 10-6M. 
This range in concentrations was necessary for the construction 
of satisfactory Scatchard plots. The exact reservoir concen-
tration in different experiments was determined by assay of an 
aliquot of the solution, and whichever experimental condition 
was employed the bound and unbound drug in 12-16 samples was 
determined. 
The serum albumin concentration was measured using the 
bromocresol green method by a technicion AutO-Analyser. 
}.lethotrexate concentrations were measured by radloimr:;unoaszay 
using the 75Se-i-,:TX lab el. Curve fitting for the Scatchard 
plots was carried out on the North~brian Universities ~ultiple 
Access Computer (n1fl.:.A.C) using a least quares fitting proerar:une 
ba~ed on Numerical Analysis Group (~AG) routines. 
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Serum Serum Class I Class II 
Age Ast . Alt Bilirub:tn Alb~,,in 
K1 x 104M- 1 Subject Sex (y) (iul-1 ) (iul-12 (,umoll- 2 (gl ) 
.JiL -1!L K2 x 104M- 1 
M MCA F 35 22 11 8 41 0.25 19.4 1.58 0.09 
D.G. r.1 18 20 21 9 43 0.18 43.6 1.92 0.10 
E.B. F 22 28 15 10 49 0.13 95.1 3.52 0.03 
E.R. F 35 19 12 5 42 0.17 31.6 1.05 0.24 
:.; . 
F.B. F 33 21 18 13 45 0.18 124.0 2.89 0.07 
VI. S. M 31 19 23 12 44 0.12 91.6 2.74 0.20 
C "cN • .1\1 M 25 26 22 6 46 0.09 71.4 1.38 0.21 
s. rw~. M 30 26 18 1 41 0.12 86.5 1.03 0.49 
rw~ean 28.6 22.60 18.25 8.15 43.88 0.16 11.15 2.01 0.18 
!.S.D. 6.;·0 .3.54 3.69 2.82 2.75 0.05 .35.98 0.9) 0.15 
Table.19 Eiochemical values and binding parameters in eight volunteers. 
Linear protein binding of 94.24% ± ).67 was observed 
til the total concentration exceeded 30 x 10-6M. Between 
-6 -, . ~ 30-50 x'O ~ol 1 small alterations of only 2-4~ occurred. 
No great change in the percentage bound therefore occurred until 
-G -, the concentration exceeded 50 x 10 Moll, when it rapidly 
decreased (Fig. 29). Examination of Scatchard plots indicated 
two distinct groups of binding sites. In the high 
affinity group (Class I) there were 0.,6 ± 0.05 (S.D.) binding 
sites (N,) with an intrinsic association constant (1<,) of 
71.15 x 104 fle1 ± 35.98 (S.D.), whereas in the lower affinity 
group (Class II) N2 = 2.01 ± 0.93 binding sites and the 
association ~onstant K2 = 0.18 x 104 M-1 ± 0.15 (Ta~le 19 ). 
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Figure 29 The effect of increasing serum methotrexate 
concentrations on the percent bound drug 
2.3.4. The Protein Binding o:f 1:ethotrex1'l.te by the SeruP.L2f. 
! Patients vdth Neoplastic Disease. , To approach maximum inhibition of DNA synthesis enough I,iTX 
'must be present intracellularly in concentrations greater than 
necessary to saturate dihydrofolate reductase (Goldman, 1974). 
It is generally accepted that plasma protein binding can 
influence the amount of drugs entering cells (Van Os, 1964; 
I\Tartin, 1965; Booker and Darcey, 197 j; Schoeman and Azarnoff, 1975; 
Levy, 1976; Wagner, 1976; Gibaldi and McNamara, 1978). Further, 
albumin metabolism (Steinfeld, 1960; Waldman, et 0.1., 1962) 
and electrophoretic behaviour (Petermann et 0.1., 1948; 
Rotfino, et 0.1., 1948; Neely and Neil, 1956) can bo considerably 
modified by the presence of neoplastic disease. Al~erations 
" in the nature of albumin-methotrexate interaction in ~leoplastic 
disease is therefore possible but this has not been explored. 
Knowledge of an individuals protein-LTX binding and anomalies 
therein may therefore be crucial in establishing effective 
~hemotherapy with minimum toxicity. 
Patients: Recently diagnosed patients admitted to hospital 
consented to donate )0 mI. ~f blood before initiation of 
chemotherapy for a variety of neoplastic disease states. 
Table 20 • gives patient particulars and some relevant biochemical 
values. Patient data was compared to results obtained from an 
age and sex matched 'control' group of patients attending an 
outpatients clinic for a number of non-malienant conditions 
(Table 21). 
Methods: The methods employed for the elucidation of binding 
parameters have been described previously (Page 67). A reservoir 
-6 
concentration of 750 x 10 M was used as before which allowed 
the study of protein binding over the total concentration range 
of 50-1000 x 10-6ti necessary for the construction of Scatchard 
plots. Group comparisons between normal SUbjects and patients 
were made by the l,~ann Whitney 'U' test. 
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j Patient 
E.G. 
E.L. 
R.S. 
J. S. 
E.R. 
A.P. 
D.P. 
H.B. 
M McB 
M.D. 
C McS 
A.T. 
C.T. 
M.C. 
Mean 
!'-S.D. 
~ Age (Y) 
F 66 
M 
F 
F 
F 
F 
F 
F 
F 
F 
63 
48 
40 
62 
49 
53 
. 73 
6.3 
71 
80 
64 
77 
56 
61.79 
11.56 
Disease 
Carcinoma 
Breast 
Carcinoma 
Lung 
Brain 
Tumour 
Carcinoma 
Lung 
Carcinoma 
Breast 
Carcinoma 
Breast 
Osteo-
sarcoma 
Carcinoma 
Caecum 
Carcinoma 
Lip 
Melanoma 
Lymphoma 
Colon 
Carcinoma 
Lung 
Carcinoma 
Breast 
Carcinoma 
(Jvary 
AST 
(iul-1) 
23 
17 
19 
22 
24 
13 
21 
18 
22 
19 
20 
20 
58 
22.71 
10.96 
11 
30 
19 
12 
17 
18 
18 
1~ 
13 
16 
11 
16 
42 
18.62 
8.59 
Serum 
Bilirubin 
'(M mo 1 1-1 ) 
5 
7 
14 
6 
6 
6 
6 
7 
4 
6 
65 
6 
4 
9 
10.79 
15.80 
Table 20 Clinical det.alls and biochemical valves of the 
pa Uen t group. 
Serum 
Albumin 
( -1, gl I 
45 
44 
39 
38 
40 
46 
41 
32 
38 
37 
35 
29 
43 
38.79 
4.89 
JontrolS 
r=-
E.B. 
E.C. 
R.J. 
M.B. 
W.A. 
J.A. 
J.P. 
Mean 
I i s.D• 
Table 21 
Serum 
AST ALT Bilirubin 
.ill Age (y) Disease ~'iUl-1) (iul-1 ) (Llmol 1-1) 
F 67 Diabetic 14 17 ·11 
Hyper-
tensive 
F 79 C.V.A. 21 18 7 
M 70 C.V.A. 23 24 6 
M 45 C.V.A. 32 20 15 
F 64 C.V.A. 18 17 7 
F 56 Coeliac· ., 11 
F 56 Coeliac 22 17 29 
M 76 Angina 16 11 11 
64.13 20.86 17.71 .12.13 
11.35 5.90 3.90 7.43 
Clinical details and biochemical values of the 
con trol group. 
. Serum 
Albumin 
(gl-1) 
39 
32 
36 
37 
40. 
28 
34 
35 
35.13 
3.87 
.. .... 
Curve fitting for the Scatchard plots was carried out on 
!the Northumbrian Universities JIo;ultiple Access Computer Omr.:AC) or on the Varian V71 computer using a least squares fitting 
I programme. The fitting was found to be satisfactory by either 
system and comparison of results attained by fitting on both 
computers showed almost identical results (differences occasionally 
occurrinG only at the second decimal place in parameter valuea). 
Results: No significant difference could be demonstrated 
between the percent bound in the control group and the patients 
with neoplastic disease (Table 2~. The mea~ protein binding 
at a total cor-centration of 50 x 1 O-~,~ was 92·04 :!:. '4·04 (S.D.) 
in the controls compared to 92.77% ± 4.50 (S.D.) in the putientc. 
Few bio·chemical abnormalities were observed b,,~ a low 
1 serum albumin was found in one patient (C.T., 29 gl-1) and one 
-1 
control (W.A., 28 gl ). The percent bound in both subjects 
was considerably reduced, being 81.10% and 82.97% bound respec-
I 
tively. But the nature of the methotrexate - protein interaction 
. did not alter in response to hypoalbu~inaemia in these subjects, 
since the binding parameters did not differ ereatly from the 
mean value in their respective groups (T,~ble 23:24). A high se:cum 
bilirubin was observed in patient C.McS (65 x 10-~J) which 
again did not appear to affect the nature of the drug-protein 
interaction. The percentage bound KTZ may, however, be altered 
although the reduction in binding is small, being 88.85~ 
compared to the group mean of 92.77% ± 4.50 (S.D.). 
Inspection of the Scat chard plots generated by both groups 
suggested two classes of binding sitos. Tho analysis of these 
curves in the control eroup indicated 0.19 ~ 0.04 (S.D.) binding 
sites (N1) ~~th an intrinsic association constant (K1) of 
45.04 x 104 l.r1 .:t. 7.)4 (S.D.) in the high affinity group (Class I). 
In the low affinity group (Class II) N2 = 2.)1 .:t. 1.53 (S.D.) and 
4 _1 ) ( K2 = 0.16 x 10 M !. 0.10 (S.D. Table 22). In the group of 
patients vdth malignant disease N1 = 0.19.:t. 0.04 (S.D.). 
K1 = 51·29 x 104 r.r1 .:t. 30.10 (S.D.) and N2 = ).06.:t. 1.79 (S.D.). 
4 -1 K2 = 0.11 x 10 M .:t. 0.10 (S.D.) (Table 22). 
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Group 
Patients 
Controls 
Iilann 
Whitney 
IU' Test 
,--\ 
Serum 
Albumin Class I 
Age (Y) (gl-1) % Bound* N, K1 ~ 104 1C1 
61.79 ± 11.56 38.79.t 4.89 92.77 _+ 4.50 0.19 :!: 0.04 51.29 :t 30.10 
64.13 + 11.35 35.13 ! 3.87 92.04± 4.04 0.l9 .:!:. 0.04 45.04 1: 7.34 
N.S. N.S. N.S. N.S. 
Table 22 Croup comparison of patient and control groups. 
Values refer to binding at a total drug concentration of 50 p=. 
ClassTI 
N2 
4 -1 K2 x 10 M 
3.06 _+ 1.79 0.11 + 0.10 
2.31 .:!:. 1.53 0.16 + 0.10 
-
N. S. N.S. 
I Class I ClnsR II 
* 
" 104 M- 1 104 M-1 Controls % Bound' N1 ~x N ~2 x 
-L 
M.R. 93.90 0.16 44.72 0.55 0.31 
E.B. 92.01 0.18 55.95 5.04 0.04 
E.C. 93.60 0.23 )cl.91 4.01 0.09 
R.J. 93.58 0.14 32.88 1.44 0.21 
liT. B. 9h .02 0.21 49.63 1.93 ' 0.13 
W.A. 82.97 0.27 43.78 1.70 0.15 
S.A. . 90.16 0.18 42.73 2.72 0.06 
'I J.P 94.11 0.15 51.73 1.06 0.25 
Mean 92.04 0.19 45.04 2.31 0.16 
.:!:.S.D. 4.04 0.04 7.34 1.53 0.10 
", 
Table 23 Individual protein binding data of the control group. 
Values rcfe~ to binding at a total drug concentration 
of 50 r':' 
Ltient 
Class I Clnsn II 
* 4 -1 4 -1 % Bound N K1 x 10 M N2 K2 x 10 1.1 
-L 
-
E.G. 92.99 0.26 12.20 4.13 0.03 
E.L. 91.73 0.23 14.70 5.,6 0.03 
R.S. 98.01 0.17 1 J3.00 1.86 0.12 
J.S. 97.64 0.20 90.20 3.11 0.05 
E.R. 96.13 0.17 50.00 5.73 0.05 
A. P. 93.30 0.18 40.00 4.02 0.05 
D. P. 90.75 0.17 51.18 5.52 0.05 
H.B. 92.77 0.21 35.07 3.Se; 0.04 
'I M McB 90.06 0.13 56.76 1.19 0.30 
M.D. 91.50 0.13 51.35 1.39 0.23 
C McS 80.85 0.16 36.00 1.04 0.·20 
I 
A.T. 96.83 0.24 50.18 0.70 0.06 
C.T. 81.10 0.22 37.87 2.86 0.05 
III. C. 97.09 0.18 51.50 1.75 0.15 
Mean 92.77 0.19 51.29 3.06 0.11 
+S.D. 4.50 0.04 30.10 1.79 0.10 
-
.. 
Table 24 Individual protein binding data of the pat5.ent c;rou.p. 
Values Tc':er to bincin.:; at a to tal drllG COlleen tr'l tic.n 
of 50 p:. 
..-\ 
)
1 No significant difference could be demonstrated when the 
, groupS were compared (Table 22). There was a greater scatter 
of values around the mean for K1 in the patient 'group (Table 22) 
due mainly to the very high values obtained in patients 
R.S. and J.S. There was no biochemical or obvious clinical 
abnormality to which these anomalous values could be related • 
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Discussion: A large number of treatment schedules using llTX 
have been developed, such as high dose therapy with folinj.c acid 
rescue (Levitt, et al., 1973; Pratt, et al., 1975; Stoller, et al., 
I 
1977) in an endeavour to gain the greatest therapeutic response 
with tolerable toxicity. It is surprising that this approach 
has not included studies of the nature of MTX - serum protein 
interaction. Protein binding could be of critical importance 
in that anomalies therin might gree.tly affect the di~tribution 
and excretion of this agent. Further, the studies of MTX 
protein binding which have been recorded have suffered from 
certain irreconcilable deficiencies. Simple ultrafiltration 
was used in some studies to separate 'bound' and 'f~ee' drug 
(Liegler, et al., 1969; Taylor and Halprin, 1977) so non-~pccific 
· .... 1 binding to membranes or ultracentrifugation cones cmmot be 
eliminated. The !,~TX concentrations Vlere not assayed but rather 
radio-labelled drug was employed to estimate the percentage 
bound (Henderson, ct al., 1965; Taylor and Hal~~in, 1977; 
Liegler, et al., 1969). Crystalline serum albumin reconstituted 
in phosphate buffer has alRo been used (Taylor and Halprin, 1977) 
and this cannot be considered to be phys:!.ological in nature. 
These deficiencies probably explain the discrepancies between 
published studies (50-94%) and the results of percentage bindj.ng 
reported here (94.24 .! 3.67%). In the present. study the r,:TX 
concentrations in the ultrafiltrate were measured by a specific 
radioimmunoassay of high precision. Further, continuous ultra-
filtration overcame many of the membra.ne binding problems and 
individual sera were used rather than reconstituted crystalline 
albumin. The system described tore is thus an invitro system 
which more closely reflects that occurring in ~ivo. 
It is v;1.dely accepted that the protein binding of a drug 
can modify its distribution in the body (Vap Os, 1964; X.;artin, 
1965; Levy, 197£.; ',':agner, 1976; Gibaldi and X:cNamara, 1978) 
'and in 50 doinS also influence the dose respon8e relation~hips 
including toxicity as only the free drug concentration contributes 
to the rate of transport across cell me~branes. 
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Further, the amount of drug which a protein can bind depends 
Ion the total drug concentration, the protein concentration, 
I the number of binding sites on the protein and the association 
conBtant. 
According to Van Os (1964) plasma proteins will only 
have an appreciable effect on drug distribution if the drug 
has an il1trinsic ~ssociation constant greater than 1 x 104 M-'. 
lIe also predicted that drugs which :ind with a high affinity 
will have a dosage-range within which small increases in dose 
will produce relatively large increases in the concentration 
of free drug. This appears to be true of ~liTX since j~ ts high 
affinity sites have an intrinsic association constant greater 
than 1 x 104 r.;,-1 and increasing a total concentra t:!.:.>n of 
'I 50 pl,:01. 1-1 by 1.5 times will increase the free d:-"'1.1g concen-
tration by 2-3 times in the majority of patients. lilTX therefore 
shows the non-linear protein binding phenomenon predicted for 
I 
drugs vdth a high association constant. Such total serum 
-1) 
. concentrations ( 50 f r:'.ol. I however, are attained only 
under a high dosing regimen. It is likely that the improvement 
in the therapeutic index ohtained by hig1 .. dose 1';TX chemotherapy 
is at least partially related to the greater increase in free 
drug rather than on the increase in total drug concentration. 
It is also likely that the percent bound r,~TX will be dependent 
on the concentration of serum albumiil, particularly as albumin 
is the main protein component in serum to which 11'rX binds. 
However, the binding of 1ITX remains reasonably steady over a 
wide range in concentrations, (1-50 ,?tol. 1-'). It is possible 
that the capacity of serum albumin even in reduced concentrations, 
to bind 1:TX would be sufficient at the low serum levels of drug. 
Conversely, high dosin~ regimens may result in a pronounced 
increase in available drug. In the two subjects with hypoal-
bu~anaemia, assuming the same degree of bindine in vivo, 
two - three times more ~TX would be available at a concentration 
of 50 f t:ol. 1-1 than in pa tien ts with norr.;al serum albumin levels. 
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r" effect of this situation in terms of response (efficacy and toxicity) is difficult to predict at present. It could potentially be a major factor in deciding, not only the doso of 
! 
r,iTX, but also the extent of folinic acid t rescue t given to 
individual patients. 
The presence of neoplastic disease did not appear to modify 
the interaction of r.ITX with serum albumin when the parnmeter 
values were compared to the control~. As patients were only 
recently diagnosed and were otherwise reasonably fit it is 
perhaps not surprising that the results did not show wide 
deviations frum controls. Neoplastic disease can nevertheless 
result in cachexia in which alterations in interme~iory 
metabolism may in turn affect the nature of 11'rX prvtcin binding 
due to aberrent albumin metabolism. In addition, pLolonged 
treatment with J.iTX might be associated wi th a1 terations in tho 
binding properties of the drug depending on changing nutritional 
, 
status associated with response (or failure of response) to 
therapy. The concurrent use of other drugs (cytotoxic3, 
analgesics, antiemetics, antibiotics etc.) may complicate 
protein binding by competi~g for binding sites or displacing 
llTX from sites which it already occupies. The results reported 
here are only the first pext of a study to determine the effect 
on J.lTX protein binding, if any, of these factors. It is, however, 
interesting that there was a wide scatter of values for K1 
in the patient group which may be the start of a progressive 
binding aberration in some patients depending on the factors 
mentioned above. 
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'\ 2.4- ELI'MIHATION STUDIES 
. I 
. I 
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2.4.1. Renal Clearance of Methotrexate 
r,:ethotrexate is used, in clinical practice, over a wide 
dose range. In the light of this there is surprising paucity 
of published data relating the pharmacokinetics of the drug to 
dose range studied. Some evidence fnvouring saturable methotrexate 
elimination has accumulated but the range of plasma levels at 
which non-linear pharmacokinetics may apply is unclear. 
A disproportionate in~rease in plasma methotrexate 
concentration followed infusion of a 20 g. dose of the drug 
(Goldie, et al., 1972) but another group of workers reported 
roughly proportional peak serum methotrexate levels with dose 
over a 50 to 200 mg. Kg-1 range (Stoller, et al., 1975). 
Attempts to model the pharmacokinetics of high dose me tho-
trexate infusion led to postulation of a saturable ~enal 
elimination process (Leme, et al., 1975; Reich, et al., 1977) 
though the extent to which this is quantitatively important is 
unclear. Recently, however, Shen ann Azarnoff (1978) have 
reported preliminary findings consistent with a marked fall-off 
in methotrexate renal clearance at plasma concentration levels 
-1 
above 0.1 pe ml • 
The impetus to study this particular aspect of the 
pharmacokinetics of methotrexate sterr£ in fact not from the 
suggestions in the literature but from a previous study 
(see page99 of this thesis) primarily designed to assess 
bioavailability of the drug after divided doses (CaIman, et al., 
1979). In ttis study three out of eight patients showed 
prolongation of methotrexate's apparent terminal half-lifo in 
association vdth higher peak levpls of the drue - an effect 
consistent with saturable elimination. Accordingly the present 
study was designed to examine specifically the effect ~f dose on 
the clinical pharmacokinetics o~ methotrexate. 
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r.~ethods : 
I Six patients receiving methotrexate for the treatment of a variety of rr,alir;nant diseases consented to take part in the study • 
. The clinical details' of these patients are summarised in Table 25. 
All but one received combination cr.emotherapy as indicated but, 
for the purpose of this study administration of other drugs 
was delayed until 24 h. after MTX dosing. Following cannulation 
of veins in both antecubital fossae, patients received a bolus 
intravenous MTX injection - 25 mg. followed after a minimum of 
one week by 100 mg. (or vice versa -. the order of adrrdnistration 
behind random). Sar.;ples for MTX serum deterlnination were removed 
at appropriate times until 48 h. after drug administration. 
Urine for MTX assay was also collected up to 48 h. ~ftAr drug 
'\ administration. 
~ethotrexate concentrations in serum and urine were measured 
by radioimmunoassay using the 75 Se-labelled derivative. 
Areas under the I;ITX serum concentration-time curves were 
, 
<estimated using the logarithmic trapezoidal rule. The logarithmic 
rather than the linear trapezaidal rule was used in view of 
the long intervals between sampling timeo after 12 h. this is 
in keeping with the recommendation of Chiou (1978). Terminal 
UTX serum half lives were derived from log-linear least squares 
fitting of the final portion of the concentration-time curves 
and these were used to derive AUCO • Renal cleara~ces were -0'.) 
calculated until 48 h. only because of the difficulty in 
extrapulating urinary drug recovery to infinity. 
Within-subject differences in these parameters were tested 
for significance using the \'lil.coxon matched-pairs signed-rank 
test. 
Resu.lts: 
Fig.30 sho ..... s the LTX serum concentration-time curves for 
all six patients and Table 26 surr.marises the ~';TX levels attained 
followed bolus intravenous inj ection of the drug. Mean l,.TX 
seru~-conccntration-time curves after 25 mg. and 100 mg. are 
also sho~~ for the six individuals (Fig. 31 ). 
118 
!patient 
Serum 
Additional Creat:ininc; 
Diaenosis Theran:y (w'!ol 1-1 ) 
A MeG Carcinoma Cyclophosphamide 19 89 of Breast ~-FluQrou.l·acil 500 mg 
W.T. Carcinoffia Cyclophosphamide 19 97 of Breast 5-Fluorouracil 500 mg 
Jl.T. Ovarian Cyclophos:phamide 19 90 Carcinoma 5-Fluorouracil 500 mg 
l.1 Mer Carcinoma Cyclophosphamide 19 6il of Breast 5-Fluorouracil 500 mg 
V.L. Carcinoma Cyclophosphamide 19 52 of Breast 5-Fluorouracil 500 mg 
• 
J. G • Penile None 
.... 1 Carcinoma 
Table 25 Clinical de tails of patients. 
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Figure 30 concentration/time curves of each patient after 100mg. and 25mg. i.v. bolus injection. 
2.S'M~ 
IOO~ 
" 
Concentration (% Dose 1-') 
Patient A.MeG. !!1'.. 1!:1. M.MeI. hl· ~. 
.~ Dose Jrngl 25 JOO 25 100 25 100 22 100 25 100 25 100 
10 min. 24.46 31.00 25.43 29.32 28.00 24.60 18.40 36.53 16.56 27.82 
20 min. 16.52 2).05 12.42 22.05 21.70 18.00 21.60 15 .. 60 13.60 21.02 5.32 18.59 
40 min. 6.)8 11.02 6.19 16.)2 15.15 14.00 12.80 11.20 7.20 10.69 ).64 7.58 
1 hour 5.44 14.16 . 4.56 12.43 10.34 11.60 10.96 6.73 5.53 8.13 3.00 6.59 
------------------------------------------------------------
1.5 hours 4.48 8.74 3.80 7.54 5.04 7.61 5.22 5.34 2.82 8.05 2.40 6.35 
2 hours ).60 7.36 3.40 7.10 4.08 6.51 ).57 4.)8 2.61 5.0) 1.94 5.22 
3 hours 2.40 6.45 3.12 6.40 2.76 5.37 3.88 1.80 4.60 1.30 5.11 
4 hours 1.52 5.59 1.92 5.60 1.88 5.02 1.60 3.00 1.24 4.04 0.85 3.34 
6 hours 0.88 3.88 1.32 2.95 1.01 1.92 0.66 2.08 0.42 2.02 
10 hours 0.32 1.12 0.37 1.20 0.68 0.88 0.25 0.54 0.24 0.77 0.22 0.62 
12 hours 0.27 0.61 0.29 0.86 0.30 0.70 0.18 0.;0 0.15 0.62 0.16 0.42 
24 hours U.D. 0.19 U.D. 0.12 0.06 0.25 0.03 0.21 0.01 0.19 0.04 0.04 
36 hours U.D. 0.07 U.D. 0.02 U.D. 0.13 U.D. 0.01 U.D. 0.06 U.D. 0.01 
48 hours U.D. 0.02 U.D. 0.01 U.D. 0.06 U.D. U.D. U.D. 0.02 U.D. U.D. 
U .D. = n'nde tectab1e. 
Table 26 Individual data points for eaeh patient obtained after 100mg. and 25mg. i.v. bolus injection. 
lIDHOTREXATE 
r.tlli CENTRATION 100, 
~ \~ 
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Figure 31 Mean methotrexat'! 3erum concentration/time curves after 
100mg. and 25mg. i.v. colus injection. 
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true levels are expresncd in terms of ~G dose per litre, a ormalisation which should result in super-imposable curven if the drug's pharmacokinetics are linear (Wacner, 1975). 
Drug levels so expres.~;ed.are consistently hiener following 
I . 
the 100 mg. dose from 1.5 h. after Josing (Table 26). 
As a result of this divereence in serum concentration-time 
curves AUCo __ cn after 100 rwc. methotrexate bolus is dispropor-
tionately greater (p = 0.05) than A'.:Co_ aJ after 25 mc. (Tublc 27). 
Similarly total 1.~TX clearance is consiste!ltly lower at tho 
hieher dose (p = 0.05) as is renal clearance of the drug. 
Recovery of 1.~T}: in urine up to 48 h. vrar; 85 ±. 11% after the 
25 mg. dose but only 57 ±. 17% following 100 mg. 
While the total and renal cleara.nee values CluO ~ cd are not 
1 directly comparable due to the difficulties outlined ~bove, 
inferred extra-renal clearance of the drug is sIT-all and does 
not change consistently with increased dose. 
'
''0 ,--
Patie"t 
A. MeG 
\V.T. 
M.T. 
M. r.~eI 
V.L. 
J.G. 
~:!ean 
ZS.D. 
~ble 27 
-' 
-1 Clearance (rnl min ) 
, AUC Total Renal \ -1 
D08f" 0- t'J (ne; h ml J '0-0) 0-48 h. Inferred extra-!'enal 
25 mg. 7,)80 56 55 1 
100 mg.' 67,)75 25 11 14 
25 mg. 7,465 56 )9 17 
100 mg. 67,0)0 25 9 6 
25 mg. 9,677 4) 42 1 
100 mg. 60,871 27 22 5 
25 mg. 8,655 48 )9 9 
100 mg. 41,72) 40 24 1,6 
25 mg. 6,044 69 54 15 
100 reg. 54,975 )0 2) 7 
25 mg. 4,29) 97 89 8 
100 ng. 44,)27 )8 19 19 
25 mg. 7,252.:!:. 1,904 62 .:!:. 19 5) .:!:. 19 9 + 7 
100 rr.g. 56,050 + 11,090 )1 .:!:. 6 18 + 6 11 + 6 
Ratio of AUC after 100 mg. 
'0-(1) .-
= 7.7 
Aue after 25 ~~. 
0-0) 
~e At:C 2nd cleara!'1ce values of 
i.v. bolus injection. 
t.'1~ l!l~i ~i d~u! pe. ti en ts after 25:ng. a.'"ld 1 OO::r:g. 
~ 
!i DISCU~SImr Goldie, et , with saturable al., (1972) reported observations consistent methotrexate elimination when they sU8CefltCJd 
that a dis-proportionate increase in plasma methotrexate concen-
tration followed infusion of a 20 g. dose. That others workers 
using comparable methotrexato doses (Stoller, et al., 1975) 
did not observe this phenomenon probably simply reflects i.l1ter-
individual variation in methotrexatA clearance. Within patient 
comparisons led Leme, et a1., (1975) to incorporate a saturable 
renal elimination process in the model they proposed .to describe 
the handling of methotrexate in doses above 80 me/m2. 
A modificatipn of this model was later used by Reien, et al., 
(1977) to describe the handling of doses of methotrexate between 
I 50 and 200 me/kg. 
Renal excretion constit~tes the main route whereby 
methotrexate is eliminated (Shen and Azarnoff, 1970) and as 
. much as 50% of the infused dose has been recovcJ.'cd in urine 
within 12 h. after high dose methotrexate (Pratt, et al., 1974; 
Stoller, et a1., 1975). While Liegler, et a1., (1969) estimated 
the renal clearance of methotrexate at b€:,,,ween 144 and 217 ml 
mi~-1 these authors were working at steady state plasma levels 
of 90-200 ne/ml. Huffman, et al., (1973) reported a renal 
clearance of 78 ml min-1 following a single dose of 30 mg m-? 
(resulting in plasma levels up to 1,000 ng ml-1 ). This estimate 
is more in keeping with the findings of the present study 
(v/here maximum IT,ethotrexate serum concentrations were up to 
-1 -1 6,000 ng ml after 25 mg. and up to 40,000 ng ml after 100 mg.). 
The preliminary studies cited by Shen and Azarnoff (1978) 
yielded net renal clearance estimates of 20-50 IIll min-1 at 
-1 plasma levels between 0.1 and 5CO pg ml • While, as these 
authors poin~ out t~at the exact relationship between renal 
clearance and ~ethoLrcxate plasma levels awaits clarification, 
the results presented here show that the effect of met~otrexctels 
saturable renal elimination can become apparent after modest 
doses administered by bolus 1. V. injection. 
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I Methotrexate appears to utilise the general organic acid transport mechanism for its tubular secretion as demonstrated by reduced methotrexate clearance in the presence of sulicylate 
J 
and para-aminor..i.ppura te (Liegler,. et a1., 1969). Sa turab1l1 ty 
of this renal tubular secretion of the drug is the likely 
mechanism for falling renal clearance of methotrexate with 
increased drug dose. 
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2.4.2. Biliary Excretion of Methotrexate 
The biliary clearance of a number of drugs constitutes an 
important elimination process (Riggs et a1., 1977; Spring, 1968; 
Caldwell et a1., 1971). Varying amounts of drugs excreted in 
this way may undergo enterohepatic cycling and result in 
persistence of drug in the body. Such a cycling proceSD may also 
be responsible for intestinal toxicity, such as that observed 
for indomethacin (Duggan, et al., 1S75). Although little is 
knovm about the elimination of MTX by tbis route, particularly 
the quantity of drug excreted, radio-labelled tracer studies 
have indicated. that 1-2% of the activity of an intrav'enously 
administered dose is excreted in faeces (Henderson at 0.1., 1965; 
Huffman et a1., 1973; Wan et al., 1974) •. This fiCl....ro referred 
to the parent drug plus metabolites, and it was assw~ed that 
most of the drug was absorbed by the intestinal mucosa. 
Wan et al., (1974) have reported that only 4-6% of a total dose 
of 30 mg. m-2 is e7creted i~ faeces after oral administration. 
Therefore, considerable enterohepatic cycling of IIITX may occur 
after intravenous dosing since 1-2% may be recovered from the 
stool. In this study an €~timate of bilIary clearance was made 
by measuring MTX concentrations in bile obtained by T-tube 
drainage. 
Patient History: A cholecystectomy had been performed in a 
patient for the relief of chronic cholecystitis and fibrosis 
of the gall bladder and a choledochal T-tube inserted. 
A breast IUrr.p was biopsied at that time which proved to be 
malignant (adenocarcinoma) and chemotherapy was initiated. 
Treatment consisted of 500 mg. 5-fluorouracil given intravenously 
followed 24 h. later by a 50 mg. bolus injection of MTX. 
The patient was also receiving Ampicillin (500 mg. q.i.d.) 
and flurazepam (10 rr~.). 
Samrle collections: Bile was collected by T-tube drainage and 
the volume measured and the time interval noted. 
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24 h. pretreatment sample of urine and bile was collected, . and 
a sample of serum obtained immediately before r.lTX was eiven. 
Samples were collected at appropriate times until 75 h. post 
drug administration. All samples were stored at _20 oe. until 
they could be assayed.. Recovery of bile by T-tube drains.ce is 
not complete, but was assumed to be 65/; efficient as reported 
in the literature (Riggs et al., 1977). The va.lues reported 
here have been corrected accordingli' 
Hethods: Drug levels in serum, urine and bile were measured 
by radioimmunoassay employing the 75selenium label. Appropriate 
dilutions of the pretreatment bile and urine, depending on the 
dilutions of the samples, were added to the standaT1 curve when 
the MTX in these fluids was being assayed. This ph)cedure 
"'1 eliminated any non-specific cross-reactivity which lil.i.ght other-
vase have influenced the measurement of drug levels in these 
body fluids. 
., 
Serum biologic half life (tt) was measured from the slope 
of the log-linear regression line drav .. n through the terminal 
portion of the serum concentration time curve. Renal and biliary 
clearance from 0-75 h. was calculated from the relationship. 
clearance = Amount excreted in urine or bile 
AUe (i.v.) 
The area under the serum concentration time curve (AGe) 
VIas computed by the Trapezoidal Rule. 
Results: The disappearance of MTX from serum followed a triphasic 
pattern (Fig.33). The serum biologic half life (t,) of the 
~ 
final elimination phase was found to be 12.2 h. The area under 
the serum concentration time curve (AUe) from 0-75 "h. was 
-1 7.32 \lgh ml • 
Bile flow varied throughout the study, the mean value 
-1 being 10.51 .:!:. 6.46 (S.D.) mI. h and the cumulative bile 
volume at 75 h. wa~ 610 mI. (Fig. 32). The total amount of 
MTX excreted over 75 h. was 0.10) mg. or O.205~ of the ~TX 
dose administered and the biliary clearance was 0.2) ml ndn-1 • 
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Figure 33 Concentration/time curve obtained after 50mg. methotrexate i.v. bolus. 
I· The amount of MTX excreted in urine was 34.0 me. or 68% . of the ~;jTX dose, and the renal clearance was 77.4 mle min -1. The biliary excretion : renal excretion ratio was 0.003 : 1 and 
I 
remained constant over the time course of the experiment. 
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iscussion: This study indicated that biliary clearance is of 
inor importance corr:pared to the renal clearance in the elimination 
lof r.~TX. In view of the small amount of MTX in bile enterohcpatic 
cycling would be negligible, certainly in terms of the effect 
of intestinal absorption of this qUElI'.ti ty of drug on serum 
levels. However, the concentration in bile during the final 
elimination phase remains about six times greater than that 
observed in serum over this period of time. At 75 h. the 
concentration in bile is 2.2 x 10-8M (serum concentration at 
this time being 0.44 x 10-8M) which just exceeds the concentration 
threshold (2.0 x 10-8M) necessary to produce t~xicity in 
gastrointesti.nal epithelium reported by Young and C;.abncr (1973). 
This small but persistent quantity of MTX in bile ffiay therefore 
1 contribute to the gastrointestinal toxicity which ha~ been 
observed after intravenous administration. 
The serum concentration decay profile and the bioloeic 
half life (t.;.) is ccnsistent with what is expcc~;;ed for !\;TX 
given in this dose by intravenous injection. There is, therefore, 
no obvious kinetic evidenc~ to suggest that the biliary 
clearance figure found in this patient wc~ld be grossly different 
from that observed in any other subject. However, it is kno~n 
~. that concomitant administration of other drugs can influence 
not only bile volume per se, but excretion of drugs in bile. 
Phenobarbital is perhaps that most striking ex~;ple of this 
phenomenon (Bach",r et 0.1., 1974; Harris, 1976; Klassen, 1977), 
.~. 
but this effect is produced predominantly by microsomal enzyme 
induction. Since r.ITX is not metabolised to a..."ly great extent 
when given intravenously (Andersen et al., 1970; Huffman ct a1., 
1973; Vtan et al., 1974), an effect produced by this mechanism 
is unlikely to be significant. 
The radioirr~R~oassay used i~ extremely specific and does 
• 
not cross-react wi t!". 7-hydroxymethotrexate (70lit:'I'X) but the 
assay has not been ex~~ined for cross-reactivity \rlth 
polyeluta~ates which have been found in the liver (Jacobs ct al., 
1975; Rosenblatt et a1., 1978). 
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land may be expected to be present in bile. Also since it was not possible at the time of trds study to ascertain what quantity of polyglutamate metabolites were present, if any, 
it is assumed that the clearance value is that for unmetabolised 
MTX. The hepatic-biliary clearance is unlikely to be affected 
to any great extent by polyglutamates since they contribute 
only a small degree to the over-all metabolism of MTX (Jacobs et al., 
1975). The cumulative bile volume (610 mI.) is in the range 
expected and would therefore suggest that no increase in 
bile flow had been promoted by the other drugs (5-fluorouracil, 
flurazepam, ampicillin). 
'1 . 
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GENERAL ,DISSCUSION 
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Methotrexate has been used for the treatment of cancer for 
over thirty years but as yet there are certain aspects of its . 
. clinical pharmacology which remain unresolved. ~h:i..s present . 
Vlork describes studies which were undertaken to answer certain 
questions ingendered in response to clinical observations. 
It also sets out to clarify fundamental but ambiguous observations 
in the literature related to methotrexate bioavailability, 
protein binding and elimination. An attempt was made to relate 
the results of these studies to parameters of methotrexate 
therapy, such as efficacy, toxicity and resistance. The relevance 
to clinical practice was also discus::.ed with some suggestions of 
how therapy may be modified to relieve patient stre~~. 
A priori in any pharm~cokinetic or pharmacoloe~cal investigation 
I is a specific and sensitive assay of hieh precision. The cross-
reacti vi ty of 7-0II I.:TX described in this thesis and the excellent 
work of Paxto~ et al., (1970) indicated a rewarkable specific 
rC'.dio-immunoassay. Allied with the exceptional) y lovi lirai t of 
detection and the high degree of preCision, this assay becomes 
an excellent choice for mcasurine drug levels in body fluids. 
It ably facilitated the ac~~rate measurement of pharmacokinetic 
ptirameters from drug levels in body fluids. 
There Vias an extre!!1ely wide rar.ge in the values of kinetic 
parameters obtained in these studies. This VIas undoubtedly 
due in part to the nature of the disease in these patients. 
The values for the biological half-lives (t~) recorded in the 
present studies ~ere particularly widely scattered. It is critical 
that concentrations in plasr::a be measured for long enough to 
determine the true terDinal half life. However, truncated data 
1.s sometimes u.'1avoidable due to 1imi ta tions imp0sed by the limit 
of detection of the assay. If the ter~nal biological half-lives 
between individu3.ls were comparc::! it is unlikely that such a. 
'tride scatter of vall1 '3s would be observed. For the purpose of 
the presc~t studies individuals were comp3red accordine to the 
drug regimen and the (t,) values compared from a..'1alysis of data 
~ 
collected over the sa~e tirr.e course. 
12J 
~'he detection limit' of the radio-immunoassay enabled the measurement 
10f methotrexate in plasma over several days. A reasonable 
!estimate of the half life in this body fluid could therefore be 
made, even so it remains likely, since methotrexate persists in 
enythrocytes and probably in other oody compartments, that tho 
true terminal bio~ogic half life is very much longer. 
It w~s concluded that continuous ultrafiltration is a 
credible method for the study of prv~ein binding, not only of 
methotrexate but of a number of other drugs. A satisfactory 
membrane could be found which would allow efficient separation 
of bound and f .• .'ee drug. Methotrexate was found to be binding 
predominantly to serum albumin. Thi3 binding was 1 ;near over a 
wide range in drug concentration, but as the serum woncentration 
..... \ increase above 50 Jl Mol. 1-1 the binding became overay non-linear. 
Such concentrations are only observed after high intravenous 
doses. Although the percentage bound methotrexate in patients 
did not differ significantly from en age and sex matched group, 
at higher concentra~ions the bin dine did appear to depend on the 
concentration of serum albumin. This was to be expected from the 
non-linear nature of the a!~umin/methotrexate interaction at 
high drug concentrations. ~dler et al., (1950) observed that 
plasma albumin concentration varies inversely ,nth the stage of 
the malignant process, progressively decreasing as the disease 
becomes more disse~nated. Stenfeld (1960) also Observed follo\rlng 
eighty three patients with various types of cancer over a period 
of one month to five years, that serum albumin concentrations fell 
on average 10 g. 1-1 • It is therefore to be expected that the 
percent methotrexate bound to plasma albumin would decrease with 
progression of disease. ilo difference could be demonstrated 
between controls a~d patients when the binding parameters were 
compared. It is also possible tr.at anomalies Tray occur in Some 
patients particularly if their disease is unchecked and albumi~ 
synthesis is progressively corr:promised. 
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The following sentence should be amended to read: "There was a significant 
correlation between orug concentrations in plasma and parotid saliva although 
such partition appears to be impoded as predicted from the physico-chemical 
properties of methotrexate". 
" It has been observed that some patients on methotrexate 
/
therapy show signs and symptoms of conjunctivitis and oral 
toxicity. Although the physico-chemical processes which determine 
, the partition bctween plasma and saliva would tend to seclude 
methotrexate from secretions of the salivary glands very little 
information is available concerning these factors in tears. 
This is !-"3rhaps due to the fact that very few assay systems are 
sensi tive enough to measure drug levels in tea.rs, particularly 
as only small volumes can b'c readily collected. In any case 
there are few indications to measure drug levels in tears. 
It has been por::;sible to demonstrate that methotrexate' can d.istrj.butc 
into tears and saliva. Distribution into tears appears to be d.cpendc.I).t. 
on the unbound levels in plasma, but no clear rela+; ons;lip between 
"\ tear concentrations of drug and conjunctivi tus could be derived. 
FoliniC acid administration does appear to be effective in 
preventing the manifestations of this reaction sugccstinc that 
it is an effect dependent on methotrexate cytotoxicity rather 
* 'the.n a purely chemi~al conjunctivitis. AlthouG~ there was a 
significant correlation between drug concentrations in plasma 
and parotid saliva it is cH:~ar,as expectfld, that metilotrexate i~ 
secluded from secrection into saliva. The predictive value of 
determining pla.sma levels of methotrexate from that in pa:rot:'d 
saliva is unfortunately poor. The collection of sar.:ples is time 
consuming an impractical particularly for the collection of 
saC'lples from children where a painless and non-invasive meth(ld of 
monitor:tng plasma drug levels would be most acuteJy felt. 
Although no incident of oral toxicity was observed in these 
studies altcraticns in plasma protein bind.ing of methotrexate 
result inc; in increased. lE·vels of drue may preci~')i tate thiz.: toxic 
reaction if the disease is not controled. It would be cxv~ctfd 
that t~e incidelce of conjunctiv-l tis may also incretise fort:~e 
seT::e reasons. 
The concentrations of ffiethotrexate in C.S.P. or mixed saliva 
did not ~~p any clec::.r relationshi;> to tt!? le·/el.s of druc in 
plasua. 
1 )0 
~\ 
J
Thcre was a close corielation betvleen drug levels in C.S.P. and 
the levels in L,ixed saliva \':hic11 could be of ereat clinic .. :..l 
potential. It may provide a rapid, simple,painless and non-invasive 
method of obtaining an estimate of C.S.]'. concentrutions of 
methotrexate. These results clearly indicate the need for further 
work to determine. confidence limits. They also huve widel' implj.cEl. tiotl:3 
however tenuous the proposition may be on this evidence, since 
there is the possibility th.B t the trlmsport mechanisms between 
plasma and C. S. F. and plasrr,a and saliva are similar. In addition 
saliva levels may provide a simple way of monitoring C.S.F. leveln 
of centrally acting drues if the same relatj.onship as that between 
the concentrations of methotrexate in saliva and C.S.F. can be 
confirmed. 
Methotrexate enters and persists for long perioos, perhaps 
for several weeks within enythrocytes. The possibility exists 
that in SO doing it may influence the expression of toxicity nnd 
resistance. The concentration time profile is ~onsistent with a 
slowly exchanging kinetic compartment which does not appear to 
be influenced by folinic acid administration, at least not in 
an obvious manner. 
It vms demonstrated that the bioBvailability of orally 
administered methotrexate as a syrup was dose dependent. This 
result was consistant with publish results by other workers. 
This problem was conviently overcome at least partly, by dividing 
high oral doses into units of 25 mg. given at two hourly interva.ls. 
, 
l{;ethotrexate formulated as a palateable syrup therefore permitted 
oral therapy to be considered as a possible alternative to the 
high dose intravenously mode. T}1is has great advantages for the 
patient since treatment would be less traumatic and they could in 
some cases undergo treatment as an outpatient. It woud also 
help to relieve the strain on avdlable facilities which often 
exists in busy oncology units. 
kethotrexate elimination is predomina~tly by re~al excretion 
although small quantities are excreted in bile. These small 
quantities encountered in bile suggest that enterohepatlc 
cycling if it occurs would be negligible. 
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ti s small, but persi s ten t, quan ti ty of me tho trexa te may nevel'-
Jheless contribute to intestinal toxici~ particularly after hieh oses are e.dministered. 'ilie results presentGd here also show 
that renal elimination of methotrexate is saturable, and that 
this effect can be apparent after mode~t doses administcrcd by 
intravenous bolus. After high intravenous doses methotrexate 
may therefore persist in plasma for longer than expected and may 
increase the incidence of toxlci ty. Non! toring of plasma drug 
concentration is therefore advocated since increased doses of 
. folinic acid or more prolonged rescue may be necessary •. 
A reduction in plasma albumin resul ting in increased free levels 
of methotrexate may furt.."1er complicate high dose ther::...,t)Y. Drugs 
such as analGesics or other cytotoxic agents which are likely to 
'be given concomitantly could also displace methotrcxatl' from 
binding si tes and further increase tho throat of severe toxici ty. 
'-
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) 
.h. rr::>::rnI x I 
AJ1 example v:ork sheet is illustrated for methotrexate 
absorption when given as 25 mg. X 4 (~;ec paGe 100 for a dN:eription 
of the study &'1d resul ts). The ,,,ork shee t sho,,' the fea turer:; of 
all the sb~dies reported in t:us theds. S2l!lples were collected 
for long periods and raeticulous attention vTaS paid to recoreinc 
the exact time of s8.mplc collection. Due attention '1'<'.8 alro eivcn 
to mar.ifestations of toxicity and actninir:tration of other drugs. 
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Department of Materia Medica 
University of Glasgow 
Methotrexate 25 me. x 4 
~ ................................................................. . 
•••••••••• ~ •••••• \'It (Kr;) •••••••••• Heir;ht (em.) 
•••••••••••• 
Preparation ••••••••••••••••• Route of administration ••••••••••••••••• 
Date of Study ••••••••••••••• 
Diagnosis Histoloey: 
Primary site: 
Metastases: 1 
2 
3 
History (circle) Liver disease Renal Disease 
Blood disease Other: 
Blood Laboratory Reoort: 
Bilirubin Alk.Phosphatase 
Albumin GT 
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Smokes o + ++ 
Alcohol 0 + ++ 
Creatinine or 
Crea t. clear~o.r. C 1-: 
ALT 
AST 
/ 
Route 
Other Druo;s 
(in week preceding study) 
Concurrent Druljs 
Cornments: e.go Nausea, Vomi tins, Allergy. 
,'I 
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1 
Ii Elapsed time 
0 
(START) 
+ 10 min. 
+ 20 min. 
+ 30 min. 
+ 4·5 min. 
+ 60 min. 
+ 90 min. 
+ 120 min. 
Ideal 
time Event 
Light breakfast 
Insert i.v. cannula (nVenflontl) 
Withdraw blood for control, 
Biochemical calues 
(20 mle clotted) 
Administer first dose of drue 
orally (= time zero) 
(25 mg. Methotrexate) 
5 mI. blood (plain tube) 
.. , 
5 mI. blood 
5 mI. blood 
5 mI. blood 
5 mI. blood 
5 mI. blood 
5 mI. blood 
N.B. immediately before 
the second dose 
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Time 
done 
I 
rlapsed Ideal Time 
time time Event done 
0 min Administer 2nd dose of drug orally 
(= time zero) 
(25 mg. Methotrexate) 
+ 10 min. 5 mI. blood 
+ 20 min. 5 mI. blood 
+ .30 min • 5 mI. blood 
+ 45 min. 5 mI. blood 
+ 60 min. 5 mI. blood 
,,+ 90 min. 5 mI. blood 
1+ 120 min. 5 mI. blood 
N.B. immediately before 
the third dose 
,') 
0 min. Administer .3rd dose of druG 
orally (= time zero) 
(25 me. Methotrexate) 
+ 10 min. 5 mI. blood 
+ 20 min. 5 mI. blood 
+ .30 min. 5 mI. blood 
+ 45 min. 5 mI. blood 
+ 60 min. 5 mI. blood 
+ 90 min. 5 mI. blood 
+ 120 min. 5 mI. blood 
N.B. immediately before 
the fourth dose 
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1 
I 
/Elapsed Ideal Time 
I time time Event done 
0 min. Administer 4t~ dose of drue; 
orally (= time zero) 
(25 mg. r.lethotrexate) 
+ 10 min. 5 mI. blood 
+ 20 min. 5 mI. blood 
+ 30 min. 5 mI. blood 
+ 45 min. 5 mI. blood 
+ 60 min. 5 mI. blood 
+ 90 min. 5 mI. blood 
+ 120 min. 5 mI. blood 
and remove cannula 
·1 
12 h. 5 mI. blood 
-FROM START 
24 h. 5 mI. blood 
36 h. 5 mI. blood 
50 h. 5 mI. blood 
ALL BLOOD SA~~PLES SHOULD BE SEPARATED AS SOON AS POSSIBLE 
AFTER WITHDRAWAL AND THE SERt7TiI STORED IN THE DEEP FREEZE. 
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NOR F ALB I 0 C H E g I CAL V A L U E S 
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1 
I The Normal Ranee of Some Relevant Serum Biochemical Values 
Creatinine ................... 
Creatinine clearance ••••••••• 
Total Protein •••••••••••••••• 
. 
Albumin .0 •••••••••••••••••••• 
A.S.T. (aspartate transaminase) 
A.L.T. (alanine transaminase) • 
Bilirubin •••••••••••••••••••• 
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60 - 120 -1 llMol. 1 
90 - 120 rol. min-1 
60 
- 75 g 1-1 
36 52 -1 
-
g 1 
13 
-
42 iu 1-1 
11 55 iu 1 -1 
5 - 2Ol'Mol. 1 
-1 
i 
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